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Colorectal cancer (CRC) is a multistep mutagenic process that provides tumour cells 
with a growth advantage for clonal expansion. The Wnt signalling pathway is crucial for 
regulating ISC maintenance and differentiation, whilst aberrant Wnt activation is a 
hallmark of human CRC. Recent advances in genome-scale analysis of large cohorts of 
CRCs have uncovered a large number of novel mutations that had not been previously 
characterised. Interestingly, hierarchical clustering analyses of the related expression 
data reveals a cluster of differentially expressed genes that is enriched in the previously 
reported ISC markers, Wnt targets and/or Wnt inhibitors. We hypothesised that some of 
the genes within the cluster are expressed at the intestinal crypt bottoms to antagonise 
Wnt signalling to form part of a negative feedback mechanism for ISC homeostasis. The 
aim of my project was to screen for novel Wnt regulators within this gene cluster.  
Comprehensive analysis of the cluster identified two potential Wnt regulators: the 
SH3 domain-binding protein 4 (SH3BP4) and the serine/threonine kinase ZAK/MAP3K20. 
Here we show that both Sh3bp4 and Zak are expressed at the ISC compartment and 
are enriched in Apc-mutated tumours. Deletion of Zak enhances radiation-induced 
intestinal regeneration, suggesting a growth inhibitory role of ZAK in the intestine. Loss 
of SH3BP4 in vivo exacerbates the Apcmin tumour phenotype by promoting the total 
number of adenomas and high-grade dysplasia. Mechanistically, ZAK and SH3BP4 
suppresses Wnt signalling downstream of b-catenin phosporylation. The data revealed 
novel roles for both ZAK and SH3BP4 in intestinal homeostasis and tumourigenesis via 
Wnt/b-catenin signalling regulation. 
Taken together, the findings highlight the crucial role that these newly identified 
genes play in Wnt negative feedback mechanisms in intestinal regeneration and 






Colorectal cancer (CRC) is a leading cause of cancer-related death worldwide. 
In-depth characterisation of the molecular mechanisms underlying CRC 
development is important for therapeutic advances. Comprehensive genetic studies 
over the past few decades have demonstrated the crucial role of Wnt signalling in a 
variety of cancers and other diseases. In particular, aberrant Wnt activation is the 
primary cause of most CRCs. However, there is still lack of efficient drugs to target 
Wnt signalling in the clinic. Recent advances in high-throughput sequencing have 
further revealed many novel recurrent Wnt pathway mutations in addition to the well-
characterized APC mutation in CRC. Understanding how these mutations contribute 
to cancer development may open exciting avenues for drug targeting and 
personalised medicine.  
Based on the combined knowledge of Wnt signal regulation during both 
normal ISC homeostasis and CRC progression, we have identified two novel Wnt 
inhibitors - SH3BP4 and ZAK. Our results suggest that both SH3BP4 and ZAK are 
direct Wnt transcriptional targets, which function to inhibit Wnt signalling as a 
negative feedback mechanism for normal ISC homeostasis. Functionally, loss of 
Sh3bp4 promotes intestinal tumour initiation and progression, whereas Zak depletion 
promotes intestinal regeneration. These findings contribute to a better understanding 
of the Wnt signal regulation during ISC homeostasis, regeneration and tumorigenesis 
in the field of stem cell and cancer biology.  
In this project, we have generated novel ZAK knock-out mouse models using 
state-of-the-art CRISPR/Cas9 targeting in different mouse strain backgrounds. The 
development of the new mouse models provides a significant contribution to the 
broader scientific community, allowing the study of the role of ZAK in different 
contexts. In fact, our new Zak-null mice are currently being used by another 
laboratory to gain insight into the functional significance of ZAK in muscle 
hypertrophy.  In addition, we have also generated Sh3bp4-flag knock-in mice, which 
allow us to locate the tagged protein expression in primary tissues to overcome the 
lack of reliable, commercially available antibodies. The endogenous tagged protein 
may further be used for biochemical studies to identify other molecular interplays, 
such as immunoprecipitation. 
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Finally, scientific communication is a sine qua non for progress in science. 
During my PhD, I co-authored a review titled “Targeting Wnt signaling in colorectal 
cancer” in 2015, I presented a poster at the International Wnt signalling Gordon 
Research Conference in 2017, and I am also an author on a paper published in Cell 
Reports. Furthermore, we intend to submit two research articles to communicate our 
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Chapter 1. Introduction 
 
The gastrointestinal tract plays a crucial role in nutrient absorption, and 
provides a physical barrier to pathogens and toxic compounds present in the 
intestinal lumen. The constant exposure to the hostile environment results in 
continual cell loss that needs to be continually replaced. Replenishment of the 
intestinal epithelium is supported by intestinal stem cells (ISCs) that are located at 
the bottom of intestinal crypts. The high proliferation rate in this region makes the 
intestine a very attractive model for the study of stem cell proliferation and 
differentiation. Intestinal epithelial homeostasis is tightly regulated by multiple 
signalling pathways, including Wnt, Notch, epidermal growth factor (EGF) and bone 
morphogenetic protein (BMP) signals. Wnt signalling constitutes the key pathway to 
maintain the stem cell population and drive proliferation (Korinek et al., 1998). EGF 
signals are essential for the high mitotic cell cycles of the transit-amplifying (TA) cells 
upon engagement of their receptors (EGFRs) (Wong et al., 2012). Notch signalling 
is believed to determine the absorptive or secretory lineage differentiation of early 
progenitor cells (Fre et al., 2005). The BMP pathway is active in the villus 
compartment to drive differentiation and repress “stemness” genes (Haramis et al., 
2004). The role of these pathways in intestinal homeostasis is discussed in more 
detail later in this chapter. Many other signalling pathways, such as Eph/Ephrin, 
Hedgehog and Hippo signalling, are also important in regulating intestinal 
homeostasis, and their roles have been extensively addressed elsewhere and will 
not be discussed here (for reviews see (Beumer and Clevers, 2016; Meran et al., 
2017; Sailaja et al., 2016)). 
The Wnt signalling pathway is the gatekeeper for normal intestinal 
homeostasis, whilst aberrant activation is the major cause of human colorectal 
cancer (CRC). Activating mutations in the Wnt pathway initiate the formation of 
intestinal adenomas (Fearon, 2011), which require subsequent accumulation of 
other driver mutations for malignant transformation (Fearon and Vogelstein, 1990). 
This chapter summarises the current understanding of intestinal stem cell biology 
and the signalling pathways involved, with the major focus placed on the Wnt 
signalling pathway. The recent advances in CRC biology and different Wnt activating 
mechanisms are also addressed in detail.  




1.1 Intestinal architecture and stem cell biology  
 
The intestine is anatomically divided into the small intestine and the colon. 
The small intestine can be further subdivided into the duodenum, jejunum and ileum 
regions and is organised into crypts of Lieberkühn and villi (Figure 1.1A). The colonic 
epithelium has two distinctive features when compared with the small intestine: 1) 
colon has a flat epithelial surface without protruding villi, and 2) Paneth cells found 
at the base of small intestinal crypts are absent from colon (Figure 1.1B).  However, 
recent studies subsequently revealed that cKIT+ cells and Reg4+ deep crypt 
secretory cells located at the crypt bases function as Paneth-like niche cells to 
support stem cells in colon (Rothenberg et al., 2012; Sasaki et al., 2016).  
The intestinal epithelium is the most regenerative tissue in adult mammals 
(Heath, 1996). Given that the entire crypt-villus architecture is renewed 
approximately every 5-7 days, it represents one of the best models for the study of 
epithelial cell development. The high cell turnover is supported by ISCs located at 
the crypt bottoms. ISCs divide and produce rapidly proliferating daughter transit-
amplifying (TA) cells.  The TA progenitor cells continue to divide and migrate 
upwards towards the villi, where they differentiate. It is believed that the early 
progenitor cells at the TA compartment retain a certain degree of plasticity during 
regeneration (Tetteh et al., 2016), whilst cells reaching the crypt-villus junction will 
terminally differentiate into one of the two main epithelial cell lineages: absorptive or 
secretory. The absorptive lineage comprises enterocytes, whilst the secretory 
lineage includes mucous-secreting goblet cells, hormone-secreting enteroendocrine 
cells and Paneth cells (Noah et al., 2011). Paneth cells provide innate immunity and 
secrete anti-microbial defensin peptides (such as cryptdins) and digestive lysozymes. 
These cells have a relatively low turnover rate and they are the only differentiated 
cell type that migrates back towards the crypt bottom due to repulsive 
EphB3/EphrinB interactions (Batlle et al., 2002). There are other differentiated cell 
types present in the epithelium including Tuft cells and M cells, although their lineage 
and function are not yet fully characterised yet (Gerbe et al., 2012; Miller et al., 2007). 
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When the differentiated cells reach the tip of the villus, they undergo apoptosis and 








Intestinal stem cells. The existence of 
the “stem cell zone” composed of columnar 
cycling cells, intercalated between Paneth cells, was first suggested more than 40 
years ago by Cheng and Leblond (Cheng and Leblond, 1974a, b). The development 
of clonal marking techniques provided further evidence that the crypt base columnar 
(CBC) cells were the ISCs that divide and give rise to all intestinal epithelial cell types 
(Bjerknes M, 1999). This was later proven to be correct using in vivo lineage tracing 
experiments after the discovery of the first CBC cell marker, leucine-rich repeat-
containing G protein-coupled receptor 5 (LGR5) (Barker et al., 2007). The 
development of multicolour lineage tracing techniques further demonstrated that ISC 
Figure 1.1 Intestinal biology 
in homeostasis and disease. 
(A) Eosin-haematoxylin 
staining (H&E) of a mouse 
small intestine showing villus 
and crypt structure. (B) H&E 
of a mouse colonic epithelium. 
(C) Expression pattern of the 
two stem cell specific markers 
Lgr5 (upper panel) and Olfm4 
(lower panel) using RNAscope 
in situ hybridization 
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typically divide symmetrically to generate two daughter cells (Lopez-Garcia et al., 
2010; Schepers et al., 2011; Snippert et al., 2010b). The fate of these ISC daughter 
cells is believed to be stochastic depending on complex interplay between internal 
and external signals from the surrounding niche, which either regenerates another 
ISC via self-renewal, or a more differentiated progenitor. Previous studies have 
shown that subepithelial myofibroblasts contribute to crypt niche signalling by 
secreting various growth factors and cytokines that promote epithelial proliferation 
(Mills and Gordon, 2001; Powell et al., 1999). Cell-cell interaction with Paneth cells 
has also been suggested as a key determining factor for “stemness”, since they 
secrete various essential stem cell niche factors such as EGF, Wnt3 and Notch 
ligand (Sato et al., 2011). However, Paneth cells are unlikely to be the only source 
of niche signals as intestinal homeostasis can be maintained in their absence 
(Durand et al., 2012; Kima et al., 2012), probably due to other redundant sources of 
Wnt proteins (Farin et al., 2012).  
As mentioned above, Lgr5 is exclusively expressed by CBC cells (Figure 
1.1C). Lineage tracing experiments using the Lgr5-EGFP-IRES-CreERT2; R26R-
LacZ reporter mouse model confirmed that the Lgr5+ cells are the main pool of self-
renewing ISCs that can give rise to all differentiated epithelial cell types (Barker et 
al., 2007). The Lgr5+ ISCs are located at position 1-4 (counting up from the crypt 
base) and are evenly distributed between Paneth cells. The ability of sorted-Lgr5+ 
cells to generate three-dimensional intestinal organoid cultures in vitro with full self-
renewal and differentiation potential provided further supportive evidence of their 
stemness (Sato et al., 2009). Several other markers such as Ascl2 and Olfm4 have 
also been reported to be exclusive expressed by CBC cells (van der Flier et al., 
2009a; van der Flier et al., 2009b) (see Olfm4 expression in (Figure 1.1C). In addition 
to this fast-proliferating stem cells, a label-retention study performed by Potten in 
1974 showed evidence of a second pool of quiescent/slow-cycling stem cells (Potten, 
1977). More recent lineage tracing experiments with histone 2B yellow fluorescent 
protein (H2B-YFP) (Buczacki et al., 2013) and green fluorescent protein (H2B-
GFP)(Roth et al., 2012) have confirmed the existence of these long-lived cells 
population that can act as stem cells in regenerative processes.  
Several studies have suggested the presence of other stem cell markers such 
as Bmi1 (Sangiorgi and Capecchi, 2008), Hopx (Takeda et al., 2011), mTert 
(Montgomery et al., 2011), and Lrig1 (Powell et al., 2012). However, comprehensive 
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expression analysis of these markers demonstrated that most of them are expressed 
broadly at the base of the crypt as well as in Lgr5+ cells (Itzkovitz et al., 2011; Munoz 
et al., 2012). As a matter of fact, recent evidence supported the idea that cells at the 
crypt of intestine have great plasticity and could change their expression profile and 
contribute to the regenerative process following tissue insults. For example, ablation 
of the Lgr5+ ISC population is tolerated during intestinal homeostasis by enhanced 
rates of proliferation of Bmi1+ cells (Hua Tian et al., 2011; Yan et al., 2012). This 
same observation has been made for Hopx-expressing cells (Takeda et al., 2011). 
A more recent study further showed that Bmi+ cells are enteroendocrine progenitors 
and goblet cell precursors, which can rapidly dedifferentiate in response to ablation 
of Lgr5+ ISCs (Jadhav et al., 2017). Several other studies have shown that secretory 
progenitors (van Es et al., 2012b) and enterocytes (Tetteh et al., 2016) can also 
support regeneration of intestinal epithelium following damage to Lgr5+ ISC 
population. However, despite the fact that Lgr5+ seem to be dispensable for 
homeostasis of the intestine, they are fundamental for intestinal regeneration upon 
irradiation-induced injury (Metcalfe et al., 2014), showing that in certain insults, the 
cells in the stem cell niche are not able to compensate Lgr5+ cells loss.  
Taken together, the recent evidence supports the notion of a high degree of 
plasticity in the intestinal crypt where earlier progenitors can dedifferentiate to 
produce stem cell-like properties in response to tissue insults. 
 
  Wnt signalling is the key pathway to drive ISC maintenance, proliferation and 
differentiation of the epithelial cells (Wetering et al., 2002). Characterisation of the 
expression patterns of various Wnt components in the intestine demonstrated that 
the Wnt pathway is non-uniformly active along the crypt-villus axis with the highest 
activity at the crypt bottoms (Gregorieff et al., 2005). Importantly, transcriptomic 
analysis of Wnt/T cell factor (TCF) targets identified LGR5 as a Wnt target gene (Van 
der Flier et al., 2007), which subsequently led to the discovery of LGR5 as a stem 
cell marker (Barker et al., 2007). In the next section, I will discuss the Wnt signalling 
pathway in detail and summarise the main studies regarding the role of Wnt 
signalling in the intestine. 
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1.2 Wnt signalling pathway 
The Wnt signalling pathway is highly conserved throughout the animal 
kingdom and plays principal regulatory roles in many developmental and biological 
processes (Clevers, 2006; Logan and Nusse, 2004). Wnt signalling is also found to 
be aberrantly activated in many human diseases, including cancers and metabolic 
disorders (Clevers and Nusse, 2012). In the adult intestine, it is well established that 
Wnt signalling plays complementary roles in physiology and pathology: in health, it 
maintains crypt stem cell compartments, but, when activated by mutation/s, it is the 
cause of CRC. Wnt signalling is commonly divided into b-catenin dependent (also 
known as canonical) and b-catenin independent (non-canonical or alternative) 
pathways. Here, I provide an overview of both pathways and discuss the canonical 
Wnt pathway in detail at different subcellular levels of the signalling cascade: Wnt 
ligands and receptors, cytoplasmic destruction complex and nucleus.  
 
1.2.1 b-catenin independent pathways 
 
The mechanisms by which Wnt proteins regulate different pathways have yet 
to be fully characterised. However, cumulative evidence suggests that initiation and 
diversification of the Wnt signalling responses is determined at the level of ligands, 
co-receptors and cytoplasmic effectors. Interestingly, b-catenin independent 
pathways seem to be activated by specific Wnt ligands, such as Wnt5a (Gao et al., 
2011; Moon et al., 1993) and Wnt11(Heisenberg et al., 2000). On the other hand, 
several other studies suggest the existence of cross-reactivity of the Wnt-frizzled 
receptors (FZD) interactions, whilst only limited evidence supports the formation of 
specific ligand-receptor pairs. It is possible that the specificity of ligand-receptor 
interactions is most likely conferred by cellular context as determined by the 
expressed receptors and signal transducers rather than different properties of the 
Wnt ligands themselves. There are two distinct b-catenin independent intracellular 
cascades: Wnt/planar cell polarity (PCP) signalling and Wnt/Calcium signalling.  
Wnt/PCP signalling controls various aspects of cell migration (Castanon et al., 
2013) and polarity (Wu et al., 2013) that affect tissue morphogenesis. During 
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Wnt/PCP signalling, Wnt ligands bind to the tyrosine-protein kinase transmembrane 
receptor1/2 (ROR1/2)-FZD receptor complex (Kelley, 2008; Krausova and Korinek, 
2013) to recruit and activate Dishevelled (DVL) (Tree et al., 2002). DVL binds to the 
hydrolyse guanosine trisphosphate (GTPase) ras homolog gene family member A 
(RhoA), a key regulator of cytoskeletal architecture (Habas et al., 2001), through the 
DVL associated activator of morphogenesis 1 (DAAM1) protein. The Wnt-induced 
DVL-Rho complex triggers activation of the rho-associated coiled-coil-containing 
protein kinase (ROCK) and c-Jun N-terminal kinase (JNK). Moreover, DVL can also 
activate small GTPases ras-related C3 botulinum toxin substrate 1 (Rac1) for JNK 
signalling activation. This leads to transcriptional responses via activating 
transcription factor 2 (ATF) (Zallen, 2007).  
Wnt/Ca2+ signalling, on the other hand, is triggered by G-protein 
phospholipase C (PLC). The activation of PLC upon engagement of the ROR1/2-
FZD receptor complex leads to intracellular calcium fluxes that activate 
calcium/calmodulin-dependent kinase II (CamKII), protein kinase C (PKC) and 
calcineurin (Sheldahl et al., 2003), which subsequently activates downstream Ca2+-
dependent transcriptional responses.   
The Wnt/PCP and Wnt/Ca2+ signalling branches have been implicated in 
inflammation and promotion of cancer (Dissanayake et al., 2007; Wang, 2009). 
Although intestinal midgut elongation has been reported upon deregulation of 
alternative Wnt signalling pathways (Cervantes et al., 2009; Yamada et al., 2010), 
little is known about the role of non-canonical Wnt signalling in intestinal homeostasis 
and disease. The b-catenin independent Wnt signalling has been extensively 
reviewed previously and will not be addressed in detail here (Kikuchi et al., 2011; 
van Amerongen, 2012). 
 
1.2.2 Wnt/b-catenin pathway 
 
b-catenin is the key downstream effector of canonical Wnt/b-catenin 
signalling.  The b-catenin level is tightly regulated by the cytoplasmic  b-catenin 
destruction complex that consists of the scaffold proteins AXIN, adenomatous 
polyposis coli (APC), casein kinase 1 (CK1), glycogen synthase kinase 3 (GSK3) 
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(Figure 1.2, left). In the absence of Wnt ligands, the destruction complex 
phosphorylates b-catenin and targets it for proteosomal degradation upon 
ubiquitination mediated by b-TrCP, a component of the E3 ubiquitin ligase complex 
(Aberle et al., 1997; Liu et al., 2002). In the nucleus, the transcriptional repressor 
Groucho binds to the TCF transcription factor/lymphoid enhancer-binding factor 
(LEF) transcription complex to inhibit Wnt target gene transcription (Cavallo et al., 
1998; Roose et al., 1998). When the Wnt ligands engage with FZD and the low-
density lipoprotein related protein 5/6 (LRP5/6) co-receptor complex, the destruction 
complex is recruited to the membrane, where b-TrCP is dissociated from the complex 
(Li et al., 2012). As a consequence, b-catenin is no longer ubiquitinated and 
degraded, leading to saturation of the destruction complex. Alternative models of 
destruction complex inhibition have been suggested, such as the dynamic regulation 
of b-catenin phosphorylation, and AXIN-complex assembly mediated by 
phosphorylation (Hao et al., 2012; Hernández et al., 2012). Consequently, the newly 
synthesized b-catenin accumulates in the cytoplasm and is translocated into the 
nucleus. Nuclear b-catenin displaces the Groucho repressor to form the active b-
catenin/TCF/LEF transcriptional complex, resulting in Wnt target gene transcription 
(Molenaar et al., 1996) (Figure 1.2, right).   
Constitutive Wnt/b-catenin signalling activation is a frequent event in many 
cancer types. In particular, mutations in the negative Wnt/b-catenin signalling 
regulators are the hallmark of the majority of human CRCs (Nagase and Nakamura, 
1993). Therefore, for the purposes of my thesis, I will only focus on exploring the 
Wnt/b-catenin signalling pathway in detail in the following sections.





Figure 1.2 Schematic diagram showing overview of Wnt/β-catenin signalling 
pathway. 
In the absence of Wnt (left panel), the Wnt/β-catenin transcription program is blocked 
due to the degradation of β-catenin by the cytoplasmic destruction complex. Wnt 
engagement with the receptors (right panel) activates Wnt signalling cascade by 




1.2.3 Receptors and ligands for Wnt/b-catenin signalling  
 
Wnt protein. The discovery of the Wnt protein was a fascinating scientific 
story which began in 1982 (Nusse and Varmus, 1982). The Wnt gene was initially 
named as Int1 proto-oncogene (to denote the first common integration site), which 
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was later found to be homologous to the Drosophila Wingless. In the early 90s it was 
then renamed as Wnt1 (for Wingless-related integration site) (Nusse et al., 1991). 
As Nusse and Varmus wrote, “to understand how those facts were unearthed and 
assembled into coherent concepts, it is necessary to probe the history of a field—to 
learn about the sequence of events, the logical and illogical connections between 
those events, and the people who participated in them” (Nusse and Varmus, 2012).  
Wnt proteins are members of a family of signalling molecules that are 
evolutionarily conserved (Holstein, 2012). In mammals, 19 independent genes 
encode for Wnt proteins. Wnt proteins are 40 kDa proteins rich in cysteines that are 
post-translationally modified by attachment of glycoproteins (glycosylation) and lipids, 
mainly palmitate and palmitoleic acid (acylation) (Rios-Esteves and Resh, 2013; 
Takada et al., 2006; Willert et al., 2003). Interestingly, Wnt glycosylation seems to 
be crucial for protein secretion but not for their signalling capability. For example, 
Wnt3a mutants lacking glycosylation results in impaired secretion (Komekado et al., 
2007). On the other hand, purification of Wnt5 proteins in vitro that are 
deglycosylated, remain capable of activating intracellular signal cascades (Kurayoshi 
et al., 2007). The attachment of palmitoleic acid functions as a binding motif to the 
Wnt protein receptors (Janda et al., 2012) and is crucial for signalling activation 
(Komekado et al., 2007; Rios-Esteves et al., 2014; Willert et al., 2003). It also renders 
the Wnt protein hydrophobic, which may contribute to the restricted range of action 
of the protein (Nusse and Clevers, 2017). This modification is mediated by Porcupine 
in the endoplasmic reticulum (ER) (Rios-Esteves and Resh, 2013) at the conserved 
cysteine sites. After Wnt proteins are modified in the ER, they are transported and 
secreted by the multiple pass transmembrane protein Wntless/evenness interrupted 
(Wls/Evi) (Nusse and Clevers, 2017). The intracellular trafficking complex Retromer 
is also fundamental for Wnt protein secretion (Coudreuse et al., 2006). One of the 
key functions of Retromer is the recycling of the Wls/Evi endosomal vesicles back to 
the trans-Golgi network (Port et al., 2008). In addition, vacuolar acidification and 
specific cargo proteins, such as the p24 family are required for Wls transport and 
release of Wnt protein (Buechling et al., 2011; Coombs et al., 2010). At the 
membrane, Wnt proteins are secreted via exocytosis to activate Wnt signalling in 
neighbouring cells. How extracellular signal is transferred to target cells remains 
unclear. Evidence suggests that Wnt proteins are incorporated into exosomes in 
such a form that Wnt ligand is presented in the outside membrane of the exosome 
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and presented to the receptors of the target cell (Gross et al., 2012; Korkut et al., 
2009; Saha et al., 2016). 
The existence of 19 Wnt proteins raises questions regarding their specificity. 
On one hand, deletion of different Wnts results in different phenotypes, supporting 
the idea of their distinct developmental roles (Chen et al., 2017; Farin et al., 2012; 
Stark et al., 1994). However, the high degree of conservation throughout evolution 
together with some in vitro experiments suggests that many Wnt proteins perform 
similar roles (Nusse and Clevers, 2017). It is generally believed that the signalling 
and functional specificity is driven by a combination of factors, including the local 
expression of individual Wnt proteins and the specific ligand-receptor interactions.  
 
Wnt/FZD/LRP co-receptors complex. FZD proteins are seven-pass 
transmembrane receptors with an extracellular N-terminal cysteine-rich domain 
(CRD) (Bhanot et al., 1996). In humans, there are 10 FZD genes.  As previously 
described, Wnt proteins interact with both FZD receptors and another single-pass 
transmembrane receptor LRP5/6 (Pinson et al., 2000; Tamai et al., 2000). The FZD-
LRP co-receptor complex transduces Wnt signal by engaging with cytoplasmic 
proteins, particularly with DVL and AXIN. DVL proteins contain three main functional 
domains: DIX (Dishevelled-Axin); PDZ (postsynaptic density 95, disc large, zona 
occludens-1), and DEP (Dishevelled, Egl-10, Pleckstrin). The PDZ and DIX domains 
are essential for DVL to bind with FZD (Wong et al., 2003) and AXIN (Schwarz-
Romond et al., 2007). Some studies have also suggested that DEP is important for 
DVL-FZD interaction (Simons et al., 2009; Tauriello et al., 2012; Wong et al., 2003). 
PDZ binds to the FZD KTxxxW motif (Umbhauer et al., 2000; Wong et al., 2003), 
thus facilitating the interaction between the AXIN and Wnt receptors. Wnt activation 
induces the LRP6 signalosome that aggregates receptors, DVL and AXIN to promote 
LRP6 phosphorylation (Bilić et al., 2007). AXIN recruitment to the membrane leads 
to the phosphorylation of the cytoplasmic LRP tail PPP(S/T)P motif by GSK3 and 
CK1 (Davidson et al., 2005; Zeng et al., 2005). It has been reported the DVL-AXIN 
interaction inhibits the b-catenin destruction complex by interfering with AXIN 
oligomerisation via the DIX domain (Fiedler et al., 2011). Furthermore, DVL 
polymerization is also believed to be essential for signalling activity (Schwarz-
Romond et al., 2007). In addition, b-TrCP has been reported to dissociate from the 
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destruction complex when it is recruited to the membrane, resulting in suppression 
of b-catenin ubiquitination and Wnt signal activation (Li et al., 2012).  
 
LGR5/R-spondin and Wnt signal regulation. The Wnt target gene and stem 
cell marker Lgr5 and its homologues Lgr4 and Lgr6 have been show to play crucial 
roles in mediating Wnt/b-catenin signalling (de Lau et al., 2011; Glinka et al., 2011). 
Lgr6 marks stem cells in the hair follicle (Snippert et al., 2010a). Lgr4 and Lgr5 genes 
are co-expressed in the ISC compartment. However, whilst Lgr5 is exclusively 
expressed by ISCs, expression of Lgr4 is detected throughout all crypt cells (de Lau 
et al., 2011). It is now clear that the orphan 7-transmembrane proteins LGR4/5/6 
constitute receptors for the Wnt agonist R-spondin (RSPO) required for Wnt signal 
amplification (Carmon et al.; de Lau et al., 2011). Indeed, transgenic expression of 
RSPO1 has previously been shown to strongly promote hyperproliferation of 
intestinal crypt cells via Wnt/b-catenin signalling activation (Kim et al., 2005). The 
transmembrane E3 ubiquitin ligases RING finger 43 (RNF43) and zinc and RING 
finger 3 (ZNRF3) have been recently reported to suppress Wnt/b-catenin signalling 
by removing the FZD/LRP Wnt receptors from the cell surface (Hao et al., 2012; Koo 
et al., 2012) (see section Wnt/bcatenin inhibitors). The association of RSPO with 
LGR4/5 receptors is believed to boost Wnt signalling by neutralising the Wnt negative 
feedback mechanism mediated by RNF43 and ZNRF3. The formation of the 
LGR/RSPO/RNF43-ZNRF3 complex prevents Wnt receptor internalization, thereby 
potentiating the Wnt signalling response (Hao et al., 2012; Lau et al., 2014).  
 
Alternative Wnt signalling ligands and receptors. Apart from RSPO, the 
cysteine-knot protein, Norrin, has also been reported to bind to LGR4 (Deng et al., 
2013) and FZD4 (Xu et al., 2004) to activate Wnt/b-catenin signalling. On the other 
hand, the secreted Dickkopf (Dkk) proteins inhibit Wnt signalling by directly binding 
to LRP5/6 (Glinka et al., 1998). Binding of Dkk1 to LRP and the transmembrane 
Kremen proteins promotes Wnt receptor internalisation and signalling inactivation 
(Mao et al., 2002a).  
Another transmembrane tyrosine kinase, Ryk receptor, has also been shown 
to bind to Wnt1 and Wnt3a and might function as a co-receptor along with FZD (Lu 
et al., 2004). The study also suggested that the association between FZD and DVL 
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may occur indirectly through Ryk to drive Wnt/b-catenin signal activation. However, 
the underlying molecular mechanism of Ryk-mediated Wnt activation remains 
unknown. 
As mention in section 1.2.1, the kinase receptors ROR family are also known 
to bind Wnt ligands (Green et al., 2014). ROR receptors are evolutionarily conserved 
across vertebrates and most of the species contain two homologs, ROR 1 and ROR2 
(Green et al., 2014). The extracellular portion of the receptor contains a CRD domain 
with close homology to the FZDs and SFRPs CRD- domains (Jose Saldanha et al., 
1998). It has been shown that Wnt5A is a ligand for ROR1 (Fukuda et al., 2008) and 
ROR2 (Oishi et al., 2003). Yamamoto and collaborators have shown that Wnt5A 
induces the formation of a complex between ROR2 and FZD, resulting in the 
recruitment of DVL, AXIN, and GSK3b, the same proteins involved in the Wnt3A-
induced phosphorylation of LRP5/6 (Yamamoto et al., 2007). Therefore, the identity 
of the Wnt ligand determines whether the FZD co-receptor will be LRP5/6 or ROR2, 
thus dictating whether β-catenin-dependent or -independent signalling is activated, 
respectively (Grumolato et al., 2010).  
 
1.2.4 The b-catenin destruction complex  
 
b-catenin is the central player in the Wnt/b-catenin signalling to drive Wnt 
target gene transcription. Its intracellular concentration is closely regulated by the 
cytoplasmic destruction complex. The scaffold protein AXIN directly interacts with all 
components of the complex, including b-catenin, APC, DVL, and two kinase families 
(CK1a, -d, -e, and GSK3a and -b). CK1a is the major isoform responsible for b-
catenin phosphorylation (Liu et al., 2002). GSK3a and -b appear to have redundant 
functions in the destruction complex (Doble et al., 2007). APC contains multiple 15 
and 20 amino acid repeats that bind to b-catenin (Spink et al., 2001). Between the 
second and the third 20 amino acid repeats, there is another highly conserved 
regulatory domain, the b-catenin inhibitory domain (CID), which is believed to be 
essential in downregulating b-catenin levels (Kohler et al., 2009; Roberts et al., 2011). 
However, little is known about the underlying mechanism.  CK1 and GSK3 
sequentially phosphorylate b-catenin at a series of highly conserved Ser/Thr 
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residues near its N terminus. CK1 initially phosphorylates b-catenin at Ser45 (Amit 
et al., 2002; Liu et al., 2002), which primes the subsequent GSK3-mediated 
phosphorylation at Thr41, Ser37 and Ser33. Phosphorylated b-catenin is then 
recognised by the F box/WD repeat protein b-TrCP. As a consequence, b-catenin is 
ubiquitinated and targeted for rapid destruction via proteasomal degradation (Aberle 
et al., 1997).  
In addition to b-catenin degradation, the stability of the scaffold protein AXIN 
is also known to be important for Wnt signalling. Wnt activation has previously been 
shown to promote AXIN degradation (Yamamoto et al., 1999). Recent studies have 
further identified two E3 ligases, RNF146 and SIAH1/2, that are responsible for AXIN 
degradation (Ji et al., 2017; Zhang et al., 2011). However, multiple studies have 
demonstrated that b-catenin stabilisation precedes AXIN degradation (Li et al., 2012; 
Liu et al., 2005; Yamamoto et al., 1999), suggesting that AXIN degradation might be 
important to sustain, rather than initiate, Wnt signal activation.  
 
1.2.5 Wnt signalling in the nucleus  
 
The Wnt-induced transcription programme is mediated by TCF/LEF binding 
to the WNT transcriptional enhancers, which requires the co-activator β-catenin. β-
catenin interacts with an assembly of other proteins, collectively named the Wnt 
enhanceosome (Fiedler et al., 2015). Pygopus recruits β-catenin via the BCL9 
adaptor chromatin reader to the enhanceosome (Fiedler et al., 2015; Flack et al., 
2017). Together with other coactivators such as TATA-binding protein (TBP), 
Brahma-related gene-1 (BRG-1) (Barker et al., 2001), CREB-binding protein 
(CBP)/p300(Cadigan and Waterman, 2012), Mediator subunit 12 (MED12) (Kim et 
al., 2006) and Hyrax/Parafibromin (Mosimann et al., 2006), the Wnt transcription 
program is activated. Recent studies have shown that b-catenin interaction with the 
Wnt enhanceosome induces conformational changes (Tienen et al., 2017), which 
enable ubiquitination of the co-repressors Groucho/transducing-like enhancer of slipt 
(Gro/TLE) by the ubiquitin ligase UBR5 (Flack et al., 2017). Ubiquitination of Gro/TLE 
also involves the ATPase valosin-containing protein (VCP/p97) that regulates the 
folding of various cellular substrates including the ubiquitylated Gro/TLE (Flack et al., 
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2017). This modification of Gro/TLE destabilises the tetramer structure, thus relieving 
chromatin compaction to allow transcriptional activation. Conversely, silencing of the 
Wnt transcription program requires new chromatin compaction via the action of 
Gro/TLE on the SWI/SNF chromatin remodelling complex (Collins and Treisman, 
2000; Sekiya and Zaret, 2007). 
Functional studies have confirmed that the b-catenin/TCF/LEF transcription 
programme is essential for maintenance of the crypt progenitor compartments in the 
intestine. For example, deletion of theTcf4 transcription factor or conditional 
depletion of b-catenin in the intestinal epithelium results in loss of intestinal epithelial 
integrity (Ireland et al., 2004; Korinek et al., 1998). Vertebrates harbour four Tcf/Lef 
genes. All of them contain a highly conserved high-mobility group (HMG) box which 
has a DNA binding function and a peptide motif of basic residues (HMG DBD) that 
can increase the DNA binding (Klaus Giese et al., 1991; Love et al., 1995; Wetering 
and Clevers, 1992). TCF4 is the only isoform without HGM DBD (Kennell et al., 2003). 
Chromatin immunoprecipitation experiments have confirmed that the 
AGATCAAAGG sequence is the consensus TCF4/β-catenin binding motif (Blahnik 
et al., 2010; Bottomly et al., 2010; Hatzis et al., 2008). 
The process by which b-catenin enters the nucleus is still not fully understood. 
b-catenin itself has no nuclear localisation signal (NLS), whilst its import is believed 
to be via nuclear pore machinery such as importin/karyopherins (Fagotto et al., 1998). 
b-catenin can also be actively transported back to the cytoplasm, through either an 
intrinsic nuclear export signal or as cargo of Axin (Cong and Varmus, 2004) or APC 
(Rosin-Arbesfeld et al., 2000). The β-catenin shuttle between cytoplasm and nucleus 
seems to be a dynamic mechanism that may require upstream signalling regulation 
as another regulatory mechanism for this pathway. 
 
1.2.6 Wnt/b-catenin inhibitors 
 
Biological signalling pathways are precisely regulated to control cellular 
processes such as proliferation, apoptosis and differentiation that are critical for 
tissue homeostasis. Wnt signalling is regulated at different levels by a wide range of 
intracellular and extracellular effectors. The presence of agonists and antagonists is 
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of extreme importance to control Wnt signalling at the correct level. Wnt agonists 
such as RSPO and Norrin were described earlier. In this section, I discuss several 
important antagonists of the Wnt pathway in detail. The link between deregulation of 
Wnt inhibitors and CRC will also be discussed in a later section. 
 
Dickkopf proteins. As mentioned earlier, DKKs are secreted glycoproteins 
that act as antagonists in Wnt/b-catenin signalling by directly binding to the receptors 
LRP5/6 (Glinka et al., 1998). In vertebrates, the DKK family comprises 4 members, 
DKK1-4. However, DKK3 appears to be a divergent member (Krupnika et al., 1999; 
Luke et al., 2003) and does not affect Wnt signalling (Mao and Niehrs, 2003; Mao 
et al., 2001). DKKs inhibit Wnt signalling by preventing the interaction of Wnt ligands 
with LRP receptors, thus disrupting the formation of the Wnt induced FZD-LRP 
complex.  DKKs also bind to another class of receptors, Kremen1 and 2 (Krm1/2). A 
study from Mao et al in 2002 showed that DKK1 forms a ternary complex with Krm2 
and LRP6, thus promoting the internalisation of LRP6 and its subsequent inactivation 
(Mao et al., 2002b). 
 
WISE and SOST. WISE has been reported to be a context-dependent 
activator or inhibitor of the Wnt signalling pathway. Both secreted and intracellular 
WISE are able to inhibit Wnt signalling by competing with Wnt ligands to bind to LRP6 
at the membrane level (Itasaki, 2003). Another close family, Sclerostin (SOST), has 
also been shown to antagonise Wnt signalling by binding to the first two YWTD-EGF 
repeat domains of LRP5/6 to disrupt the FZD-LRP co-receptor complex formation 
(Semënov et al., 2005). Interestingly, structural analysis revealed that WISE and 
SOST belong to a subfamily of cysteine knot BMP antagonists, although the precise 
mechanism of action is unclear (Avsian-Kretchmer and Hsueh, 2004).   
 
WIF-1. Wnt-inhibitory factor 1 encodes a 379- amino acid protein that contains 
a WIF domain to prevent Wnt proteins from binding to its receptors, leading to Wnt 
signalling suppression. WIF-1 can bind to several Wnt proteins, including Wnt3A, 
Wnt4, Wnt5a, Wnt7a, Wnt9a and Wnt 11 to regulate Wnt activity(Surmann-Schmitt 
et al., 2009).  
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SFRPs. The secreted frizzled-related proteins comprise a family of five 
members, SFRP1-5 in humans. SFRP1, -2, and -5 form a subgroup that diverges 
from SFRP3 and -4 (Cruciat and Niehrs, 2013; Jones and Jomary, 2002). These 
proteins contain a CRD domain at the amino-terminal similar to the FZD receptors 
(Hoang et al., 1996), and a netrin-related motif (NTR) at the carboxy-terminal 
(Ramesh A. Bhat et al., 2007). Both CRD and NTR domains appear to be important 
for Wnt ligand binding and signalling inhibition (Wawrzaka et al., 2007). Another 
alternative mechanism for SFRP-mediated Wnt inhibition could be via formation of 
non-functional complexes with FZD receptors, since CRDs have dimerization 
potential (Cruciat and Niehrs, 2013; Dann et al., 2001).  
 
1.2.7 Wnt/b-catenin negative feedback loop 
 
 Apart from the Wnt inhibitors summarised in the previous section, there are 
several other Wnt inhibitors that belong to the negative feedback loop of the Wnt/β-
catenin signalling. These inhibitors are transcriptionally regulated by the β-
catenin/TCF complex and function as a negative feedback mechanism to control Wnt 
signalling at various levels of the cascade. Being Wnt transcriptional targets, these 
negative feedback Wnt inhibitors are often expressed at the bottom of intestinal 
crypts where Wnt activity is high. 
 
Notum. Notum encodes a protein of 671 amino acid residues that are related 
to plant pectin acetylesterases of the α/β-hydrolase superfamily. This sequence 
similarity suggests that Notum could hydrolyse glycosaminoglycan chains of 
glypicans (Doerks et al., 2002; Giráldez et al., 2002), therefore removing the post-
translational modifications of the Wnt ligands, and affecting its capacity for binding 
Wnt receptors. More recently, Kakugawa and colleagues revealed that Notum is 
indeed an extracellular deacylase that removes the palmitoleate moiety from Wnt 
proteins (Kakugawa et al., 2015). It has been reported that Notum expression is 
induced by Wnt signalling, thus placing Notum in the category of negative feedback 
Wnt inhibitors (Giráldez et al., 2002; Torisu et al., 2008) 
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RNF43 and ZNRF3. As previously discussed, RNF43 and ZNRF3 are 
capable of removing the FZD/LRP Wnt receptors from the cell surface, thus inhibiting 
the sensitivity to Wnt stimulation (Hao et al., 2012; Koo et al., 2012). Biochemical 
analyses further showed that RNF43/ZNRF3-mediated Wnt receptor endocytosis 
could be reversed by RSPO, suggesting that RSPO potentiates Wnt signalling by 
inhibiting RNF43/ZNRF3 (Hao et al., 2012).  RNF43 has also been proposed as a 
Wnt transcriptional target, indicating that RNF43/ZNRF3 is expressed upon Wnt 
induction to regulate Wnt/b-catenin signalling via a negative feedback mechanism 
(Koo et al., 2012; Takahashi et al., 2014). 
 
AXIN2. As described earlier, AXIN is the key scaffold protein in the 
cytoplasmic destruction complex that negatively regulates Wnt signalling by 
mediating b-catenin degradation (Behrens et al., 1998; Yamamoto et al., 1998). 
There are two AXIN homologues, AXIN1 and AXIN2 (also known as Conductin), that 
are believed to function redundantly. On the other hand, only AXIN2 is reported as a 
direct Wnt transcriptional target (Lustig et al., 2002), indicating its unique negative 
feedback role in Wnt/b-catenin signalling control.  
 
SOX9. It has been proposed that SOX9 inhibits Wnt signalling by competing 
with TCF/LEF for binding to b-catenin to control chondrocytes fate determination 
(Akiyama et al., 2004). In the intestine, Sox9 has been reported as a direct Wnt 
transcriptional target that is expressed at the Wnt-active crypt compartment to 
repress differentiation (Blache et al., 2004). Deletion of Sox9 in the gut results in loss 
of Paneth cells, upregulated Wnt target gene expression and intestinal hyperplasia 
(Bastide et al., 2007; Mori–Akiyama et al., 2007). The mechanism by which SOX9 
inhibits Wnt/b-catenin is not yet fully understood. In addition to the possible physical 
competition with TCF for b-catenin, Sox9 has also been shown to promote b-catenin 
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1.3 Notch signalling 
 
Intestinal homeostasis requires the correct balance between self-renewal, cell 
death and differentiation. In addition to Wnt signalling, multiple other pathways are 
also involved in regulating intestinal homeostasis. In the stem cell niche, activation 
of both Wnt and Notch signals are fundamental for stem cell maintenance (Korinek 
et al., 1998; van Es et al., 2005). Notch signal transduction is initiated when the 
membrane-bound Notch ligand (Delta/Jag) binds to the Notch receptor of a 
neighbouring cell (Figure 1.3). This results in cleavage of the receptor by the g-
secretase protease complex to release the Notch intracellular domain (NICD). The 
released NICD translocates into the nucleus, where it binds to the recombining 
binding protein suppressor of hairless (RBPJ-K) to activate Notch target gene 
transcription (Tamura et al., 1995). Activation of the Notch transcription programme 
results in the expression of the Hairy and Enhancer of Spit (Hes) class genes that 
repress expression of the Notch ligand, Delta. Thus, activation of Notch signalling 
represses the production of the Delta ligand, resulting in an important lateral 
inhibition process. A cell with lower Notch activity produces more ligand, which 
subsequently activates Notch signalling in the neighbouring signal-receiving cell. In 
the case of the intestine, Notch signalling is key to drive both stemness and lineage 
specification. Paneth cells have been shown to express Notch ligand to activate 
Notch signalling in the ISCs (Sato et al., 2011). In the TA compartment, Notch high 
progenitors will differentiate to absorptive enterocytes, whilst the neighbouring 
progenitor cells with low Notch activity will commit to the secretory fate (Sancho et 
al., 2015). 
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Notch signalling plays a crucial role in intestinal stem cell and progenitors 
differentiation. ISCs pool is maintained by constant Notch ligand provided by Paneth 
cells. In the TA compartment, Notch acts to promote differentiation. Notch-high 
earlier progenitors will differentiate to enterocytes, whilst Notch-low neighbouring 
cells commit to a secretory fate (enteroendocrine cells, goblet cells, Tuft cells and 
Paneth cells). Notch signal is initiated when a cell-surface-expressed Delta ligand 
binds to Notch receptor expressed on the neighbour cell. The membrane-tethered 
Notch is cleaved by ADAM10 and  g-secretase complex to release the intracellular 
fragment of Notch (NICD). NICD translocates to the nucleus and binds to a 
transcriptional activation complex that relieves repression of Notch target genes such 
as Hes family. The Hes family of transcriptional repressors reduces the levels of the 
Notch ligand Delta, thus resulting in a feedback loop between the two neighbouring 
cells, known as lateral inhibition - the cell with lower Notch activity produces Delta 
ligand, due to derepression of the transcription factor Atoh1. This allows the cell to 
constantly present the ligand to the neighbouring cell and activate Notch. This 
activation reduces the Delta ligand production which allow the cell with lower Notch 
activity to increase its ligand production even further since it keeps receiving low 
signal back. Therefore, the difference in Notch activity between adjacent cells is 
amplified promoting fate specification into different lineages.  
Figure 1.3 Intestinal homeostasis and Notch signalling. 




1.4 EGFR signalling 
 
The EGF receptor tyrosine kinase (EGFR) signalling cooperates with other 
pathways such as Wnt/b-catenin to promote normal tissue development, whilst the 
crosstalk of the pathways appears to be context-dependent. For example, in 
Drosophila eye, it has been shown that EGFR signalling antagonizes Wnt signalling 
(Freeman and Bienz, 2001) and the EGFR transcriptional target Phyllopod blocks 
Wingless (Nagaraj and Banerjee, 2009). On the other hand, both pathways act 
together to induce male hook development in C.elegans (Yu et al., 2009). Different 
crosstalk mechanisms have been proposed between Wnt/b-catenin and EGFR 
signalling. These include transactivation of EGFR upon Wnt binding to FZD receptors 
(Civenni et al., 2003), direct activation of b-catenin signalling by EGFR through 
Ras/MAPKs signalling (Yang et al., 2011) and modulation of the cadherin-b-catenin 
binding via EGFR-mediated b-catenin phosphorylation (Lilien and Balsamo, 2005).  
In the intestine, EGFR signals are thought to be important for ISC 
maintenance and cell differentiation (Sato et al., 2011) (Figure 1.4).The EGF-
mediated proliferation of intestinal epithelial cells is tightly regulated by the 
expression of the EGFR inhibitor Lrig1 (Wong et al., 2012), where its genetic 
inactivation results in rapid expansion of the proliferative compartment (Powell et al., 
2012; Wong et al., 2012). Ras is activated through GTP-loading by Ras guanine 
nucleotide exchange factors (RasGEFs). A study from Depeille et al. has shown that 
Ras activation through different RasGEFs can result in different outputs (Depeille et 
al., 2015). Two distinct RasGEFs, RasGRP1 and SOS1, act functionally opposite to 
one another (Depeille et al., 2015). RasGRP1 restricts EGFR-SOS1-Ras signalling 
via a negative feedback mechanism. Increased crypt proliferation and goblet cell 
numbers were also observed upon RasGRP1 deletion (Depeille et al., 2015), 
suggesting that the level of EGFR-Ras signalling is crucial for intestinal stem cell fate 
control. A recent study further demonstrated the cooperative role of EGF, Wnt and 
Notch signalling in regulating enteroendocrine cell differentiation in the intestine 
(Basak et al., 2016). Taken together, the data indicate the essential role of EGF 
signalling in intestinal homeostasis via crosstalk with the Wnt pathway. 
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EGFR is required for intestinal epithelial “stemness”. It is active at the bottom of the 
crypt in a gradient manner similar to Wnt signalling. Paneth cells constitute the niche 
for ISC by providing growth factors like EGF. Upon engagement of the EGFR, EGF 
initiates the RAS/ERK MAP kinase signalling activating a transcriptional program that 
promotes stem cell migration, proliferation, and inhibits apoptosis.
Figure 1.4 EGFR signalling in intestine. 
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1.5 BMP signalling 
 
Bone morphogenic proteins (BMPs), are extracellular signalling cytokines 
belonging to the large transforming growth factor-beta (TGF-β) superfamily. BMPs 
are known to play crucial roles in many organ systems. To date, more than 20 BMP 
ligands have been identified in humans. The BMP ligand initiates signalling by 
binding to and bringing together BMPRI and BMPRII receptors (Rahman et al., 2015). 
The intracellular proteins SMADs (mothers against decapentaplegic) are 
fundamental for signal transduction. These proteins transduce the signal from 
membrane to nucleus through receptor-mediated phosphorylation of SMAD 
transcription factors (Massagué et al., 2005). Eight SMAD proteins are encoded in 
human and mouse genomes. SMAD1/2/3/5 and 8 signal through the TGF-β receptor 
and are commonly known as regulated SMADs (R-Smads). SMAD6 and 7 are 
inhibitory SMADS that can interfere with receptors or with SMAD–SMAD interactions. 
SMAD4, also known as C-SMAD, serves as a common partner for all R-Smads 
(Rahman et al., 2015).  
In mouse intestine, Bmp4 appears to be exclusively expressed in the 
mesenchyme surrounding the villi (He et al., 2004). BMP signalling functions as a 
negative regulator of crypt progenitors. Conditional deletion of the Bmpr1a receptor 
results in hyperproliferative crypt epithelial cells (He et al., 2004), whilst 
overexpression of the BMP inhibitor Noggin and Gremlin results in ectopic crypt 
formation in the villi (Davis et al., 2015; Haramis et al., 2004). A recent study further 
demonstrated that BMP signalling restricts ISC stemness by direct SMAD-mediated 
repression of ISC signature genes (Qi et al., 2017). Mutations of BMP components, 
including SMAD4 and BMPR1A mutations, have been reported in different types of 
CRCs and in a subset of juvenile polyposis syndrome (Howe et al., 2001; Howe et 
al., 1998). Similarly, Gremlin1 duplication has been reported in hereditary mixed 
polyposis syndrome patients (Jaeger et al., 2012). This highlights the crucial role of 
BMP signalling in both intestinal homeostasis and CRC development. 
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1.6 Colorectal cancer biology 
 
CRC is a leading cause of cancer-related death in developed countries 
(Ferlay et al., 2013; Siegel et al., 2017; WHO, 2014). Over the past decades, genetic 
studies have reveal critical mutations underlying CRC. Loss of adenomatous 
polyposis coli (APC) function and subsequent mutations in other tumour suppressors 
or oncogenes such as TP53, SMAD4, KRAS and PI3K are required for cancer 
progression (Fearon, 2011; Sjoblom et al., 2006). Therefore, CRC is a result of 
multistep accumulation of genetic events known as “the Vogelgram sequence” 
(Fearon and Vogelstein, 1990), in which the number of mutations increases from the 
early adenomatous lesions to carcinomas and metastatic tumours.  
Large genomic studies of CRC samples have revealed a wide range of 
possible players in CRC. In addition, events such as epigenetic silencing, crosstalk 
between different signalling pathways, intertumour heterogeneity across individual 
CRC patients, intratumour heterogeneity, tumour microenvironment and gut 
microbiota, add further complexity and challenges to the understand of CRC initiation 
and progression.  
Patients diagnosed with CRC are broadly divided into two major groups based 
on their molecular profile: microsatellite instability (MSI) or microsatellite stable 
(MSS). MSS-CRCs constitute more than 80% of CRCs. Loss of function of APC 
protein and low prevalence of somatic copy number alterations (SCNAs) are the 
hallmark of this group of patients (TCGA, 2012). On the other hand, the molecular 
fingerprint of patients with MSI tumours is the presence of insertions or deletions of 
nucleotides in microsatellite repeat regions, widespread in the entire genome, due to 
the defective DNA mismatch repair machinery. For this reason, MSI-CRCs are 
featured by hypermutator and hypermethylated phenotype.  
Wnt pathway is aberrantly upregulated in both MSS and MSI-tumours, 
however in the MSI-CRCs, mutations in key components of the Wnt pathway, such 
as APC, β-catenin and Axin2 are only observed in a subpopulation of MSI-CRCs 
(TCGA, 2012), suggesting an alternative Wnt activating mechanism for this tumour 
type. MSI-CRCs patients have worse overall survival and worse relapse-free survival 
(De Sousa et al., 2013; Guinney et al., 2015). This type of tumours shows 
upregulation of genes associated with matrix remodelling, epithelial-mesenchymal 
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transition and immune infiltrate, mainly composed of TH1 and cytotoxic T cells, along 
with strong activation of immune evasion pathways, which could potentially explain 
the worse prognosis (De Sousa et al., 2013; Guinney et al., 2015; Llosa et al., 2015). 
In this section, I will discuss CRC biology with a particular focus on the Wnt 
activating mechanism in CRCs, starting with the most common mutated gene in CRC 
- APC. 
1.6.1 APC mutations in colorectal cancer 
APC germ-line mutations. Mutations in APC is the cause of the familial 
adenomatous polyposis (FAP) syndromes. These syndromes are characterised by 
the early onset of multiple adenomatous polyps throughout the colon and rectum. 
Although a few adenomas progress to CRC, these patients have an increased 
predisposition to CRC development during lifetime (Fearon, 2011).  
The germ-line mutations are distributed throughout the 5’ region of the gene 
and the majority are frameshift mutations resulting in premature truncation of the 
protein. Interestingly, mutations in particular regions of the gene are associated with 
different polyposis status. Mutations between codons 1250 and 1464 are associated 
with more profuse polyposis whereas mutations at N-terminal or C-terminal show 
more attenuated phenotype (Galiatsatos and Foulkes, 2006). Biallelic loss of APC in 
FAP patients is achieved through either loss-of-heterozygosity or additional somatic 
mutations as second hit. Some patients show combination of FAP syndromes with 
other tumours, such as brain tumours, known as Turcot syndrome, or epidermoid 
cysts and osteomas, known as Gardner syndrome (Galiatsatos and Foulkes, 2006). 
 
APC somatic mutations. APC mutations are found in approximately 80% of 
sporadic CRCs. These mutations are frequently clustered between codons 1309 and 
1450, which is known as the mutation cluster region (Fearon, 2011). Similar to the 
germ-line mutations, the majority of sporadic APC mutations are frameshift and 
nonsense mutations that cause premature protein truncation. APC protein truncation 
activates Wnt/b-catenin signalling through abrogation of the normal b-catenin 
destruction complex (Korinek et al., 1997). This aberrant activation of Wnt/b-catenin 
signalling, and the accumulation of further mutations in other genes, results in the 
progression from adenomas to carcinomas.  
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1.6.2 CRC molecular subtypes  
As mentioned above, CRCs have been previously broadly classified into two 
groups – MSS and MSI - based on their hypermutation profiles (TCGA, 2012). More 
recently, Guinney et al. performed a comprehensive cross-comparison of various 
genomic and transcriptomic studies of large collections of CRC cohorts, leading to 
an improved molecular classification system of CRC into four consensus molecular 
subtypes (CMSs) (Guinney et al., 2015). CMS1 group constitutes approximately 15% 
of all CRCs featuring the typical hypermutated MSI phenotype. These tumours are 
characterised by hypermethylation status – in particular, MLH1 hypermethylation 
resulting in defective DNA repair machinery (Ionov et al., 1993; Thibodeau et al., 
1993), low prevalence of somatic copy number alterations (SCNAs) and extensive 
immune infiltration (Llosa et al., 2015), mainly cytotoxic T lymphocytes, T helper 1 
cells and natural killer cells (Guinney et al., 2015). Tumours with chromosomal 
instability are more heterogeneous at the gene-expression level and they can be 
subdivided into three groups: CMS2, 3 and 4. Tumour development of CMS2-4 
generally follows the model proposed by Vogelstein (Fearon and Vogelstein, 1990) 
(Figure 1.5). CMS2 tumours are SCNA-high with approximately 80% of the cases 
having APC mutations, therefore displaying strong upregulation of WNT 
transcriptional targets. CMS3 tumours harbour high prevalence of APC and KRAS 
mutations but low SCNAs and intermediate levels of hypermethylation. Enrichment 
of several metabolic components is also observed in CMS3, suggesting a metabolic 
adaptation in this tumour subtype. Finally, CMS4 tumours display upregulation of 
genes involved in epithelial-to-mesenchymal transition, TGF-b signalling activation, 
angiogenesis and stromal infiltration (Guinney et al., 2015). This subtype is also 
characterised by poor disease outcome. 









Figure 1.5 Molecular subtypes of colorectal cancer. 
Simplified schematic diagram of the histopathological changes aligned with genetic 
abnormalities observed in different subtypes of CRC. Tumours with microsatellite 
instability (MSI – CMS1) are characterised by hypermutations, hypermethylation and 
immune infiltration. The most commonly observed mutations in CMS1/MSI tumours 
are highlighted, especially the frequent occurrence of BRAF mutations (Guinney et 
al., 2015; Rajagopalan et al., 2002). CMS1 CRCs carry APC mutations in less 
frequency than those described in CMS2-4, suggesting involvement of different 
genetic changes (such as RNF43 and RSPO) but analogous pathological 
transformation. Tumours with microsatellite stable, chromosomal unstable (MSS – 
CMS2-4), follow the Vogelgram sequence. Adenoma formation is initiated with APC 
loss. Progressive step-wise accumulation of additional mutations such as KRAS, 
SMAD4 and TP53 results in progression from early adenoma to carcinoma. CMS3 
is characterised by high frequency of KRAS mutations and is associated with multiple 
metabolism signatures. CMS2 and 4 cannot be distinguished by their mutation 
spectrum. However, CMS2 CRCs show upregulation of Wnt signalling pathways, 
whereas CMS4 tumours are characterised by activation of TGFb, EMT and VEGF 
signalling activation.




1.6.3 Cells of origin of CRC  
 
The identification of various ISC markers subsequently led to the discovery of 
CRC origin. Barker et al. demonstrated that Apc deletion in Lgr5+ cells resulted in 
early adenoma transformation and progressive neoplasia (Barker et al., 2009). In a 
complementary manner, deletion of Apc in non-stem cells compartment, particularly 
TA cells, only led to small lesions that do not form tumours (Barker et al., 2009). A 
recent study further showed that Lgr5+ cells are indeed cancer-initiating cells that are 
required for metastasis (de Sousa e Melo et al., 2017). However, although ablation 
of Lgr5+ cells showed restriction of primary tumour growth, tumour regression was 
not observed. The Lgr5+ cells are believed to continuously proliferate and replenish 
the Lgr5+ cancer stem cell pool (de Sousa e Melo et al., 2017).  
Several studies have also shown the presence of other normal stem cell 
markers such as CD133+, CD44+ and EpCAM30high in a subpopulation of CRC 
tissues that are able to initiate tumour formation in mice, suggesting that these 
markers may also be cancer stem cell markers (Dalerba et al., 2007; O'Brien et al., 
2007; Ricci-Vitiani et al., 2007; Snippert et al., 2009; Zhu et al., 2008). In addition, 
EphB2+ cells – which is highly expressed in ISCs - have also been shown to have 
tumour-initiating capacity (Merlos-Suarez et al., 2011).  
 In contrast to the studies showing stem cells as the cells of origin of CRC, 
there is some evidence supporting the notion of CRC developing via non-stem cells 
in mouse. For example, deletion of Apc in the differentiated Dclk1+ tuft cells does not 
result in tumourigenesis (Nakanishi et al., 2013). However, if these cells are 
challenged with dextra sulphate sodium to induce inflammation, they are capable of 
originating tumours (Westphalen et al., 2014). In another study, it has been shown 
that β-catenin mutations in differentiated cells do not result in transformed epithelium 
(Schwitalla et al., 2013). Yet, if mutations in β-catenin happen together with activation 
of NFKB pathway, tumours are formed. This same study has also showed that 
activation of the NFKB pathway result in crypt-like structures in the villus (Schwitalla 
et al., 2013). Davis and colleagues have also shown that a mouse model with 
aberrant activation of the BMP antagonist GREM1 resulted in the formation of crypt-
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like structures in the villi, similar to was observed upon NFKB activation (Davis et al., 
2015). The accumulation of additional mutation in these cryp-like structures also 
resulted in intestinal tumours (Davis et al., 2015). 
Altogether, these studies suggest that Wnt/β-catenin signalling activation 
alone in non-stem cells is not sufficient to drive adenoma formation. However, if cells 
acquire additional mutations or if changes happen in the normal intestinal 
microenvironment, it could then result in tumour formation.  
 
1.6.4 Mutations in Wnt signalling components in CRC 
 
Aberrant Wnt activation is the hallmark of CRCs in both MSS (mostly CMS2-
3) and MSI-tumours (CMS1) compared with normal tissues. Mutations in multiple key 
components of the Wnt pathway are found in the majority of CRCs (TCGA, 2012). 
More than 80% of MSS CRCs harbour APC mutations, as compared with 50% in 
MSI cases. On the other hand, epigenetic silencing of Wnt inhibitors in MSI tumours 
has been proposed as an alternative Wnt activating mechanism. Several studies 
have reported hypermethylation of extracellular Wnt inhibitors (Qi et al., 2006; 
Rawson et al., 2011; Silva et al., 2014; Suzuki et al., 2004; Taniguchi et al., 2005; 
Voorham et al., 2013) and of key scaffold proteins of the destruction complex 
(Esteller et al., 2000; Fu et al., 2012; Koinuma et al., 2006; Murakami et al., 2014). 
Recent studies have further identified genetic alterations in other Wnt pathway 
components (such as RNF43 and RSPO) in MSI tumours required for Wnt signal 
activation (Giannakis et al., 2014; Seshagiri et al., 2012). In this section, and in 
addition to APC mutations mentioned aboved, I will summarise the mutations in Wnt 
pathway components commonly found in different CRC subtypes. 
 
AXIN. Mutations of the negative Wnt regulators AXIN1 and AXIN2 are found 
in both sporadic and familial CRCs (Salahshor and Woodgett, 2005). Germline 
mutations in exon 7 (Lammi et al., 2004; Marvin et al., 2011) and exon 5 (Rivera et 
al., 2014) of AXIN2 have been reported with genetic predisposition to CRC and tooth 
agenesis. Several studies have described somatic mutations of AXIN2 in MSI CRCs, 
the majority of which are also localised in exon 7 (Liu et al., 2000b; Thorstensen et 
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al., 2005). In addition, epigenetic silencing of AXIN2 has also been reported in MSI 
CRCs (Koinuma et al., 2006). Although no germline mutation of AXIN1 has been 
identified in CRCs, several studies have reported AXIN1 somatic mutations (Jin et 
al., 2003; Shimizu et al., 2002). Similar to APC mutation, loss of AXIN disrupts the b-
catenin destruction complex function, resulting in constitutive Wnt/b-catenin 
activation. A recent study has further shown that AXIN mutants form non-amyloid 
nanometer-scale aggregates that affect its normal interaction, and therefore the 
function of the b-catenin destruction complex (Anvarian et al., 2016).  
 
WTX. WTX (also known as FAM123B or adenomatous polyposis coli 
membrane recruitment 1, AMER1), is an X-linked gene mutated in Wilms tumours. 
Previous studies suggest that WTX plays a dual role in Wnt signalling. On one hand, 
WTX interacts with the destruction complex to promote b-catenin ubiquitination and 
degradation (Major et al., 2007). On the other hand, WTX seems to promote Wnt-
induced LRP6 phosphorylation (Tanneberger et al., 2011). In patients, truncating 
mutations of WTX are frequently observed in kidney and CRCs. More recent 
sequencing data revealed high prevalence of WTX mutations in MSI CRCs (TCGA, 
2012). Further characterisation of the role of WTX in the Wnt signalling pathway will 
shed light on its clinical significance. 
 
RNF43. Recent whole-exome sequencing of a large cohort of human CRCs 
identified a large number of non-silent somatic mutations in RNF43 predominantly 
associated with MSI cases (Giannakis et al., 2014). As mentioned above, RNF43 
and ZNRF3 are expressed at the bottom of intestinal crypts to negatively regulate 
Wnt signalling by controlling Wnt receptor endocytosis (Hao et al., 2012; Koo et al., 
2012). Loss of function mutations in these proteins leads to increased sensitivity to 
the Wnt ligands and subsequent Wnt/b-catenin signalling activation. Therefore, the 
Wnt activating mechanism of this CRC subtype is dependent on exogenous Wnt 
signal, indicating that drugs targeting Wnt ligand/receptor (such as porcupine 
inhibitor) could represent an ideal therapeutic strategy. 
 
CTNNB1. CTNNB1 (b-catenin) is the key mediator of Wnt signalling pathway. 
As previously described, phosphorylation at ser45 by CK1, followed by GSK3-
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mediated phosphorylation at ser33, ser37, and thr41 are critical for b-catenin 
degradation (Liu et al., 2002). Mutations at these amino acid residues will result in b-
catenin stabilisation and activation of Wnt signalling. Indeed, hotspot mutations at 
these NH2-terminal serine/threonine residues of CTNNB1 such as S45F and T41A 
are frequently found in CRC, particularly in the MSI subtype (Morin et al., 1997). b-
catenin is also a subunit of cadherin protein complexes that play essential roles in 
coordinating cell-cell adhesion. A recent study has suggested that E-cadherin can 
act as a buffer to sequester mutated b-catenin, thus limiting the transforming 
properties of activating b-catenin mutations (Huels et al., 2015). 
 
RSPO. As discussed earlier, RSPO proteins are potent Wnt agonists that 
enhance Wnt signalling via engagement with the LGR and FZD receptors in the 
presence of Wnt ligands (de Lau et al., 2011; Glinka et al., 2011). Overexpression of 
RSPO1 in mice results in hyperproliferation and expansion of the intestinal crypts 
(Kim et al., 2005). Two recurrent gene fusions have recently been discovered in 
CRCs, RSPO2-EIF3E (eukaryotic translation initiation factor 3) and RSPO3-PTPRK 
(receptor-type tyrosine- protein phosphatase) (Seshagiri et al., 2012). Interestingly, 
these fusions were found in non-APC-mutated CRCs, indicating an alternative Wnt-
activating mechanism.  
 
TCF. TCF family proteins, including TCF7 (also known as TCF1), LEF, 
TCF7L1 (TCF3) and TCF7L2 (TCF4), are the downstream effectors of Wnt/b-catenin 
signalling. Point mutations, deletions, and translocations of TCF7L1 and TCF7L2 
have been reported in CRCs (Bass et al., 2011; Cuilliere-Dartigues et al., 2006; 
Duval et al., 1999; TCGA, 2012), whilst their Wnt-activating potential remains 
incompletely understood. Specific TCF7L2 frameshift mutations identified in MSI 
CRCs have been shown to be activating mutations via the selective loss of the 
TCF7L2 isoform with binding ability to the transcriptional repressor CtBP (Cuilliere-
Dartigues et al., 2006). In mouse intestine, Tcf4 deletion results in crypt degeneration, 
whereas loss of Tcf1 and Tcf3 do not result in any apparent defect (van Es et al., 
2012a). Further investigation is required to explain the discrepancy between the 
impact of mutations between different TCF members and to characterise 
transcriptional regulation mediated by TCF1, TCF3, and TCF4. 




1.6.5 Crosstalk between Wnt/b-catenin signalling and other pathways in 
CRC 
 
Signal transduction pathways often function in complex signalling networks 
that require high levels of regulation for precise control of cellular processes. In CRC, 
crosstalk of Wnt/b-catenin signalling with other pathways adds further complexity to 
CRC biology. Here, I describe some examples of pathway crosstalk reported in CRC. 
 
EGFR. As described above, EGF signalling cooperates with Wnt signalling to 
regulate proliferation and differentiation of stem and TA cells. Therefore, deregulation 
of the EGFR signal machinery can potentiate CRC initiation and progression. For 
example, deletion of RasGRP1 results in increased proliferation of intestinal 
epithelial cells (Depeille et al., 2015). In fact, APC-mutated adenomas in mice have 
been shown to be associated with increased EGFR activity (Moran et al., 2004). In 
addition, EGFR signalling has been reported to modulate cadherin-b-catenin 
interaction via phosphorylation of b-catenin Y654 (Lilien and Balsamo, 2005). 
Accordingly, expression of the phospho-mimicking Y654E b-catenin mutant in Apc-
driven mouse model resulted in increased intestinal tumour frequency via enhanced 
Wnt signalling (van Veelen et al., 2011). The data suggest that EGFR and Wnt 
signalling function synergistically to promote intestinal tumour initiation and 
progression. 
 
Notch. Crosstalk of Notch and Wnt signalling is crucial not only for normal 
intestinal homeostasis, but also for intestinal tumourigenesis. It has been reported 
that Notch signalling is activated downstream of Wnt/b-catenin via both induced 
expression of Notch ligand/receptor and b-catenin-mediated Hes1 transcription 
(Peignon et al., 2011). Synergistic activation of both pathways in mice results in a 
dramatic increase in colonic tumours, which is uncommon in mouse models with only 
Apc mutation (Fre et al., 2009). On the other hand, inactivation of Notch signalling 
using g-secretase inhibitors suppresses proliferation in Apc-driven intestinal tumours 
by inducing post-mitotic goblet cell differentiation (van Es et al., 2005). However, 
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several other studies have proposed a negative regulatory role for Notch in Wnt/b-
catenin signalling. The membrane bound-Notch was shown to directly associate with 
unphosphorylated b-catenin that preceded subsequent degradation in lysosomes 
(Kwon et al., 2011). Expression of Notch1 in Apc-driven mouse models revealed an 
unexpected conversion of high-grade adenoma to low-grade adenoma via Wnt 
signalling suppression (Kim et al., 2012a). Together, the data suggest a complex 
interplay between Notch and Wnt/b-catenin signalling in intestinal tumorigenesis. 
 
mTOR. The serine/threonine kinase mTOR is a key component of the 
mechanistic target of rapamycin complex 1 (mTORC1) that is implicated in cell 
growth control by regulating protein synthesis. Previous studies have shown that Apc 
mutated intestinal tumours are dependent on mTORC1 signalling required for tumour 
growth (Faller et al., 2014; Fujishita et al., 2008). Faller and colleagues showed that 
mTORC1 is required for the proliferation of Apc-deficient cells by mediating 
translational elongation through eEF2 kinase (Faller et al., 2014). Moreover, reduced 
mTORC1 signalling in Paneth cells has been shown to enhance ISC function in 
response to caloric restriction (Yilmaz et al., 2012). In addition, autophagy, a process 
regulated by mTORC1, is believed to negatively regulate Wnt signalling by promoting 
DVL degradation (Gao et al., 2010). Consistently, a reverse correlation between DVL 
expression and autophagy is observed in late stages of CRC (Gao et al., 2010). In 
addition, autophagy has been shown to be an alternative mechanism for b-catenin 
degradation under stress conditions via the formation of a b-catenin/LC3 complex 
(Petherick et al., 2013). Taken together, mTOR signalling is believed to be closely 
associated with Wnt/b-catenin signalling, which may represent an attractive 
therapeutic target for Wnt activated CRCs.  
 
1.7 Hypothesis 
The current evidence strongly suggests that CRC initiation and progression 
is closely linked to alterations in the ISC pool (Barker et al., 2009; Merlos-Suarez et 
al., 2011). Therefore, unravelling novel genes that contribute to ISC regulation is 
important for better understanding of both intestinal homeostasis and CRC biology. 
Wnt/b-catenin signalling is the gatekeeper for ISC regulation. Precise control of the 
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Wnt pathway is critical for ISC maintenance and differentiation. In addition to the 
central key players of the Wnt pathway components, several new regulators such as 
RSPO/LGR and RNF43/ZNRF3 have been recently identified as additional 
regulatory mechanisms required for Wnt signalling. Interestingly, some of the Wnt 
negative regulators, such as RNF43/ZNRF3 and AXIN2, are direct Wnt 
transcriptional targets that are expressed at the ISC crypt compartment. This 
highlights an important negative feedback mechanism of the Wnt pathway for ISC 
regulation.  
As discussed earlier, aberrant Wnt activation is observed in the majority of 
human CRCs. In most MSS tumours, Wnt/b-catenin signalling activation is driven by 
mutation in the APC gene that result in hyperproliferation of the stem cell 
compartment (Figure1.6). In the subset of non-APC mutated CRCs several other 
genetic alterations in Wnt antagonists have been described, such as AXIN2 and 
RNF43 (TCGA, 2012). This data suggests that, the Wnt negative feedbacks, 
generated by genes expressed at the stem cell compartment, are fundamental to 
maintain intestinal homeostasis.  
To gain insight into the Wnt negative feedback mechanism in CRCs, I 
analysed the publicly available genome-wide transcriptomic data from a large cohort 
of human CRCs (TCGA, 2012). Interestingly, hierarchical clustering analysis 
revealed a cluster of genes that are enriched in previously reported ISC markers, 
Wnt targets and/or Wnt inhibitors (see Chapter 3). From here onwards, this cluster 
will be referred to as the “Stem-Cell/Wnt cluster”. Notably, differential expression of 
various genes is observed among normal, MSI and MSS CRCs samples. In particular, 
most genes in this cluster show downregulated expression in MSI CRCs compared 
with MSS samples. This supports the notion that inhibition of the Wnt negative 
feedback mechanism is the alternative Wnt activating mechanism in MSI CRCs. We 
hypothesise that some of the genes within this “Stem-Cell/Wnt cluster” are Wnt 
inhibitors responsible for a negative feedback loop to fine-tune the levels of Wnt/b-
catenin signalling for tissue homeostasis (Figure 1.6).



























































































































































































































































































































































































































































































































The aim of my PhD thesis is to identify and characterise novel Wnt 
regulator(s) from the “Stem-Cell/Wnt cluster” that may play a crucial role in both ISC 
homeostasis and CRC development. I aim to gain insights into CRC biology through 
identification and characterisation of novel, potential Wnt inhibitors.  
I have shortlisted two potential novel Wnt regulators, ZAK and SH3BP4 based 
on the comprehensive analysis described in Chapter 3. The specific aims of my 
project are to determine: 1) the regulatory role of these two genes in the Wnt 
signalling pathway, and 2) their functional significance in intestinal homeostasis, 
regeneration and tumourigenesis.  
 
  




Chapter 2. Materials & Methods 
2.1 Cell culture, transfection and TOPFlash assay 
HEK293T, LS174T and SW480 cells were maintained in DMEM GlutaMAX 
(Gibco) supplemented with 5% foetal bovine serum (FBS) (Gibco) and 100 units/ml 
penicillin (Gibco) and 100 µg/ml streptomycin (Gibco). All cell lines were incubated 
in a humidified atmosphere of 5% CO2 at 37°C. Cells were seeded in plates 24hrs 
before transfection and plasmids were transfected using Polyethylenimine 
(Polysciences) according to the manufacturer’s instructions. For the TOPFlash 
luciferase assay, cells were seeded at a density of 1x105 cells/well in a 24-well plate 
one day before transfection. The cells were then transfected with 200ng of TopFlash 
or FopFlash plasmid constructs (optimal and mutate TCF luciferase-reporter 
constructs, respectively). The former consists of 5 binding motifs for TCF, cloned 
upstream of a minimal promoter, and the latter harbours mutations in those motifs as 
previously described (Korinek et al., 1997). Transfection efficiency was normalised 
against the co-transfected renilla luciferase activity (10ng/well). Control or Wnt3A-
conditioned medium was added to the cells 24hrs post-transfection, as indicated. 
Treated cells were lysed after 16hrs using luciferase lysis buffer (Promega), and 
luciferase activity was measured using the Dual-Luciferase-reporter assay system 
(Promega) in a luminometer. MAPK inhibitors (PD0325901, XMD8-92, SCH772984, 
SP600125 – Selleckchem) and Rapamycin (Sigma) or vehicle dimethyl sulfoxide 
(DMSO) were added simultaneously with Wnt3A as indicated.  
2.2 Cells gene Editing by CRISPR/Cas9 System 
To generate ZAK and SH3BP4 knock-out HEK293T cells, single guide RNAs 
(sgRNA) were designed for specific target regions, as previously described (Ran et 
al., 2013). HEK293T cells were transfected with plasmids encoding Cas9 and 
sgRNAs (PX459, #62988, Addgene, a gift from Feng Zhang lab). ZAK was targeted 
using the gRNA: 5’-TCGAGCCAAATGGATATCAC-3’ and SH3BP4 with the gRNA: 
5’-GGGCGACCATCTCTACGTCT-3’. LS174T cells were targeted for SH3BP4 
deletion with the same sgRNA. 48hrs after transfection, cells were selected using 
2µg/ml puromycin. Single, puromycin-resistant cells were selected and expanded for 




genomic DNA extraction. The targeted locus was then polymerase chain reaction 
(PCR) amplified and subcloned into a TA-cloning vector. Indel mutations were 
confirmed by sequencing, and loss of protein by Western blot (see primers for 
genotyping in Table 1 and antibodies used in Table 2). 
 
Table 1. List of primers used.  




Table 2. List of antibodies 
 
2.3 DNA cloning and plasmids 
Full-length ZAK, SH3BP4 and MACC1 were amplified by PCR from HEK293T 
cell genomic DNA. Briefly, 50ng of DNA was amplified using Phusion® High-Fidelity 
PCR Master Mix (Biolabs) using the following reagents: 0.5µM forward and reverse 
primers in 3% DMSO in volumes of 25 µl. The thermocycler consisted of 35 cycles 
of 98°C for 30s, 56-62°C (depending on the construct) for 30s, and 72°C for 30s per 
kilobase of amplification. PCR products were visualised and size verified on a 1% 




w/v agarose/TAE (40mM Tris-acetate, 20mM acetic acid, 1mM EDTA 
(ethylenediaminetetraacetic acid) in deionized water) gel containing 5ng/mL ethidium 
bromide. PCR products were cloned into pcDNA-FLAG plasmids using the In-
Fusion® DH Cloning Kit, according to the manufacturer’s instructions. Cloning 
primers with a XhoI cutting site were used to confirm insertion. 
The SH3BP4 dead domain constructs were generated using the In-Fusion® 
DH Cloning Kit with primers specifically designed for each domain. Each primer 
contained a homology arm of 15 base pairs (bp) (see primers in Table 1). 
The constructs with site directed mutagenesis were generated by PCR of the 
original construct with mutagenic primers (Table 1). Phusion® High-Fidelity PCR 
Master Mix was used and non-mutated parental DNA template was digested with the 
restriction endonuclease DpnI. 
2.4 Immunoblotting and immunoprecipitation 
Cells were lysed in cold lysis buffer containing 150 mM NaCl, 30 mM Tris (pH 
7.5), 1 mM EDTA, 1% Triton X-100, 10% Glycerol, 0.1 mM PMSF 
(phenylmethylsulfonyl fluoride), 0.5 mM DTT (dithiothreitol), protease inhibitor 
cocktail tablets (EDTA-free) (Roche), and phosphatase inhibitor cocktail tablets 
(Roche). Lysates were pelleted for 30 min at 13200 r.p.m. and supernatants kept for 
protein quantification (Bradford assay). Equal amounts of cellular protein were 
resolved in 10% sodium dodecyl sulfate–polyacrylamide gels (SDS-PAGE) and 
subsequently transferred to polyvinylidene difluoride (PVDF) membranes. 
Membranes were blocked using 5% milk (OXOID) or 5% bovine serum (BSA) 
(Sigma) for phosphorylated proteins immunoblots, in Tris-buffered saline TBS 
(50mM Tris, 150mM NaCl, pH7.6) containing 0.1% Tween-20 (Sigma) (TBST) for 1 
hour, and primary antibodies were added in blocking solution. See full list of 
antibodies and dilutions in Table 2. Primary antibody incubations were carried out at 
4°C overnight. After washing with TBST, the appropriate HRP-conjugated secondary 
was added (1:5000 in blocking buffer) for 2 hours at room temperature. Antibody 
binding was detected using chemiluminescence ECL Prime Western Blotting 
Substrate (GE Healthcare).  




For immunoprecipitation experiments, cells were washed and collected with 
the above indicated lysis buffer. After clarification by centrifugation (14,000 rpm for 
30 min at 4° C), cellular lysates were precleared with IgG-agarose beads (Millipore) 
for at least 2h at 4°C. Immunoprecipitation was performed by incubating the cellular 
lysates with the desired antibodies at 4°C overnight. SH3BP4 Knock-out cells 
(DSH3BP4) were generated by CRISPR to use as negative control and to validate 
the specificity of the interaction. Earlier truncation and loss of protein were confirmed 
by sequencing and western blot, respectively. Protein G PLUS-Agarose beads 
(Santa Cruz Biotechnology) were added and incubated at 4°C for 2-4hrs. 
Immunocomplexes were washed with cold lysis buffer six times, and resuspended in 
Laemmli-SDS sample buffer (50 mM Tris-HCl pH 6.8, 2% SDS, 10% glycerol, 1% β-
mercaptoethanol, 12.5 mM EDTA,0.02 % bromophenol blue). cocktail tablets 
(EDTA-free) (Roche), and phosphatase inhibitor cocktail tablets (Roche).  
2.5 Crypts/Villi fractionation 
Small intestine was washed with cold PBS and cut into small pieces. 
Sequential incubations with 1mM EDTA for 20min at 4°C were performed. The 
resulting fractions of crypts and villi (in increasing purities) were passed through a 
70µm cell strainer each time. Fractions from above and below the strainer were 
collected and checked under the microscope for purity. Fractions of similar purity 
were combined, and RNA extraction was performed using the RNeasy® Kit-Qiagen, 
according to the manufacturer’s protocol. 
2.6 Real-time quantitative RT-PCR 
 1µg of RNA was reverse transcribed to cDNA using the cDNA synthesis-
Thermo scientific kit, following the manufacturer’s instructions. qPCR was performed 
in triplicates in a 15µl reaction mixture containing 7.5μl of 2X SYBR green, 8μM of 
each primer and 25ng of cDNA. The reaction mixture without template cDNA was 
run as a control. After 40 cycles of cDNA amplification, samples were normalized to 
β-actin and data were expressed as mean ± standard error. 





Cells were grown on poly-L-lysine-coated (Sigma) glass coverslips in 12-well, 
fixed with 4% paraformaldehyde (PFA) for 15 min, and permeabilised using 0.5% 
Triton X-100 in PBS for 10 min. Cells were blocked with 1% BSA in PBS for 1h before 
overnight incubation with primary antibodies at 4°C. Cells were washed three times 
with PBS and incubated with secondary antibodies conjugated to Alexa-Fluor 488 or 
568 at room temperature for 1h in the dark. Cells were washed three times with PBS 
and stained with DAPI for 10 min. Coverslips were washed another three times with 
PBS and were then mounted with Aqua Poly/Mount (Polysciences). Images were 
taken using a Leica SPE confocal microscope. Each fluorophore was imaged 
separately using 405, 488 and 561 channels. Confocal images were taken as Z-
stacks and processed using Fiji (Schindelin et al., 2012). 
2.8 Immunohistochemistry  
Small intestine and colon tissues were fixed in 10% buffered formaldehyde 
for 16hrs time and embedded in paraffin. For staining, 4µm sections were de-
paraffinized using xylene and rehydrated through a graded series of ethanol. Antigen 
retrieval was performed for 20 min at high temperature in either 0.01M citrate buffer 
(pH6) or Tris-EDTA (10mM Tris base, 1mM EDTA solution, pH9). Samples were 
blocked using 1% BSA and incubated overnight with the desired antibody or negative 
control at 4°C. Finally, slides were incubated with the secondary antibody for 1h and 
washed three times with PBS. For colorimetric staining with diaminobenzidine (DAB) 
slides were incubated with peroxidase substrate, and mounted. Protein expression 
was visualised using a bright-field microscope.  
2.9 RNA in situ hybridization 
In situ hybridisation (ISH) for Lgr5, Olfm4, Axin2, Sh3bp4, Zak was performed 
using the RNAscope FFPE assay kit (Advanced Cell Diagnostics, Inc., Hayward, CA, 
USA) according to the manufacturer’s instructions. Briefly, 4µm formalin-fixed, 
paraffin-embedded tissue sections were pre-treated with heat and protease digestion 
before hybridisation with a target probe. Thereafter, an HRP-based signal 
amplification system was hybridised to the target probe before colour development 




with 3,3′-diaminobenzeidine tetrahydrochloride (DAB). The housekeeping gene Ppib 
served as a positive control. The DapB gene, which is derived from a bacterial gene 
sequence, was used as a negative control.  
 
2.10  Intestinal organoid culture and imaging 
Organoids were established from freshly isolated murine small intestine. 
Intestines were opened longitudinally, washed with PBS and incubated in cold PBS 
containing 2mM EDTA for 30 minutes under agitation. The mixture of crypts and villi 
were passed through 70µm cell strainer multiple times until a pure fraction of crypts 
was obtained. Crypts were counted using a microscope and 200 crypts were seeded 
in 20 µl of Cultrex® BME Type 2 RGF PathClear (Amsbio, 3533-010-02) in individual 
wells of a 24-well plate and cultured as previously described (Sato et al., 2009). The 
organoid basal media contains EGF (Invitrogen PMG8043), Noggin, Rspondin and 
Wnt3A. Noggin and R-spondin conditioned media were generated from HEK293T 
cells. Wnt3A conditioned media was generated from L cells. Images were acquired 
using EVOS FL Cell Imaging System (Life Technologies) and processed using Fiji 
(Schindelin et al., 2012). 
2.11  Mouse experiments 
All animals were maintained with appropriate care according to the United 
Kingdom Animal Scientific Procedures Act 1986 and the ethics guidelines of the 










The list of transgenic mice used is shown in Table 3.  
Mouse strains Genetic Background Reference 
Tg(CAG-Flpo)1Afst  C57BL/6 (Kranz et al., 2010) 
Apcmin C57BL/6 (Moser et al., 1990) 
VillinCreERT2 C57BL/6 (el Marjou et al., 2004) 
Sh3bp4tm1a(EUCOMM)Wtsi 
C57BL/6 Wellcome Trust Sanger 
Institute, 2010 
Sh3bp4fl/fl C57BL/6 In this study 
Sh3bp4fl/fl Apcmin C57BL/6 In this study 
Sh3bp4fl/fl VillinCreERT2 C57BL/6 In this study 
Zak-/- (CBAxC57BL/6)F1  In this study 
Table 3. List of transgenic mice used




2.11.1 Mouse generation by CRISPR/CAS9-mediated genome engineering 
ZAK-null (ZAK-/-) mouse. Generation of Cas9 mRNA and sgRNA were 
performed as previously described (Yang et al., 2014).  In vitro transcription of Cas9 
mRNA was done using the mMESSAGE Machine T7 Kit and MEGAclear kit following 
the manufacturer’s instruction. sgRNA was transcribed using the MEGAshortscript 
T7 kit, as per the kit protocol. C57BL/6 X CBA(F1) female mice were used as embryo 
donors and foster mothers.  Superovulated female mice (7– 8 weeks old) were mated 
to males, and fertilised embryos were collected from oviducts. Cas9 mRNAs (10ng 
from a 100 ng/µl stock) were injected into zygotes, and sgRNA (25ng from 50 ng/µl 
stock) was injected into the cytoplasm of fertilised eggs with well recognised 
pronuclei in M2 medium (Sigma).  Zygote injections were performed by the Genetic 
Manipulation Service at the Francis Crick Institute. Genotyping was performed by 
targeted gene sequencing in the Illumina Miseq System according to the 
manufacturer’s instructions (see primers in Table 1).  Briefly, PCR products were 
purified using Ampure XP reagent (A63881, Beckmann-Coulter) at 1.8X sample 
concentration.  Sequencing libraries were created by ligating adaptor sequences to 
the pooled DNA using the Ion Plus Fragment Library Kit (4471252, Life 
Technologies). 50 ng of purified PCR product was end-repaired and amplicons with 
adaptors were purified with Ampure XP reagent at 1.2X sample concentration. FastQ 
reads were mapped to the Mus musculus genome version 9 (mm9). 
 
Sh3bp4::FLAG knock in (KI) mouse. In vitro transcription of Cas9 mRNA 
and sgRNA were performed as described above. A single oligo was synthesised by 
Sigma. Zygotes of C57BL/6 mouse background were injected with a mixture 
composed of 10ng of Cas mRNA, 25ng of sgRNA and 20ng of the donor oligo (200 
ng/µl). Genomic DNA from the resulting animals was genotyped as described above. 
 
2.11.2 Genotyping and PCR amplification 
Genotyping was performed by PCR amplification of genomic DNA extracted 
from ear punch biopsies taken from mice aged three weeks. Appropriate primers 
were used for amplification of each allele (Table 1). Ear punch biopsies were 




digested in 200µl of lysis buffer (10mM Tris 7.5, 100mM NaCl, 10mM EDTA, 0.5% 
Sarkosyl) at 55°C overnight. 200ng of DNA was then amplified using MyTaq™ Red 
Mix (BIOLINE) 0.4µM forward and reverse primers in reaction volumes of 25 µl. The 
thermocycler consisted of 35 cycles of 95°C for 30s, 56-62°C (depending on the 
primer) for 30s, and 72°C for 1 minute per kilobase of amplification. PCR products 
were then visualised and size verified on a 2% w/v agarose/TAE gel with 5ng/mL 
ethidium bromide. 
 
2.11.3 EdU injections 
5-ethynyl-2’deoxyuridine (EdU) (Life Technologies) was injected 
intraperitoneally (0.3mg/10g of mouse weight) from a 10mg/ml stock solution. Mice 
were culled by schedule 1 procedure (SK1) at the desired time point.  
  
2.11.4 Induction of Cre  
Tamoxifen (Sigma) was injected intraperitoneally (1.5mg/10g mouse weight) 
from a 20mg/ml stock solution, over 3 consecutive days. Mice were culled at the 
desired time point by SK1. 
 
2.11.5 Radiation injury model 
Mice were exposed to controlled 10 Gray (10Gy) total body ionising radiation 
to induce damage. Mice were culled at the desired time points by SK1. 
 
2.12  Statistical analysis  
All data are presented as the mean ± the standard error of the mean. N refers 
to independent experiments. TOPFlash luciferase assay and qPCR measurements 
were performed in three technical replicates in at least three independent 
experiments. In vivo data corresponds to at least three independent experiments, if 
not otherwise stated. Radiation experiments and administration of substances were 
performed in groups of at least two animals (one wild-type control mouse and one 




full knock-out or conditional knock-out mouse, as indicated) at least in three 
independent experiments. Histological analysis and cell counting were performed 
blind.  
Quantification of positive cells for the indicated staining in villi and crypts were 
performed in 30 villi or crypts per animal in at least 3 animals per group, unless 
indicated otherwise. Cells were counted in the jejunum, if not indicated otherwise. 
The number of positive cells for the indicated staining in adenomas were performed 
in tissue sections. 5 adenomas, with sizes between 0.8 to 1 mm and similar grade of 
dysplasia were analysed from 6 different animals per group. Measurement of villi and 
crypts length were performed in 30 villi/region in 3 animals per group. 
Statistical analyses were performed using Graph Pad Prism software. Normal 
distribution of data was determined using the D’Agostino and Pearson omnibus test. 
For parametric data, statistical significance was determined using a student’s 
unpaired, two-tailed t-test. In cases where more than two groups were being 
compared, then a one-way ANOVA was used. In instances where the N was too 
small to determine normal distribution or the data were non-parametric, a two-tailed 
Mann-Whitney U-test was used. P values of less than or equal to 0.05 were 
considered statistically significant and are represented as ***P ≤ 0.001, **P ≤ 0.01, 
*P ≤0.05, non-significant (ns- p>0.05). 
 








In the adult intestine, it is well established that Wnt signalling plays 
complementary roles in physiology and pathology. Wnt signalling maintains the crypt 
stem cell compartment by controlling the level of the key downstream modulator b-
catenin for signal transduction through the cytoplasmic b-catenin destruction 
complex. However, mutations in key components of the Wnt pathway results in 
constitutive Wnt activation, which is a frequent event in CRC. As discussed in the 
introduction chapter, human CRC can be broadly classified into four molecular 
subtypes (CMS1-4) based on their gene expression profiles (Guinney et al., 2015). 
The CRCs cohort from the TCGA network has been broadly divided into two 
molecular subtypes, microsatellite instability (MSI) and microsatellite stable (MSS), 
based on their hypermutation profiles (TCGA, 2012). The vast majority of CRCs are 
MSS, where loss of the tumour suppressor APC signals the initiation of adenoma 
formation (Nagase and Nakamura, 1993), as has been suggested for the molecular 
subtypes CMS2,3 and 4. On the other hand, around 10-15% of CRCs are caused by 
defective DNA mismatch repair machinery and these are the MSI group (CMS1). 
These are characterised by the presence of insertions or deletions of nucleotides in 
microsatellite repeat regions, which are widespread across the genome (Ionov et al., 
1993; Thibodeau et al., 1993).  
Wnt signalling is aberrantly upregulated in both MSS and MSI tumours (TCGA, 
2012). The aberrant Wnt signal activation in MSS CRC is well characterised, with 
evidence of stem cell-specific loss of APC as the origin of intestinal neoplasia (Barker 
et al., 2009). Accumulation of other alterations such as additional mutations, 
epigenetic silencing, microenvironmental signals, or pathway crosstalk are further 
required to confer tumourigenesis and the progression from adenoma to carcinoma 
(Fearon, 2011; Zeuner et al., 2014). In MSI-CRCs, mutations in key components of 
the Wnt pathway, such as APC, β-catenin and Axin2 are only observed in a 




subpopulation (TCGA, 2012), suggesting an alternative Wnt-activating mechanism 
in this CRC subtype.    
Negative feedback control mechanisms are crucial in regulating various 
biological signalling pathways (Freeman, 2000). As discussed in chapter 1, precise 
control of Wnt signalling in the intestinal stem cell compartment is governed by a 
number of Wnt inhibitors and negative feedback mechanisms at different subcellular 
levels of the cascade. For example, several extracellular proteins such as SFRPs 
and DKKs, antagonise Wnt signalling by inhibiting Wnt protein engagement to Fz or 
LRP receptors (Cruciat and Niehrs, 2013). The secreted protein NOTUM also 
antagonizes WNT signalling by deacylating Wnt proteins (Kakugawa et al., 2015). In 
addition, the stem cell E3 ligases, ZNRF3 and RNF43, inhibit Wnt signalling by 
inducing rapid endocytosis of WNT receptors (Hao et al., 2012; Koo et al., 2012). 
The latter has also been shown to regulate WNT via sequestering the transcription 
factor TCF4 to the nuclear membrane (Loregger et al., 2015). The negative Wnt 
regulator AXIN2 represents another classic, negative feedback regulation that is 
upregulated upon Wnt activation to control the signalling activity (Lustig et al., 2002). 
Loss of the negative feedback loop could result in hyperactivation of WNT 
signalling and initiate tumour growth. In fact, mutations in several WNT inhibitors 
have been reported in some CRCs, as discussed in chapter 1. For example, somatic 
mutations in RNF43/ZNRF3 are found in some human CRC cell lines and patients 
(Giannakis et al., 2014; Koo et al., 2012), as well as in many other human cancer 
types (Assie et al., 2014; Furukawa et al., 2011; Jian Wu et al., 2011 ; Jiang et al., 
2013; Ong et al., 2012; Ryland et al., 2013; Yan et al., 2017). Inactivating mutations 
of AXIN2 are found predominantly in hypermutated CRCs (Koinuma et al., 2006). 
Interestingly, both RNF43 and AXIN2 Wnt inhibitors are expressed in the Wnt-active 
intestinal crypt base (Koinuma et al., 2006; Koo et al., 2012), suggesting the 
importance of the negative feedback loop for Wnt signalling control during intestinal 
stem cell homeostasis. Based on the close link between stem cell and cancer biology 
in the context of Wnt signalling, I aim to identify and characterise novel Wnt inhibitors 
that are involved in both intestinal stem cell control and tumourigenesis.  
Recent advances in Whole Genome Sequencing have generated large 
amounts of sequencing data from many series of human tumours. The studies 
generated by the Cancer Genome Atlas (TCGA) and other consortia have provided 
valuable resources for cancer research. Such findings have uncovered novel 




mutations in a large set of genes, many of which have not been characterised. The 
next step is to systematically analyse the data for a better understanding of human 
cancer. In 2012, the TCGA published a genome-scale analysis of a large cohort of 
human CRC that allows us to obtain the global gene expression profile of the cancer 
samples (TCGA, 2012). Hierarchical clustering analysis of the expression data 
revealed a differentially expressed gene cluster that consists of many reported 
intestinal stem cell markers, Wnt targets and Wnt inhibitors. From now on, this will 
be referred to as the “Stem-Cell/Wnt cluster”. I hypothesise that a subset of negative 
Wnt negative regulators expressed by stem cells are present within this cluster, and 
that deregulation of these inhibitors will interrupt the negative feedback loop and 
cause aberrant Wnt activation and cancer. Comprehensive analysis of the Stem-
Cell/Wnt cluster identified two novel putative Wnt inhibitors: the mixed-lineage zipper 
sterile-α-motif kinase (ZAK) and the SH3 binding domain protein 4 (SH3BP4).  
 
3.2 Results 
3.2.1 TCGA hierarchical clustering reveals a “Stem-cell/Wnt cluster”  
The TCGA had previously conducted genome-scale analysis of 276 CRC 
samples by analysing exome sequence, DNA copy number, promoter methylation, 
mRNA and microRNA expression (TCGA, 2012). All data was deposited at the Data 
Coordinating Center for public access (http://cancergenome.nih.gov/). To study the 
differential expression within a large cohort of CRC samples, we obtained the gene 
expression data of 173 colon samples from TCGA, all with known MLH1 silencing 
status and defined mutation profiles. The data were mean centred and genes with 2-
fold variation in at least 10 arrays were selected, resulting in 8379 differentially 
expressed genes. Hierarchical clustering analyses of these genes readily 
segregated the samples into different subgroups, including normal (19 cases), MSI 
(37 cases, based on MLH1 downregulation and hypermutation profile) and MSS-
CRCs (105 cases with non-hypermutated profile and downregulated APC 
expression) (Figure 3.1).  
Interestingly, we identified a cluster of 468 genes that showed relatively 
upregulated expression in MSS-CRCs, compared with both MSI-CRCs and normal 
tissue. Notably, many of the genes within this cluster have been reported to be 




intestinal stem cell markers (e.g. LGR5, ASCL2, AXIN2, RNF43) (Barker et al., 2007; 
Koo et al., 2012; Lim et al., 2013; van der Flier et al., 2009b), Wnt targets (e.g. LGR5, 
AXIN2, ASCL2, TCF7) (Lim et al., 2013; Sato et al., 2009; van der Flier et al., 2009b) 
and/or Wnt inhibitors (AXIN2, RNF43, ZNRF3, NKD1, NKD2, APCDD1) (Hao et al., 
2012; Koo et al., 2012; Lim et al., 2013; Shimomura et al., 2010; Van Raay et al., 
2007). We therefore named this cluster “Stem-Cell/Wnt cluster”. We hypothesised 
that the low expression in normal samples reflects the restricted expression of these 
genes to stem cell compartment, whilst the high expression in MSS CRCs is a result 
of a hyperactivated Wnt transcriptional programme. Interestingly, there is an isolated 
cluster of twelve samples with lower expression of the Wnt signature genes than in 
MSI and MSS. These samples are metastatic cancers with increased expression of 
TGFBI, a feature of CMS4 subtype. Therefore, I hypothesise that a subset of novel 
Wnt regulators are present within this Stem-Cell/Wnt cluster, and that these Wnt 
target genes may function as negative regulators of the pathway for the feedback 
mechanism 






Figure 3.1 TCGA hierarchical clustering reveals “Stem-cell/Wnt cluster” 
Heat map showing hierarchical clustering analysis of expression data in 173 CRCs, 
obtained from TCGA. Three individual subgroups (Normal, MSI- and MSS-CRCs) 
are clustered together. The Stem-Cell/Wnt cluster is enlarged on the right. 
Representative stem cell markers, Wnt targets and/or Wnt inhibitors are indicated. 
Expression profiles of APC and MLH1 are shown at the bottom, which correlates with 
MSI and MSS status. Scale bar in log2 ratio is given at the bottom (-3 to +3). Data 
were displayed using TreeView software. Red, upregulated; green, downregulated. 
 




3.2.2 Identification of novel putative Wnt regulators by comparing the Stem 
Cell/Wnt cluster with other microarray data  
We compared the Stem-Cell/Wnt cluster with other stem cell/Wnt-related 
microarray data to shortlist putative stem cell-expressed Wnt target genes. Several 
expression microarray studies characterising the Wnt transcription signature have 
been published in the past. Specifically, Sansom and colleagues have generated 
Wnt-activating transcriptomes in vivo, using an inducible Apc deletion mouse model 
(Apcfl/fl) (Sansom et al., 2004). The expression profile of the intestinal epithelium 
before and after Apc gene deletion was compared to identify hyperactivated Wnt 
targets. Another study compared the gene expression changes in ex vivo intestinal 
organoid culture upon R-spondin withdrawal (de Lau et al., 2011). As described 
earlier, R-spondin is a potent Wnt agonist and is an essential component of organoid 
culture medium to sustain intestinal stem cell maintenance (Sato et al., 2009). R-
spondin withdrawal will therefore result in downregulated expression of intestinal 
stem cell markers and Wnt target genes. 
To identify putative Wnt target genes expressed in stem cells in our Stem-
Cell/Wnt cluster, data from the two previously published Wnt target transcriptomes 
mentioned above (Apc deletion and R-spondin withdrawal) were retrieved for 
comparison. It should be noted that the Apc deletion in vivo experiment was prepared 
from full thickness intestinal tissues including lamina propria, submucosa and muscle 
layers, whilst the R-spondin withdrawal experiment was prepared in organoid culture 
consisting of epithelial cells alone. For the organoid R-spondin withdrawal 
experiment, the average fold-change in expression of putative Wnt target genes was 
taken between days 1 and day 3 for comparison. To focus on identifying stem 
cell/crypt-expressed genes, we first compared our data with the R-spondin array. 
This identified 51 out of 468 genes with at least 2-fold downregulated expression 
upon R-spondin withdrawal (Figure 3.2 – right). Among the 51 genes, 26 also 
showed more than 1.5-fold upregulated expression in the Apc deletion microarray 
study (Figure 3.2 – left and Table 4). 
To further shortlist the 26 candidates, we followed a comprehensive analysis 
represented in Figure 3.3. Firstly, we selected genes that had not been associated 
with Wnt signalling and/or stem cells and had not been analysed in intestine before. 




Secondly, we focused on genes with no more than two potential homologues to avoid 
redundancy during the mechanistic analysis and in vivo functional knock-out studies 
in mice. Eight genes fulfilled this two criteria: FAM60A, FLJ21865, ZAK, CYP39A1, 
SH3BP4, SPAG4, CKAP2, GGH. An extensive literature review finally shortlisted two 
promising candidates: the mixed-lineage zipper sterile-α-motif kinase (ZAK); and the 
SH3 binding domain protein 4 (SH3BP4), which will be discussed in detail in chapters 
4 and 5 respectively.





Figure 3.2 Expression pattern of the potential Wnt regulator candidates in stem 
cell/Wnt–related microarray studies. 
Heat map showing 51 potential stem cell/Wnt targets with >2-fold downregulated 
expression (average) upon R-spondin withdrawal in intestinal organoid culture. 
Differential expression of genes 5 days after Apc deletion in mouse intestine (left), 
and upon R-spondin withdrawal in intestinal organoid culture at day 1, 2 and 3 (right). 
Scale bar in log2 ratio is presented on the right (-2 to +2). Data were displayed using 
TreeView software. Red, upregulated; green, downregulated.





Table 4. List of 26 genes with 1.5-fold upregulated expression after Apc deletion





Figure 3.3 Schematic diagram of shortlisting strategy for putative Wnt regulators. 
Genes in grey were excluded for not fulfilling the specified criteria. ZAK and SH3BP4 
were the two top candidates. 
 
 
3.2.3 Expression pattern of the selected candidate genes Sh3bp4 and Zak in 
the intestine 
To validate if ZAK and SH3BP4 are stem-cell expressing Wnt regulators in 
intestine, we first isolated crypt- and villus-enriched fractions from wild-type C57BL/6 
mouse intestine and compared the mRNA expression of Zak and Sh3bp4 between 
the two fractions using quantitative RT-PCR (qPCR) analysis. As expected, the 
established stem cell genes, Lgr5 and Olfm4, were highly expressed in the crypt 
fraction, whilst the differentiated marker intestinal-type alkaline phosphatase (Alpi) 
was preferentially expressed in the villus fraction (Figure 3.4A). qPCR analysis also 
revealed nearly a 2-fold increase of both Zak and Sh3bp4 mRNA levels in the crypt 
fraction when compared with the villus fraction. This fold change is similar to the stem 
cell-expressed genes, Olfm4 and Lgr5.  
To further demonstrate the spatial expression of Sh3bp4 and Zak, RNAscope 
in situ hybridization (ISH) was performed in wild-type mouse intestinal tissues. Both 
Sh3bp4 and Zak showed enriched expression in the bottom crypt stem cell 




compartments in both small intestine and colon (Figure 3.4B). Co-staining with the 
stem cell marker, Lgr5, confirmed that both Sh3bp4 and Zak are co-localised with 
Lgr5 in the crypt base columnar cells (Figure 3.4C). 
Next, we analysed the protein expression of ZAK and SH3BP4. Unfortunately, 
no commercially available antibodies were able to detect ZAK or SH3BP4 in mouse 
intestinal tissues using immunohistochemistry (IHC). We then performed Western 
blot analysis of the lysate prepared from villus-enriched versus crypt-enriched 
fractions from C57BL/6 mouse intestine (Figure 3.5A). Enriched expression of both 
ZAK and OLFM4 was detected in the crypt fraction, suggesting that the protein 
correlates with the mRNA expression data analysed by both qPCR and RNAscope 
ISH. Since no commercially available antibodies against SH3BP4 were able to 
recognise mouse protein, we generated knock-in (KI) mice with a FLAG-tag fused to 
the C-terminus of the SH3BP4 protein. The Sh3bp4::FLAG mice were generated by 
CRISPR/Cas9-mediated genome engineering and the design strategy is 
represented in Figure 3.5B. Two single-guide RNAs (sgRNAs) were designed to 
target the Sh3bp4 locus at the 3’UTR region and create a double-strand break for 
homology direct repair. A single-stranded DNA oligo was designed with homology 
arms and two interspaced FLAG sequences. Three silent point mutations were 
created to avoid sgRNAs recognition at the donor DNA oligo. Cas9 mRNA, the 
single-stranded DNA oligo and sgRNA 1 or sgRNA2 were microinjected into one-cell 
mouse embryos at pronuclear stage as previously described (Yang et al., 2014). 
Initially, all seven pups derived following sgRNA1 injection were wild-type. 
Subsequent sgRNA2 injections yielded 24 pups with only one showing incorporation 
of the donor FLAG-sequence KI. The insertion was confirmed by an increase of 57bp 
in the PCR size amplicon (Figure 3.5C). The correct orientation and insertion was 
further confirmed by sequencing. One allele contained the correct FLAG-sequence 
insertion, whereas the other allele was disrupted by non-homologous end joining 
(NHEJ). This founder mouse was then used for breeding, where germline 
transmission of the KI allele was observed in the F1 generation. Unfortunately, we 
were unable to detect FLAG expression by either Western blotting or IHC analysis in 
the heterozygous KI animal despite the correct sequence insertion. This could be 
due to either low protein abundance or incorrect protein folding. Homozygous 
animals are now being generated to see if the protein can be detected.  
 





Figure 3.4 Expression pattern of the selected candidate genes, Sh3bp4 and Zak, 
in the intestine. 
(A) Q-PCR analysis showing Sh3bp4 and Zak mRNA expression levels in crypt- and 
villus-enriched fractions isolated from C57BL/6J wild-type mouse intestine. Stem cell 
markers Olfm4, Lgr5 and the enterocyte marker Alpi were used as a control for the 
two fractions (error bars represent averages ± SD from 3 independent experiments, 
N=3). (B) Representative images of RNAscope ISH showing Sh3bp4 and Zak gene 
expression in small intestine (left) and colon (right). (C) Representative images of 
RNAscope ISH showing co-localisation of Sh3bp4 and Zak with Lgr5 within the stem 
cell region. Arrows indicate co-localised staining. Scale bars, 100µm; scale bars of 
insets, co-expression images and colon, 50µm.






Figure 3.5 ZAK and SH3BP4 protein expression analysis. 
(A) ZAK protein levels in the villus- and crypt-enriched fractions of wild-type mouse 
intestine. Western blot analysis showing enriched expression of ZAK and OLFM4 in 
crypts (representative image of n=3). (B) Schematic representation of the 
Sh3bp4::FLAG KI CRISPR/Cas9-targeting strategy. The top sequence shows the 
wild-type endogenous mouse chromosome sequence. The sgRNA1 is highlighted in 
dark blue and sgRNA2 highlighted in light blue. The bottom sequence shows the 
designed single-stranded DNA donor oligonucleotide. The 5’ and 3’ homology arms 
are indicated. Two Flag sequences are inserted before the stop codon interspaced 
with 9bp.Three point mutations are indicated with red asterisks. (C) PCR genotyping 
of the wild-type (WT), heterozygous (HET) and homozygous (HOM) Sh3bp4::FLAG 
KI animals. PCR amplicon of WT DNA yields a 323bp fragment, whereas the 
successful Sh3bp4::FLAG KI yields a larger 380bp amplicon.




3.2.4 Validation of Zak and Sh3bp4 as Wnt target genes 
To confirm if indeed Zak and Sh3bp4 expression is increased upon Wnt 
signalling activation, we performed RNAscope in intestinal tissue from the Apcmin 
mouse model (Figure 3.6A). Both Sh3bp4 and Zak showed enriched expression in 
Apcmin adenomas in comparison to adjacent normal tissue (Figure 3.6A). We then 
performed qPCR analysis in wild-type organoids and in organoids with Apc 
truncation. Briefly, APC mutation (ΔAPC) was generated in organoids isolated from 
wild-type mouse using CRISPR-targeting, resulting in a truncated form of APC losing 
all the 20 amino acid repeats. These organoids persist as cysts as a result of 
hyperactivation of Wnt signalling (Novellasdemunt et al, accepted for publication). 
As expected, we observed a strong increase in Zak (~4-fold) and Sh3bp4 (2-fold) 
expression (Figure 3.6B). In addition, we performed immunohistochemistry staining 
against SH3BP4 in human colorectal cancer samples (Figure 3.6C). As in mouse, 
SH3BP4 was exclusively expressed at the bottom of the crypt in normal adjacent 
tissue and is increased in tumour tissue. Together, this data corroborated the notion 
that both Zak and Sh3bp4 expression is modulated by Wnt/b-catenin signalling. 





Figure 3.6 Zak and Sh3bp4 expression are increased in Apcmin adenomas. 
(A) Representative images of RNAscope ISH showing Sh3bp4 and Zak gene 
expression in normal adjacent tissue and Apcmin adenomas (B) Quantitative RT-
qPCR showing activation of Sh3bp4 and Zak expression in wild-type organoids 
compared to Apc-mutated organoids. Expression data are presented as fold 
induction relative to GAPDH. Error bars represent averages ± SD from 3 independent 
experiments (N=3). ***P< 0.001. (C) SH3BP4 staining in a human sample of CRC.  
Scale bars, 100µm, scale bars of insets, 50µm.




3.2.5 Mutations identified in public databases  
Finally, we asked whether there was any genetic alteration of ZAK or SH3BP4 
reported in human CRC samples, which may provide further supportive evidence for 
their functional significance in tumourigenesis. The TCGA sequencing data showed 
that mutations of ZAK and SH3BP4 are present, but only rarely with an alteration 
frequency of approximately 2% found in 212 CRC cases (Figure 3.7A). A more recent 
sequencing study from the Dana-Farber/Harvard Cancer Center with a larger cohort 
of CRCs (619 cases) showed a slightly higher SH3BP4 mutation rate (3.4%, 21/619). 
Mutations of both ZAK and SH3BP4 in CRCs are distributed across the whole gene 
without any hotspot (Figure 3.7B). The majority of the mutations identified are 
missense, although two truncating mutations are found in both ZAK and SH3BP4. 
Interestingly, the two truncating mutations identified in ZAK are located at 
mononucleotide repeats, c.659delA at A7 repeats and c.2296delG at G5 repeats. 
Interestingly, c.659delA was also reported in a gastric cancer sample, whilst another 
mutation c.657_658insA at the same A7 repeat region was found in a lung cancer 
patient. Similarly, the truncating mutation identified in SH3BP4 by TCGA (c.581delT) 
is also located at T5 repeats. It is well known that MSI patients are prone to 
accumulate mutations at short nucleotide repeats due to the defective mismatch 
repair system. This may explain the association of downregulated expression of ZAK 
and SH3BP4 with MSI CRCs.  Further studies will be needed to characterise the 
functional significance of other specific missense mutations in CRC development.





Figure 3.7 Mutations of ZAK and SH3BP4 found in human colorectal cancer. 
(A) Alteration frequency of ZAK and SH3BP4 in CRCs in the TCGA (2012) and the 
DCFI (2016) studies. Data was obtained from the cBioPortal. (B) Graphical view of 
the mutations distributed across SH3BP4 and ZAK genes (cBioPortal (Cerami et al., 
2012)). Green dot represents missense mutations, black dot represents truncating 
mutations, brown dot represents in-frame mutations and purple dot represents 
mutations in splice region.





The advances in high-throughput sequencing over recent decades have 
provided valuable insights into the molecular events underlying CRC biology.  It has 
become clear that CRC is a heterogeneous and complex disease. Multiple signalling 
pathways are involved in CRC initiation and progression. In particular, 
hyperactivation of the Wnt signalling pathway is the hallmark of CRC. In addition to 
the APC gene, many other Wnt signalling components are mutated in CRCs. Loss-
of-function mutations in negative Wnt regulators, such as AXIN2 and RNF43, also 
appear to be common in non-APC mutated CRC. Interestingly, most of these Wnt 
regulators also play a crucial role in normal intestinal homeostasis. Expression of 
these negative Wnt regulators in the intestinal stem cells further highlights the 
importance of precise control of the Wnt signalling at the “just-right” level via negative 
feedback mechanisms during normal tissue homeostasis. In this chapter, we focused 
on uncovering novel, potential Wnt regulators that are involved in both intestinal 
homeostasis and CRC development.  
Expression profile analysis of the TCGA data identified a Stem-Cell/Wnt 
cluster that consists of several stem cell-expressed Wnt target genes. A number of 
them, such as AXIN2, RNF43, ZNRF3, NKD and WIF, have also been reported as 
negative Wnt regulators. Interestingly, genes in this cluster show differential 
expression between MSI and MSS-CRCs. In the majority of MSS-CRCs, Wnt 
activation upon APC loss results in general stem cell/Wnt target expansion (thus 
upregulated expression in the MSS-CRCs). Unlike in MSS tumours, MSI-CRCs 
might activate Wnt signalling through an alternative mechanism. For instance, 
mutations or epigenetic silencing of some Wnt inhibitors (e.g. AXIN2, SFRP1-5, 
WIF1) have been described in MSI tumours (Esteller et al., 2000; Fu et al., 2012; 
Koinuma et al., 2006; Murakami et al., 2014; Silva et al., 2014). We suggest that an 
overall downregulated expression in MSI-CRCs relative to MSS-tumours in the 
Stem-cell/Wnt cluster may represent an alternative Wnt-activating mechanism for 
non-APC mutated cancers by targeting the Wnt negative feedback mechanism at the 
stem cell region. Therefore, I hypothesised that many of the genes within this cluster 
are Wnt regulators exclusively expressed at the bottom of the crypt. Indeed, the 
genes within the cluster show relatively low expression in the normal cluster, 




supporting the notion of restricted expression in normal intestinal tissue. It should be 
noted that other secretory Wnt inhibitors such as SFRP1 and DKK1-4 are expressed 
mostly in the mesenchyme rather than the stem cell region, and are thus located in 
different clusters. 
Comparison of the gene expression profile in the Stem-cell/Wnt cluster with 
the Rspo1 withdrawal and the Apc deletion signatures allowed us to further shortlist 
genes that respond to changes in Wnt signalling. Among the 26 shortlisted 
candidates, we have selected ZAK and SH3BP4 for further downstream analysis 
based on literature review. ZAK is a member of the mixed-lineage kinases (MLKs) 
family (Gotoh et al., 2001). The role of ZAK in cancer development is controversial. 
The discrepancies between different studies could possibly be explained by the 
multiple roles of ZAK in activating distinct MAPK pathways in different cell types. 
Studies showing a direct role of the MLK family in Wnt signalling, and particularly 
ZAK, are limited and will be discussed in detail in the next chapter. SH3BP4 has 
multiple motifs including SH3 domains, 3 Asn-Pro-Phe (NPF) motifs and ZU5 
domains, suggesting multi-functional roles in various cellular processes. SH3BP4 
has been reported to regulate the mammalian target of rapamycin (mTOR) signalling 
(Kim et al., 2012b), whilst its role in Wnt/b-catenin signalling or intestine has not been 
studied.  
To study the role of ZAK and SH3BP4 in intestinal homeostasis and cancer, 
we first tested whether the two putative Wnt target genes were expressed in the stem 
cells compartment. Both qPCR and RNAscope analysis confirmed that stem cells 
expressed the two genes in the base of intestinal crypts. Increased expression of 
ZAK and SH3BP4 were also observed in the tumours of the APCmin intestinal tissues, 
supporting the microarray data. The results suggest that ZAK and SH3BP4 are 
indeed Wnt targets expressed by stem cells. I propose that ZAK and SH3BP4 may 
create a negative feedback loop to fine-tune the levels of Wnt signalling within the 
stem cell region during normal tissue homeostasis. Characterising the functional role 
of these Wnt inhibitors may help to shed light on new therapeutic strategies for 
treatment of CRCs. The role of ZAK and SH3BP4 in Wnt signalling regulation and 
intestinal homeostasis will be analysed in detail in the following chapters. 
 




Chapter 4. The ZAK kinase is a Wnt negative 




The mitogen-activated protein kinase (MAPK) pathway consists of three 
sequentially activated protein kinases: MAPK kinase kinase (MAP3K), MAPK kinase 
(MAP2K) and MAPK (Chang and Karin, 2001; Nishida and Gotoh, 1993; Robinson 
and Cobb, 1997). It is a highly conserved signalling pathway that transduces a signal 
from the surface receptor to nuclear DNA transcription in response to different 
environmental stimuli via a three-step kinase cascade activation. ZAK (also known 
as MAP3K20) is a sterile-a-motif (SAM) and leucine zipper-containing protein that 
belongs to a subfamily of serine/threonine MAP3Ks known as mixed-lineage kinases 
(MLKs) (Gallo and Johnson, 2002; Gotoh et al., 2001; Liu et al., 2000a). Several 
studies have shown that ZAK is part of the signal transduction cascade that regulates 
extracellular signal-regulated kinase (ERK), c-Jun N-terminal kinase (JNK), and p38 
(Cho et al., 2004; Gotoh et al., 2001; Liu et al., 2000a; Yang, 2002). 
ZAK is expressed in many tissues including heart, skeletal muscle, lung, liver 
pancreas (Liu et al., 2000a), as well as in intestine as shown in chapter 3. ZAK has 
two alternative splicing isoforms: ZAKα and ZAKb (Gotoh et al., 2001; Liu et al., 
2000a). ZAKα, the longer isoform, encodes an 800 amino acid protein that contains 
a kinase catalytic domain, a leucine zipper domain (LZ), and a SAM (Figure 4.1A). 
The kinase domain of ZAK is encoded by exon 2, consists of 245 amino acids (from 
16-260) and is responsible for serine/threonine phosphorylation of its substrates (Liu 
et al., 2000a). The LZ domain can mediate the homodimerisation of many MLKs 
members and is critical for ZAK’s autophosphorylation (Nihalani et al., 2000). The 
SAM domain consists of 74 amino acids (from amino acid 336 to 410) and is 
exclusively present in the longer isoform, ZAKa. Some studies have demonstrated 
that the SAM domain functions as a protein interaction domain (Stapleton et al., 
1999). ZAKb consists of 455 amino acids and shares the same N-terminal protein 
sequence but terminates shortly after the catalytic domain. This shorter isoform 




contains a conserved, unique C-terminal extension of 124 amino acids, which 
includes an extended acidic patch (Gotoh et al., 2001; Liu et al., 2014b). 
ZAK has been implicated in cancer development however, its role remains 
controversial. Several studies have proposed ZAK to be an oncogene. 
Overexpression of ZAK in skin epidermal cells resulted in neoplastic cell 
transformation when injected subcutaneously into athymic nude mice (Cho et al., 
2004). In addition, knockdown of ZAK inhibits proliferation in gastric cell lines (Liu et 
al., 2014b). On the other hand, overexpression of ZAK resulted in cell death in a 
hepatoma cell line (Liu et al., 2000a) and inhibited cell proliferation in embryonic 
fibroblasts (Yang, 2002) and lung cancer cells (Yang et al., 2010). The discrepancy 
between these results could be due to the diverse roles of ZAK in activating distinct 
MAPK pathways in different cell types. In addition, ZAK has also been reported to be 
expressed in different subcellular compartments in various cell types (Choi et al., 
2005; Gotoh et al., 2001). Several studies have further suggested that the two 
isoforms may have distinct biological functions (Gotoh et al., 2001; Liu et al., 2014b).  
Some studies have described an association between ZAK and Wnt 
signalling and CRC development. Firestein and colleagues have performed a RNAi-
based loss-of-function screen which identified ZAK as one of the top nine candidates 
to modulate both b-catenin-dependent transcription (in DLD1 cells) and colon cancer 
cell proliferation (HCT116 cells) (Firestein et al., 2008). However, only CDK8, one of 
the top candidates, was further characterise (Firestein et al., 2008) and the 
mechanistic role of ZAK in has not been studied. Furthermore, a genome-wide 
sequencing study showed significant upregulation of the ZAKα isoform in gastric 
cancers as well as in CRCs (Liu et al., 2014b). In this study, Liu and colleagues have 
analysed the effect of ZAK in several cancer-related signalling reporters and have 
shown that ZAK is capable of modulating the transcription activity of AP1, NFkB and 
particularly, the Wnt signalling TCF/LEF reporter assay (Liu et al., 2014b). On the 
other hand, ZAK has been reported to regulate expression of the SOX protein 
(Suzuki et al., 2012). Interestingly, increasing evidence suggests that many SOX 
proteins can physically interact with b-catenin and modulate b-catenin/TCF 
transcriptional activity (Kormish et al., 2010).  
As discussed in Chapter 1, crosstalk between Wnt signalling and other 
pathways is important for CRC progression. Given the potential function of ZAK in 




activating different MAPK pathways, it is worth discuss the crosstalk between 
different MAPKs and Wnt/b-catenin signalling in intestinal homeostasis and cancer.  
p38 MAPK is often deregulated in cancers but a molecular understanding of 
how p38 family members function either as tumour suppressors or oncoproteins 
remains unclear. Previous studies showed that p38 negatively regulates cell cycle 
progression (Hui et al., 2007) and induces apoptosis (Cai et al., 2006), supporting 
the notion of a role for p38 as tumour suppressor. In addition, p38 activation has 
been shown to trigger differentiation and a less transformed phenotype in colon 
cancer cell lines (Houde et al., 2001; Ordonez-Moran et al., 2008). In an in vivo 
mouse model, downregulation of p38 in intestinal epithelial cells resulted in increased 
proliferation and reduced enteroendrocrine and goblet cell differentiation in colon 
(Gupta et al., 2014). On the other hand, another study showed that p38 can directly 
phosphorylate and inactivate GSK3b, which could potentially result in an 
accumulation of b-catenin (Thornton et al., 2008). 
A study from Jeong and colleagues has shown evidence of crosstalk between 
ERK and Wnt/b-catenin signalling in the intestine. The study revealed that Wnt/b-
catenin signalling activation promotes both b-catenin and Ras stabilisation through 
the phosphorylation-ubiquitination axis mediated by the b-catenin destruction 
complex (Jeong et al., 2012). The data suggests that aberrant Wnt activation 
promotes intestinal tumorigenesis by synergistic activation of both b-catenin and 
RAS/ERK signalling. The role of MEK1/Shp2/MAPK signalling in controlling intestinal 
stem cell fate has also been reported; Heuberger and colleagues showed that the 
level of MAPK signalling determines the choice between goblet and Paneth cell fate 
(Heuberger et al., 2014). MAPK inhibition enhances Wnt/b-catenin signalling and 
promotes Paneth cells differentiation, whereas high MAPK activity or inhibition of 
Wnt signalling favours goblet cell differentiation. The study further showed that 
MAPK inhibition promotes preferential expression of the longer TCF4 isoform 
(Heuberger et al., 2014), which consists of a binding site for the transcription factor 
carboxyl-terminal binding protein (CtBP) and a C-terminal DNA binding domain 
(Weise et al., 2010). A more recent study using the organoid culture system also 
showed that ERK/MAPK signalling, downstream of EGFR, is required for the 
proliferation of Lgr5+ cells, whereas inhibition of MAPK/Wnt/Notch signalling is 
required for enteroendocrine cell differentiation (Basak et al., 2016).  




The crosstalk between JNK and Wnt signalling is less characterised. JNK has 
been shown to antagonise Wnt/b-catenin signalling in Xenopus embryos, whilst 
activation of JNK signalling in mammalian cells reduces b-catenin-mediated gene 
expression by targeting its nuclear export (Liao et al., 2006). MAP3K1 has previously 
been shown to modulate JNK activity via MMK4 (Yan et al., 1994). Interestingly, 
MAP3K1 was also found to modulate Wnt signalling activity by interacting with AXIN1 
(Sue Ng et al., 2010), although the substrate of MAP3K1 within the Wnt cascade has 
not yet been revealed.  
Taken together, it is still unclear how the crosstalk between MAPK and Wnt 
signalling regulates intestinal homeostasis and tumorigenesis. As discussed earlier, 
ZAK has been implicated in Wnt signalling and cancer, although its mechanistic role 
has not been studied. Our current data suggest that the stem cell/crypt-expressing 
ZAK is likely a Wnt target gene that may serve as a feedback regulator of the pathway. 
In this chapter, I explore the role of ZAK in Wnt signalling and intestinal homeostasis. 
In particular, I aim to characterise whether the Wnt regulatory role of ZAK is 
dependent or independent of MAPK activity. 
 
4.2 Results 
4.2.1 ZAK is a negative regulator of Wnt/b-catenin signalling 
In the previous chapter, we identified ZAK as a putative Wnt regulator 
localised in the Stem-Cell/Wnt cluster. Expression of Zak is restricted to the Wnt-
active crypt compartment, and enriched expression in Apc mutated tumours and 
organoids further suggest that Zak is a Wnt transcriptional target. Moreover, we have 
confirmed the co-expression of Zak and Lgr5 in intestinal crypts, to study the role of 
ZAK in regulating Wnt/b-catenin signalling, HEK293T cells with intact Wnt signalling 
cascade, were used for initial gain-of-function and loss-of-function studies. Deletion 
of ZAK in HEK293T cells was performed using the CRISPR/Cas9 gene editing 
system via non-homologous end-joining (NHEJ). Single-guide RNA (sgRNA) 
targeting exon2, which contains the start codon and the kinase domain, was 
designed to mutate both ZAK isoforms. The CRISPR-targeted clone (DZAK) was 
generated and homozygous frameshift mutations were confirmed by sequencing 




(Figure 4.1B). One allele contains a 189bp insertion that results in a truncated 
product of 42 amino acids. The second allele harbours a 10bp deletion also causing 
an earlier truncation at residue 88. Nucleotide sequences and predicted amino acid 
sequences are shown in appendix 1. The TCF-TopFlash luciferase reporter assay 
was used to measure Wnt/TCF transcriptional activity in the subsequent experiments 
(see chapter 2 for more details). 
As shown in Figure 4.1C, depletion of ZAK resulted in more than a 2-fold 
increase in Wnt3A-induced TCF-TopFlash reporter activity in HEK293T cells. In the 
reverse experiment, overexpression of wild-type ZAK significantly suppressed 
Wnt3A-induced TCF-TopFLASH reporter activity, suggesting that ZAK is a negative 
Wnt regulator (Figure 4.1D). To address whether the kinase function of the protein 
is responsible for inhibiting Wnt signalling, we generated a kinase-dead mutant 
version of ZAK by site-directed mutagenesis at lysine 45, the ATP binding site of the 
kinase (ZAKK45A) (Gross et al., 2002). In contrast to the wild-type protein, expression 
of ZAKK45A kinase mutant failed to inhibit Wnt3A-induced TCF-TopFLASH reporter 
activity, suggesting that the kinase activity of ZAK is indeed required to inhibit Wnt/b-
catenin signalling in mammalian cells. To further confirm the negative Wnt regulatory 
role of ZAK, we performed a rescue experiment by overexpressing ZAK in the DZAK 
mutant cells. As expected, the increase in Wnt3A-induced TCF-TopFLASH reporter 
activity upon ZAK depletion was readily rescued by expression of wild-type ZAK 
protein (Figure 4.1E). On the other hand, expression of ZAKK45A kinase mutant failed 
to inhibit the upregulated Wnt signalling caused by ZAK deletion. The TCF-reporter 
data was further confirmed by western blot analysis using an antibody against active 
b-catenin (non-phosphorylated form) (Figure 4.1F). Consistent with the TCF reporter 
data, b-catenin level was upregulated in DZAK compared to wild-type HEK293T cells 
(lane 1 and lane 2), whilst the upregulated b-catenin level was inhibited by 
expression of wild-type ZAK (lane 3) but not ZAKK45A mutant (lane 4). Together, the 
data support the notion that the ZAK kinase plays an inhibitory role in Wnt/b-catenin 
signalling.









Figure 4.1 ZAK inhibits Wnt/b-catenin signalling. 
(A) Domain structure of ZAKa and ZAKb isoforms. ZAKα is the longer isoform and 
encodes an 800 amino acids protein. ZAKb is the shorter isoform and is composed 
by 455 amino acids. Both isoforms contain a kinase catalytic domain (in red) encoded 
by exon 2. The kinase domain consists of 245 amino acids and is responsible for 
serine/threonine phosphorylation. The leucine zipper domain (LZ – in blue, 22 amino 
acids) is also shared by the two isoforms and it can mediate the homodimerisation 
of many MLKs. The sterile-α-motif (SAM –light blue) consists of 74 amino acids and 
it is only present in ZAKa. This domain seems to function as a protein-protein 
interaction domain. Both isoforms share the N-terminus but ZAKb has a unique C-
terminal region, which includes an extended acidic patch. (B) Schematic 
representation of the CRISPR/Cas9 targeting at Zak exon 2. Frameshift mutations 
detected in the selected HEK293T clone, M1 and M2, are indicated. (C) TCF-
TopFlash reporter assay showing an increase in Wnt signalling activity in DZAK 
versus WT HEK293T cells treated with Wnt3A condition medium. (D) Relative TCF-
TopFlash reporter activity in Wnt3A-induced HEK293T cells with co-expression of 
the indicated plasmids. (E) Relative TCF-TopFlash reporter activity in Wnt3A-
induced wild-type HEK293T cells or DZAK cells co-expressing the indicated 
plasmids. (F) Western blot analysis of samples obtained from (E) using the indicated 
antibodies. The Top and Fop signals were normalised to the renilla luciferase signal 
and average from three independent experiments are shown (N=3). The error bars 
represent +SD. ***P £0.001, **P £0.01 and *P £0.05. 
 




4.2.2 The Wnt negative regulator ZAK functions downstream of b-catenin 
phosphorylation/ubiquitination 
To dissect the mechanistic role of ZAK in Wnt/b-catenin signalling regulation, 
we investigated ZAK’s potential to inhibit the signalling cascade at different 
subcellular levels (membrane receptor and cytoplasmic destruction complex), using 
various Wnt activation models. A mutant form of LRP6 lacking the extracellular 
domain (DN-LRP6) has been reported as a constitutively activated Wnt receptor (Liu 
et al., 2003). The PPPSPxS motif of DN-LRP6 is constitutively phosphorylated, 
generating a persistent docking site for AXIN that mimics the membrane recruitment 
of the AXIN-destruction complex upon Wnt induction. Similar to the Wnt3A induction 
experiment, expression of wild-type ZAK, but not the ZAKK45A mutant, significantly 
inhibited DN-LRP6-induced Wnt/b-catenin activation (Figure 4.2A). The result 
suggests that ZAK inhibits Wnt signalling downstream of LRP6 phosphorylation. Next, 
we tested whether ZAK can inhibit Wnt signalling activated at the destruction 
complex level using two different models. First, we used a constitutively active form 
of b-catenin in which serine 33 was mutated to tyrosine (bCatS33Y), destroying the 
GSK3b-mediated phosphorylation site. Similarly, whilst the wild-type ZAK was able 
to suppress bCatS33Y-induced Wnt activation, the ZAKK45A mutant failed to execute 
such inhibition (Figure 4.2B). In a second model, we used an APC-truncated isogenic 
mutant line generated for a separate project in the lab. Briefly, an APC mutation at 
1225 amino acids was generated in HEK293T cells using CRISPR-targeting 
(HEK293T ΔAPC), resulting in a truncated form of APC losing all the 20 amino acid 
repeats. Data from our lab confirmed that the ΔAPC mutant significantly activates 
Wnt signalling (>1000 fold TCF-TOPFlash activity) by suppressing b-catenin 
ubquitination despite normal phosphorylation (Novellasdemunt et al., 2017). Once 
again, expression of wild-type ZAK, but not the ZAKK45A kinase mutant, inhibited the 
Wnt/b-catenin signalling in HEK293TΔAPC (Figure 4.2C). Together, the data support 
a model in which ZAK inhibits Wnt/b-catenin signalling downstream of b-catenin 
phosphorylation and ubiquitination. Interestingly, immunofluorescent staining of 
FLAG-ZAK expression in HEK293T cells revealed an exclusive cytoplasmic 
localisation of the protein (Figure 4.2D). The absence of the protein in the nucleus 
suggests that ZAK may function upstream of b-catenin/TCF transcription. Further 




investigation will be needed to characterise the precise role of ZAK in the Wnt 
signalling cascade. 
As mentioned earlier, ZAK has been reported to activate several MAPK 
pathways, in particular MEK1/2, JNK, and p38. To study if the Wnt inhibitory role of 
ZAK is dependent on MAPKs activation, I repeated the experiments using various 
MAPK inhibitors in one of the Wnt-activating models (HEK293TΔAPC). If ZAK’s 
negative Wnt regulatory role is mediated via a specific MAPK activation, treatment 
of the appropriate MAPK inhibitor should rescue the Wnt inhibitory effect observed 
in the HEK293TΔAPC cells. Wild-type and the kinase-mutant ZAK were expressed 
in HEK293TΔAPC cells treated with individual MAPK inhibitors, including 
MEK1/MEK2 inhibitor (SCH772984), JNK inhibitor (SP600125), p38 inhibitor 
(SB202190), and ERK5 inhibitor (XDM8-92) (Figure 4.3). Interestingly, treatment 
with various MAPK inhibitors did not affect the capacity of wild-type ZAK in 
suppressing Wnt/b-catenin signalling, suggesting that the Wnt regulatory role played 
by ZAK is independent of MAPK signalling. Further studies of combined treatment of 
various MAPK inhibitors will be important to rule out any crosstalk effect of different 
MAPK pathways on Wnt signalling. In summary, our data suggest that ZAK inhibits 
Wnt/b-catenin signalling downstream of b-catenin phosphorylation and ubiquitination, 
independently of either MEK1/2, JNK, p38 or ERK5 pathways alone.
 





Figure 4.2 ZAK inhibits Wnt signalling downstream of b-catenin phosphorylation 
and ubiquitination. 
(A) Relative TCF-TopFlash reporter activity induced by LRP6 expression construct 
lacking the extracellular domain (DN-LRP6). DN-LRP6 was co-expressed with 
empty-vector (EV), ZAK or ZAKK45A in HEK293T cells. (B). EV, ZAK or ZAKK45A 
constructs were co-expressed with the constitutively active b-catenin mutated at 
serine 33 (bCatS33Y). ZAK is capable of suppressing TCF-TopFlash reporter 
induced by bCatS33Y. (C) HEK293T cells containing a truncated form of the APC 
protein (HEK293TΔAPC) were transfected with EV, ZAK or ZAKK45A. ZAK but not 
ZAKK45A supresses TCF-TopFlash luciferase reporter signal. (D) Immunofluorescent 
staining of FLAG-ZAK using an antibody against FLAG epitope showing exclusive 
cytoplasmic localisation. The Top and Fop signals were normalised to the renilla 
luciferase signal and average from three independent experiments are shown (N=3). 
The error bars represent +SD. ***P £0.001 and **P £0.01.





Figure 4.3 The Wnt inhibitory role of ZAK is independent of MAPK signalling. 
Relative TCF-TopFlash reporter activity of HEK293TΔAPC cells expressing empty 
vector, ZAK or ZAKK45A construct treated with the indicated MAPK inhibitors for 
24hours: (A) 10 µM of MEK1/2 inhibitor (SCH772984), (B) 5µM of JNK inhibitor 
(SP600125), (C) 5µM of p38 inhibitor (SB202190) and (D) 10 µM of ERK5 inhibitor 
(XDM 8-92). The Top and Fop signals were normalised to the renilla luciferase signal 
and average from three independent experiments are shown (N=3). The error bars 
represent +SD. **P £0.01 and *P £0.05.




4.2.3 Zak-null mouse characterisation 
To further study the biological relevance of ZAK in intestinal homeostasis, I 
proceeded to generate Zak-null mice for functional studies in vivo. CRISPR/Cas9 
genome editing technology has been shown to be efficient in generating knockout 
mice (Wang et al., 2013). Since the sgRNA sequence previously used to target ZAK 
in HEK293T cells in section 4.2 was proven to be efficient, this was also used for 
mouse targeting as the sequence was shared between human and mouse. Both 
mRNA of the sgRNA and Cas9 were microinjected into the pronuclear stage one-cell 
mouse embryos collected from C57BL/6xCBA(F1) background mice (see chapter 2 
for detailed information). From 3 recipient females, 46 pups were obtained in total. 
MiSeq analysis confirmed that all 46 pups were positive for five different indel 
mutations generated by NHEJ. Two females and one male carrying the founder 
mutations were inter-crossed to obtain immediate Zak-null mutants in F1 generation. 
Four mutated alleles were successful germline transmitted and these are indicated 
in Figure 4.4A. Mutation 1 (M1) and 4 (M4) harbour a 10bp deletion, whilst mutations 
2 (M2) and 3 (M3) show 1bp and 5bp deletions respectively. All mutations were 
predicted to yield a truncated form of the ZAK protein, which we confirmed by 
Western blot in intestinal epithelium lysates from heterozygous Zak-/- F1 mice (Figure 
4.4B).  
The Zak-/- mice developed normally and no obvious physical or behaviour 
phenotype was observed. As mentioned above, ZAK is expressed in heart, muscle, 
lung, liver and pancreas (Liu et al., 2000a). None of these organs have shown 
macroscopic differences when compared to the wild-type animals. However, we 
have shared Zak-/- animals with two different laboratories that have reported a 
phenotype in muscle morphology and in endoplasmic reticulum function. These 
phenotypes are now being explored by our collaborators to better understand the 
physiological significance of ZAK protein in these contexts.  
To study the role of ZAK in intestinal homeostasis, intestinal tissues from 4-
month-old wild-type (WT) and Zak-/- mice were isolated for histological analysis. 
Surprisingly, no gross morphological differences were observed in Zak-/- intestine 
compared to WT animals (Figure 4.4C). Intestinal villus and crypt length was 
measured in all intestinal regions for comparison and no differences were observed 




between WT and Zak-/- mice in either duodenum, jejunum, ileum or colon (Figure 
4.4D-E). To determine the impact on intestinal homeostasis in older mice, a cohort 
was aged for one 1 year and Zak-/- and WT animals were analysed. Similar to the 
younger animals, histological analysis of the intestinal tissues from one-year-old WT 
and Zak-/- mice showed no apparent morphological differences (Figure 4.4F).  
For better characterisation, proliferation and differentiation potential of the 
intestinal epithelium in Zak-/- mice was further analysed. No significant differences in 
stem cell proliferation was observed between WT and Zak-/- intestines using Ki67 
staining or EdU (Figure 4.5A and B). An average of 10±1 EdU+ cells/crypt was 
observed in Zak-/-  and WT intestines (Figure 4.5B). Intestinal epithelial turnover rate 
was further analysed by 5-ethynyl-2’-deoxyuridine (EdU) tracing. Mitotically active 
proliferative cells were chemically labelled with EdU and traced for 3 days. Intestinal 
tissues of WT and Zak-/- mice were collected 2 hours, 1 day and 3 days after EdU 
injection. The EdU-labelled cells appeared to migrate towards the villi at similar rates 
between Zak-/- and WT intestines, indicating that loss of ZAK did not affect 
proliferation or turnover rate of the intestinal epithelium (Figure 4.5C). 
Immunostaining of the Wnt target SOX9 did not reveal any major differences either, 
suggesting that Wnt/b-catenin signalling was not affected in Zak-/- animals during 
normal homeostasis (Figure 4.5D). Analysis of the two differentiation markers 
lysozyme (Paneth cells) and periodic acid-Schiff+ (PAS) (goblet cells) also showed 
no difference in lineage differentiation in Zak-/- intestines (Figure 4.5E-G). An average 
of 6±1 PAS+ cells/crypt was observed in both WT and Zak-/- intestines (Figure 4.5G). 
Together, the results suggest that ZAK is dispensable for normal intestinal 
homeostasis. 









Figure 4.4 Generation of Zak-/- mice by CRISPR/Cas9 genome editing. 
(A) Schematic representation of the CRISPR/Cas9 targeting strategy of Zak at exon 
2. gRNA used is highlighted in blue and the PAM sequence is also indicated. Four 
transmitted frameshift mutations genotypes (M1-M4) found in F1 Zak-/- mice are 
indicated. (B) Western blotting shows the absence of ZAK protein in the whole 
intestinal tissue lysates obtained from WT and Zak-/- mice. (C) Representative H&E 
image of duodenum section from 3-month-old WT and Zak-/- mice. (D) Measurement 
of villi length in WT and Zak-/- animals in all regions of small intestine. 30 villi/region 
were measured and means ± SD of 3 mice per group are shown. ns - non-significant 
(p>0.05). (E) Measurement of crypt length in all regions of small and large intestine. 
30 crypts/region were measured and means ± SD of 3 mice per group are shown. 
(F) Representative H&E image of small intestine section from 1-year-old WT and 
Zak-/- mice. Scale bars, 100 µm.






Figure 4.5 Zak-/- intestine show normal stem cell proliferation and differentiation. 
(A) Representative Ki67 staining in small intestinal sections of WT and Zak-/- mice. 
(B) Quantification of number of EdU+ cells per crypt in WT and Zak-/- mice 2 hours 
after EdU administration. (C) Representative immunofluorescent images of EdU 
tracing between WT and Zak-/- intestine. Mice were injected with EdU and collected 
2 hours, 1 day and 3 days after injection. (D) Representative staining of the Wnt 
target- SOX9, Paneth cell marker-Lysozyme (E) and goblet cell marker-PAS (F) in 




WT and Zak-/- intestines of N=4/group (G) Quantification of number of PAS+ cells per 
villi, normalized to length of the villi in WT and Zak-/- mice. To determine the number 
of EdU+ and PAS+ cells, 30 crypts or villi were analysed, respectively in three 
mice/group. Dots represent the counting for the total 90 crypts and villi and means ± 
SD of the total 3 mice are shown in red. ns - non-significant (p>0.05). Scale bars, 
100 µm. 




4.2.4 Loss of Zak promotes intestinal regeneration after radiation-induced 
injury 
In response to radiation-induced damage, the intestinal epithelium initiates 
the regeneration process by enhancing Wnt/b-catenin signalling to drive cell 
proliferation (Kabiri et al., 2014). Since our in vitro data showed that ZAK is a negative 
regulator of Wnt, we further investigated the role of ZAK in intestinal regeneration 
after radiation-induced injury.  
Wild-type and Zak-/- animals were exposed to a sub-lethal, whole-body dose 
of irradiation (10 Gy) and the intestinal tissues were collected 3 days later. Enlarged 
and hyperproliferative crypts were observed in Zak-/- intestines 3 days post-irradiation 
(Figure 4.6A-B). Intestinal crypt length was measured in all intestinal regions for 
comparison. All regions of the small intestine (duodenum, jejunum, ileum) show 
increased crypt length in Zak-/- mice compared to WT. Colon shows no significant 
increase in Zak-/- mice, which might be explained by the fact that colon is relatively 
resistant to radiation (Potten and Grant, 1998). Moreover, incomplete recovery, 
characterised by regions where crypts were absent, was frequently observed in WT 
animals at this time point, whilst this was almost never observed in Zak-/- mice (Figure 
4.6A – arrowheads). This indicates that deletion of Zak accelerates regeneration of 
the intestinal epithelium upon irradiation. We confirmed hyperproliferation of the 
intestinal crypts in the Zak-depleted intestine by Ki67 and EdU staining (Figure 4.6C 
-D). An average of 27±9 EdU+ cells/crypt was observed in Zak-/- intestines compared 
with 15±6 in WT crypts (Figure 4.6E). We then analysed the expression of the stem 
cell marker Olfm4 which was significantly higher in Zak-/- intestinal crypts compared 
to WT (Figure 4.7A).  Expression of the Wnt targets SOX9 and CYCLIN D1 were 
also higher in the Zak-/- intestinal crypts, suggesting upregulation of Wnt/b-catenin 
signalling in Zak-deleted intestine (Figure 4.7B-C). An average of 48±2 CYCLIND1+ 
cells/crypt was observed in Zak-/- intestines compared with 31±1 in WT crypts 
Interestingly, the hyperproliferation phenotype in the Zak-/- intestine disappeared 6 
days after irradiation when normal intestinal architecture was restored (Figure 4.8A). 
Similar intestinal proliferation rate and crypt length were observed in both Zak-/- and 
WT mice at this time point (Figure 4.8B-C). The results highlight the unique role of 
ZAK in regulating intestinal regeneration after irradiation-induced injury when Wnt 




signalling is activated to support the stem cell recovery, which is in contrast to its 
dispensible role during normal homeostasis. 








Figure 4.6 Depletion of Zak promotes intestinal regeneration after radiation-
induced injury. 
(A) Representative H&E staining of all 3 regions of small and large intestine in WT 
and Zak-/- mice 3 days after whole-body exposure to 10 Gy radiation. Arrows indicate 
regions where crypts are absent. (B) Measurement of crypt length in WT and Zak-/- 
animals in all regions of intestine. 30 villi/region were measured and means ± SD of 
3 mice per group are shown. (C) Representative Ki67 staining of the intestine 3 days 
post-irradiation (dpi) showing increased proliferation in Zak-/- mice compared to WT. 
(D) Representative immunofluorescent staining showing increased number of EdU+ 
cells in Zak-/- intestinal crypts compared with WT at 3dpi. (E) Quantitation of number 
of EdU+ cells per crypt in WT and Zak-/-  mice. Numbers are mean ± SD of 100 crypts 
from a representative animal. Scale bars, 100 µm. ***P £0.001, **P £0.01, ns - non-
significant (p>0.05).





Figure 4.7 Depletion of Zak increases expression of ISC markers and Wnt targets 
after radiation-induced injury. 
(A) Representative image of RNAscope ISH of the stem cell marker, Olfm4, in 
intestinal crypts. (B) Representative Cyclin D1 and SOX9 (C) staining showing 
increases in Wnt/b-catenin signalling in Zak-/- mice compared to WT. N=3/group (D) 
Quantification of CyclinD1+ cell number per crypt. 20 crypts were analysed in two 
mice per group. Data represents means ± SD. ***P £0.001. Scale bars, 100µm.





Figure 4.8 Zak-/- mice show normal intestinal phenotype 6 days after radiation-
induced injury. 
(A) Representative H&E staining of intestinal tissues obtained from WT and Zak-/- 
mice 6 days after whole body exposure to 10 Gy radiation. (B) Representative Ki67 
staining of intestinal tissues showing no differences in proliferation between Zak-/- 
and WT animals. (C) Measurement of crypt length in WT and in Zak-/- mice. 30 
crypts/region were measured and means ± SD of 2 mice are shown. ns - non-
significant (p>0.05). Scale bars, 100 µm.




It has been reported that high Wnt/b-catenin signalling is required for the ex 
vivo culture of intestinal organoids to sustain their growth (de Lau et al., 2011; Sato 
et al., 2009). Presence of the potent Wnt agonist, R-spondin, in the culture medium 
is essential in promoting intestinal stem cell proliferation. I hypothesised that the high 
Wnt culture conditions used for ex vivo organoid culture may resemble, to some 
extent, intestinal regeneration in vivo. To test if Zak deletion had any effect on 
organoid culture, intestinal crypts were isolated from Zak-/- and WT intestines and ex 
vivo organoid cultures established. Interestingly, crypts isolated from Zak-depleted 
intestine were nearly 2-fold more likely to form organoids than crypts isolated from 
WT (Figure 4.9A-B). This could be due to the increase in number of stem cells in the 
Zak-depleted crypts, or the enhanced Wnt/b-catenin signalling upon Zak deletion that 
potentiates the capacity to form organoids. Altogether, the results suggest that ZAK 




Figure 4.9 Intestinal crypts isolated from Zak-/- mice demonstrate higher organoid 
formation efficiency as compared to WT. 
(A) Number of organoids formed per 200 crypts from both WT and Zak-/- mice. The 
number of organoids were counted 3 days after crypt isolation and culture. Data 
presented are average from four independent experiments (N=4) +SD. **P £0.01.  
(B) Representative images of intestinal organoids derived from Zak-/- and WT 
intestinal crypts after 3 days of culture.





The kinase ZAK has previously been reported to regulate various MAPK 
pathways, whilst its role in other signalling pathways has yet to be revealed. Our 
current data show that ZAK inhibits Wnt signalling downstream of b-catenin 
phosphorylation and ubiquitination in a MAPK-independent mechanism. In the 
previous chapter, we have shown that ZAK is a Wnt target, expressed exclusively in 
the intestinal crypts and co-expressed in Lgr5-expressing stem cells. Here, we 
further demonstrate that its depletion promotes intestinal stem cell regeneration after 
irradiation-induced injury. Taken together, our data suggest that ZAK is a negative 
regulator of Wnt present at the bottom of the crypts, where it acts to regulate intestinal 
stem cell proliferation via a negative feedback mechanism in conditions of Wnt/b-
catenin signalling hyperactivation, such as tissue damage or high-Wnt ex vivo culture. 
To our knowledge, this is the first time that ZAK has been directly implicated in 
regulating intestine regeneration by mediating the Wnt/b-catenin signalling pathway. 
Our current data show that ZAK was able to suppress Wnt signalling activated 
by APC truncation or expression of the b-catenin S33Y mutant. This suggests that 
the Wnt inhibitory mechanism is downstream of GSK3-mediated phosphorylation 
and ubiquitination of b-catenin. Further investigation is needed to dissect the precise 
role of ZAK in Wnt suppression. Interestingly, a tankaryase inhibitor has been shown 
to inhibit Wnt signalling in APC truncated CRC cells by stabilising the AXIN protein. 
It would be of interest to test if ZAK also functions to stabilise AXIN. Alternatively, 
ZAK may act further downstream by regulating nuclear b-catenin/TCF transcription. 
Although ZAK protein expression was detected exclusively in the cytoplasm, it would 
still be interesting to explore if ZAK could regulate levels of nuclear b-catenin or TCF 
proteins.  
In this chapter, we have generated Zak-null mice for in vivo studies. During 
my research project, Spielman and colleagues reported that complete knockout of 
both Zak isoforms using CRISPR targeting results in early embryonic lethality at E9.5, 
due to heart malformation and growth retardation (Spielmann et al., 2016). Contrary 
to their findings, we managed to obtain viable and fertile Zak-null animals using the 
same sgRNA as described in their publication for CRISPR targeting. It is unclear 
what causes the major discrepancy between our findings and their publication but 




there are two differences in the targeting methodology that are worth considering. 
Firstly, Spielman and colleagues performed gene editing by transfecting mouse 
embryonic stem cells (ESCs) with the plasmid constructs for CRISPR/Cas9 genome 
editing system, whilst we directly injected the Cas9 and sgRNA mRNA into one-cell 
mouse embryos. Secondly, the mice strains used in the two studies are slightly 
different. In this study, the Zak-null mice were generated in both C57BL/B6 and 
CBAxBL6 background, whilst Spielman used 129xC57BL/6 F1 hybrid ESCs for 
targeting in their study. In addition, it has been reported that the amounts of Cas9 
expression can increase the frequency of off-target effects (Ran et al., 2013). 
Potential off-target mutations should thus be considered, particularly when the Cas9 
plasmid was stably transfected into the ESCs in Spielman’s study.  
As previously mentioned, ZAK can activate ERK, p38 and JNK pathways 
(Cho et al., 2004; Liu et al., 2000a; Yang, 2002). Recent studies reveal that MAPK 
signalling plays an important role in regulating intestinal stem cell-fate decision 
(Basak et al., 2016; Gupta et al., 2014; Heuberger et al., 2014) and tumorigenesis 
(Abaco et al., 1996; Janssen et al., 2006; Jeong et al., 2012). In particular, activation 
of MAPK promotes goblet cell over Paneth cell differentiation, whilst enteroendocrine 
cell differentiation requires inhibition of MAPK signalling. However, no significant 
differences were observed in the number of Paneth cells or goblet cells between WT 
and Zak-null animals. This could be due to the redundancy of other MAP3Ks in the 
intestine. Alternatively, the role of ZAK in regulating both MAPK and Wnt signalling 
may represent a unique functional role in the intestine different from other MAPK 
family members. In addition, we are currently performing Chromogranin A 
immunohistochemistry to further investigate any possible effect on enteroendocrine 
cell differentiation in the Zak-/- mice. Our preliminary data suggest that the Wnt 
inhibitory role of ZAK is MAPK-independent. However, the potential crosstalk 
between MAPK and Wnt signalling cannot be completed excluded. Although the 
MAPK inhibitors have been widely used in other studies, the efficiency of the 
inhibitors should be confirmed in our system by examining changes in 
phosphorylation of MAPKs. Moreover, the compensatory roles of different MAPKs 
such as ERK5 and ERK1/2 has been previously described (de Jong et al., 2016). 
Therefore, treatments of various combined MAPK inhibitors should be examined for 
comprehensive analysis of the Wnt regulatory role of ZAK. 




One interesting finding in this project is that ZAK appears to be required to 
regulate intestinal regeneration after damage but is dispensable during tissue 
homeostasis. These results provide compelling evidence for the hypothesis that ZAK 
contributes to the negative feedback loop at the crypt bottom to fine tune Wnt/b-
catenin signalling when it is hyperactivated. It is possible that ZAK plays a role in the 
intestine predominantly during hyperproliferative conditions such as tumorigenesis, 
regeneration, inflammatory damage or ex vivo organoid culture. It would be 
interesting to investigate other pathological models to better understand the 
functional significance of ZAK in intestine in such scenarios. Moreover, as mentioned 
in section 4.2.4, WT animals frequently show regions where crypts were absent 3 
days after irradiation, whilst this was almost never observed in Zak-/- mice. This raises 
the question whether deletion of Zak accelerates regeneration of the intestinal 
epithelium upon irradiation or Zak-null animals are more resistant to damage from 
the start. To answer this question, we will analyse mice at short time points after 
irradiation, particularly 6 hours and 1 day after radiation.  
ZAK was initially identified in the Stem-Cell/Wnt cluster from the TCGA 
expression data, where changes in ZAK expression were observed between the 
different subtypes of CRCs (see Chapter 3). It would be important to further study 
the role of ZAK in intestinal tumour initiation and progression. We are currently 
generating Zak-/- Apcmin mice to further characterise the effect of Zak deletion in 
intestinal tumourigenesis. 
In summary, our data show that ZAK negatively regulates intestinal stem cell 
proliferation by inhibiting the Wnt signalling pathway. This is in contrary to the 
previous reports proposing that ZAK is an oncogene (Cho et al., 2004; Liu et al., 
2014b; Rey et al., 2015). This is mainly due to the observation that ZAK is generally 
upregulated in various cancers, but functional characterisation in those studies were 
limited to simple in vitro assays in established cancer cell lines. However, these 
observations described in this chapter should be interpreted with caution. As 
demonstrated in the previous chapter, ZAK is potentially a Wnt target gene. It is 
therefore not surprising that ZAK, and many other Wnt targets such as AXIN2 and 
RNF43, are upregulated in APC-mutated CRCs. ZAK is mostly associated with the 
MAPK pathway in the current literature, whilst its role in Wnt signalling regulation is 
largely unknown. Importantly, the functional role of ZAK in the intestine has never 
been examined in vivo. Our current data provide the first in vivo evidence that ZAK 




is involved in repressing stem cell proliferation during intestinal regeneration by 
negatively regulating Wnt signalling. Further studies of the Zak-/- mice in intestinal 
tumour models will help to re-evaluate the role of ZAK in CRC. 
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Chapter 5. SH3BP4 inhibits intestinal tumour initiation 
and growth by negative regulation of Wnt 
signalling  
 
5.1  Introduction 
 
SRC homology 3 domain-binding protein 4 (SH3BP4) encodes a 963 amino 
acid protein with multiple structural domains and sequence motifs. The protein 
consists of two SH3 domains, one at the N-terminus (SH3_1 family member) and a 
second one close to the C-terminus (SH3_2 family member). The SH3 domain is a 
well characterised family of protein-interaction modules (Mayer, 2001) (Figure 5.1A) 
Through selective binding affinity to proline-rich ligands, this domain plays an 
important role in many biological processes such as enzyme regulation by 
modulating intramolecular interactions, modulating the subcellular localisation of 
components of various signalling pathways and mediating large multiprotein complex 
assembly (Mayer, 2001). The N-terminal region of SH3BP4 also contains three 
conserved motifs: LIDL motif (a putative clathrin-binding motif), AP2a (an adaptor 
protein 2a) and three NPF repeats (Asparagine-Proline-Phenylalanine - putative 
Eps15 homology (EH) domain-binding sites) (Kokoszyńska et al.). The amino acids 
317 to 454 comprise the protein-protein interaction ZU5 domain. The C-terminus 
contains two death domain (DD) family members, which mediate self-association 
with DDs of other proteins to induce pro-apoptotic signals (Kokoszyńska et al.).  A 
ZU5-DD architecture has also been found in proteins related to extracellular signal 
transduction such as the netrins (Reed et al., 2004; Wang et al., 2009) and in the 
scaffold proteins, ankyrins (Ipsaro et al., 2009).  
Another recently identified protein, metastasis-associated in colon cancer 
protein 1 (MACC1), shares approximately 45% homology with SH3BP4 in both 
human and mouse. Expression of MACC1 has previously been associated with poor 
prognosis in CRC (Stein et al., 2009). These similarities are evolutionarily conserved 
in other vertebrates, such as fish and birds (Stein et al., 2010). The two proteins 
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contain similar domains and sequence motifs, apart from that the N-terminal SH3 
domain is absent in MACC1. 
SH3BP4 has previously been shown to play a regulatory role in multiple 
signalling pathways. Tosoni and colleagues first described the functional role of 
SH3BP4 in regulating clathrin-mediated internalisation of the transferrin receptor 
(TfR) (Tosoni et al., 2005). This effect was shown to be dependent on the SH3_1 
domain that binds to the GTPase dynamin in the clathrin-coated vesicle (Tosoni et 
al., 2005). In addition, SH3BP4 has also been demonstrated to regulate fibroblast 
growth factor receptor (FGFR) trafficking and the subsequent cellular responses 
(Francavilla et al., 2013). In another study, Kim et al. reported SH3BP4 as a negative 
regulator of Amino Acid-Rag GTPase-mTORC1 signalling (Kim et al., 2012b). Amino 
acids stimulate mTOR signalling via Rag GTPases, such as GTP-bound RagA or 
RagB. SH3BP4 preferentially binds to inactive GDP-bound Rag GTPase via the SH3 
domain and inhibits the formation of the active Rag GTPase complex, thus resulting 
in inactivation of mTOR signalling (Kim et al., 2012b).  
The possibility of the regulation of SH3BP4 gene expression by microRNAs 
(miRNAs) has been observed in three independent studies. Microarray analysis 
revealed enrichment of SH3BP4 expression in metastatic prostate cancer (Zhang et 
al., 2016). Then, a subsequent bioinformatics analysis of miRNAs networks further 
suggested that SH3BP4 expression could be modulated by miR-182 (Zhang et al., 
2016). More recently, SH3BP4 has also been reported as a melanogenesis-related 
gene targeted by miR-125b (Kim et al., 2017). The study showed that SH3BP4 
expression is decreased through direct binding of miR-125b to the SH3BP4 3′-UTR, 
which results in reduced number of melanocytes.  
In Chapter 3, we demonstrated that SH3BP4 is differentially expressed in 
human CRCs and that its expression is restricted to the crypt compartment in normal 
intestine. However, the role of SH3BP4 in the intestine has never been studied. Here 
we examine the putative role of SH3BP4 in Wnt/b-catenin signalling and study its 
functional significance in intestinal homeostasis and tumorigenesis in vivo. 
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5.2.1 SH3BP4 is a negative regulator of Wnt/b-catenin signalling 
We have previously confirmed that Sh3bp4 is expressed in the ISC 
compartment. Expression of Sh3bp4 is further enriched in the Apc-mutated intestinal 
tumours and organoids, suggesting that Sh3bp4 is transcriptionally regulated by 
Wnt/b-catenin signalling. To gain insight into the role of SH3BP4 in Wnt/b-catenin 
signalling, I first deleted SH3BP4 in HEK293T cells using the CRISPR/Cas9 gene 
editing system. A sgRNA targeting the first exon of SH3BP4 was designed to target 
SH3BP4 gene. Homozygous frameshift mutations in the selected CRISPR-targeted 
HEK293T clone (DSH3BP4) was confirmed by sequencing (Figure 5.1B). A 7bp- and 
a 5bp deletion were retrieved from the DSH3BP4 clone, resulting in protein truncation 
at 110 and 89 amino acids respectively. Protein depletion of SH3BP4 in the 
DSH3BP4 cells was confirmed by Western blot analysis (Figure 5.1C). Deletion of 
SH3BP4 resulted in ~2.5-fold increase in Wnt3A-induced TCF-TopFlash reporter 
transcriptional activity (Figure 5.1D) and an increase in active b-catenin protein levels 
(Figure 5.1E). To confirm the Wnt signal activation in DSH3BP4 cells, mRNA 
expression of the Wnt target genes AXIN2, CCND1 and MYC was further analysed 
by quantitative RT-PCR (Figure 5.1F). Consistently, significant upregulated 
expression of the Wnt target genes was detected in DSH3BP4 cells when compared 
with wild-type HEK293T cells.  
In a reverse experiment, SH3BP4 was overexpressed in HEK293T cells. In 
accordance with the DSH3BP4 data, expression of wild-type SH3BP4 significantly 
suppressed Wnt3A-induced TCF-TopFLASH reporter activity (Figure 5.2A). The Wnt 
signal inhibition was confirmed by reduced active b-catenin protein levels (Figure 
5.2B). As mentioned above, MACC1 shares high homology with SH3BP4 in terms of 
domains and sequence motifs. I therefore tested if MACC1 could play a similar role 
in Wnt/b-catenin signalling. However, overexpression of MACC1 did not show any 
inhibition of Wnt3A-induced TCF-TopFLASH reporter activity (Figure 5.2C), 
suggesting that MACC1 does not modulate Wnt signalling despite sequence 
homology with SH3BP4. Taken together, these data support the notion that SH3BP4 
is a negative regulator of Wnt/b-catenin signalling. 
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Figure 5.1 Deletion of SH3BP4 activates Wnt/b-catenin signalling. 
(A) SH3BP4 protein domains and motifs. (B) Schematic representation of the 
CRISPR/Cas9 targeting strategy the first exon of Sh3bp4. Genotyping of the selected 
DSH3BP4 mutant clone reveals homozygous frameshift mutations on both alleles, 
indicated as M1 and M2. (C) Immunoblot showing protein loss in the DSH3BP4 
mutant clone. (D) Relative Wnt3a-induced TCF-TopFlash reporter activity in 
HEK293T wild-type and DSH3BP4 cells. The Top and Fop signals were normalized 
to the renilla luciferase signal and averages ± SD of four independent experiments 
are shown (E) Western blot analysis of active (non-phosphorylated) form of b-
catenin. (F) Activation of the Wnt target genes AXIN2, CCND1 and MYC was 
examined in HEK293T cells by quantitative RT-PCR. Expression data are presented 
as fold induction normalised to GAPDH. Data represent means of three independent 
experiments ± SD.**P<0.01,***P< 0.001.  
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Figure 5.2 SH3BP4, but not MACC1, inhibits Wnt/b-catenin signalling. 
(A) Expression of SH3BP4 in HEK293T cells inhibits Wnt3A-induced TCF-TopFlash 
reporter activity. (B) Overexpression of SH3BP4 significantly reduces active b-
catenin level as revealed by Western blot analysis. (C) Relative TCF-TopFlash 
reporter activity in Wnt3A-induced HEK293T cells expressing empty-vector or 
MACC1. Averages of four independent experiments ± SD are shown.**P<0.01.
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5.2.2 SH3BP4 inhibits Wnt signalling downstream of b-catenin 
phosphorylation/ubiquitination 
To understand the mechanism by which SH3BP4 inhibits Wnt/b-catenin 
signalling, we followed a similar approach to that previously described in Chapter 4 
for ZAK, and activated the Wnt pathway at different subcellular levels together with 
SH3BP4 expression. Expression of SH3BP4 was able to inhibit TCF-TopFLASH 
reporter activity induced by the constitutively active form of LRP6 (DN-LRP6) (Figure 
5.3A), suggesting that SH3BP4 acts downstream of LRP6 phosphorylation. Next, we 
tested if SH3BP4 can inhibit Wnt signalling induced by GSK3b inhibitor (CHIR99021). 
CHIR99021 inhibits GSK3b-mediated b-catenin phosphorylation at Thr41, Ser37 and 
Ser33 within the destruction complex, which consequently stabilises b-catenin. TCF-
TopFLASH luciferase assay showed that SH3BP4 significantly inhibited CHIR99021-
induced Wnt/b-catenin signalling (Figure 5.3B and D). This result was further 
confirmed by expressing the constitutively active form of b-catenin (bCatS33Y) to 
activate Wnt signalling. Once again, SH3BP4 was able to inhibit Wnt signalling 
induced by the phospho-mutant bCatS33Y (Figure 5.3C and D). These data indicate 
that SH3BP4 inhibits Wnt signalling downstream of b-catenin phosphorylation. 
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Figure 5.3 SH3BP4 inhibits Wnt signalling downstream of b-catenin 
phosphorylation. 
(A) Expression of SH3BP4 in HEK293T cells significantly inhibits DN-LRP6-induced 
TCF-TopFlash reporter activity. (B) HEK293T cells overexpressing EV and SH3BP4 
were treated with 2µM of GSK3 inhibitor CHIR99021 for 24 hours and relative TCF-
TopFlash reporter activity was measured. (C) SH3BP4 supresses TCF-TopFlash 
reporter activity induced by a stabilised form of b-catenin (b-CatS33Y). Averages of 
four independent experiments ± SD are shown. ***P<0.001, **P<0.01. (D) Western 
blot shows that SH3BP4 reduces the levels of active b-catenin induced by GSK3 
inhibition and b-cateninS33Y expression.
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Next, we attempted to identify the specific domain or motif of SH3BP4 that is 
responsible for Wnt signal inhibition. Five different SH3BP4 deletion/mutant 
constructs lacking various SH3BP4 domains were generated (Figure 5.4A), where 
similar protein expression levels were observed in all constructs (Figure 5.4B). A 
construct lacking the clathrin-binding LIDL motif at the N terminus (SH3BP4DN) was 
generated due to its reported role in receptor trafficking (Francavilla et al., 2013; 
Tosoni et al., 2005) and clathrin-mediated LRP6 receptor endocytosis (Liu et al., 
2014a). For the first SH3 domain (SH3_1), a point mutation was generated to replace 
the Trp92 with alanine (SH3BP4W92A) – an amino acid that is reportedly conserved 
and is critical for SH3 domain interactions (Erpel et al., 1995; Tosoni et al., 2005). To 
test which domain is crucial for Wnt inhibition, we expressed the various SH3BP4 
mutant constructs in cells depleted of endogenous SH3BP4 (DSH3BP4) and 
measured the Wnt3A-induced TCF-TopFLASH reporter activity. As expected, 
expression of WT SH3BP4 readily rescued the Wnt activation caused by 
endogenous SH3BP4 depletion (Figure 5.4C). Similar to the WT protein, most of the 
SH3BP4 deletion/mutation constructs were also able to repress Wnt activation. 
However, one construct lacking the ZU5 domain (SH3BP4DZU5) failed to exert full Wnt 
inhibitory function, suggesting that the inhibitory role of SH3BP4 is dependent on the 
ZU5 domain (Figure 5.4C).  
The Wnt inhibitory role of SH3BP4 was further examined in another APC 
mutant system (HEK293T ΔAPC) described earlier in Chapter 4 (section 4.3), which 
activates Wnt signalling via suppression of b-catenin ubiquitination. Interestingly, 
expression of WT SH3BP4, but not SH3BP4DZU5, suppressed Wnt activation induced 
by APC truncating mutation (Figure 5.4D). Taken together, the data suggest that 
SH3BP4 inhibits Wnt signalling downstream of b-catenin phosphorylation and 
ubiquitination, and is dependent on the ZU5 domain.  
We demonstrated earlier that the homologue MACC1 did not inhibit Wnt3A-
induced TCF transcription (Figure 5.2C). Here we further tested the potential Wnt 
inhibitory role of MACC1 using the ΔAPC model. Consistently with our previous data, 
MACC1 was not able to inhibit Wnt/b-catenin signalling in HEK293TDAPC either 
(Figure 5.4E). This consolidates the hypothesis that SH3BP4, but not its homologue 
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Figure 5.4 SH3BP4-mediated inhibition of Wnt/b-catenin signalling is dependent 
on the ZU5 domain. 
(A) Different FLAG-tagged deletion or mutation constructs of SH3BP4 without 
specific domains or motifs. (B) Western blot analysis showing similar expression 
among the different FLAG-tagged constructs of SH3BP4. (C) Relative TCF-TopFlash 
reporter activity showing that deletion of the ZU5 domain fails to restore the normal 
levels of Wnt/b-catenin signalling in DSH3BP4 cells. (D) Relative TCF-TopFlash 
reporter activity showing that expression of WT SH3BP4, but not SH3BP4DZU5, 
suppresses Wnt activation induced by APC truncating mutation (DAPC). (E) 
Expression of the homologue MACC1 does not inhibit Wnt activation in DAPC cells. 
Data represent mean of at three independent experiments ± SD. **P<0.01,***P< 
0.001.
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As described earlier, SH3BP4 has previously been reported to inhibit the 
mTOR1- pathway (Kim et al., 2012b). Indeed, upregulation of p70S6 phosphorylation 
was observed in the DSH3BP4 cells, confirming the negative regulatory role of 
SH4BP4 in mTOR signalling (Figure 5.5A). To determine whether the Wnt inhibitory 
role of SH3BP4 is dependent on mTOR, we examined the Wnt activating effect of 
the DSH3BP4 cells in the presence of the mTOR inhibitor, rapamycin. As expected, 
rapamycin treatment significantly suppressed mTOR signalling induced by SH3BP4 
depletion as indicated by p70S6 phosphorylation (Figure 5.5B). However, 
suppression of mTOR signalling did not affect DSH3BP4-induced Wnt activation, 
suggesting that the Wnt negative regulatory role of SH3BP4 is independent of mTOR 
activation (Figure 5.5C). Surprisingly, we saw a further increase in Wnt activation 
upon rapamycin treatment. 
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Figure 5.5 Activation of Wnt/b-catenin signalling in ∆SH3BP4 is independent of 
mTOR pathway activation. 
(A) Western blot showing that cells depleted of SH3BP4 have higher levels of 
phosphorylation of the mitogen activated Ser/Thr protein kinase p70S6 (p-p70S6), 
confirming that depletion of SH3BP4 activates mTOR pathways as previously 
described (Kim et al., 2012b). (B) Western blot analysis confirms inhibition of mTOR 
signalling (p-p70S6) upon rapamycin treatment. (C) HEK293T and ∆SH3BP4 cells 
were treated with the mTOR inhibitor rapamycin (20nM for 24hours) as shown (non-
treated (-); treated (+)) followed by TCF-TopFlash reporter activity measurement. 
Data represent mean of at three independent experiments ± SD. ***P< 0.001
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5.2.3 SH3BP4 interacts with APC and b-catenin 
Expression of SH3BP4 has previously been reported to be localised to the plasma 
membrane, perinuclear region and clathrin-coated vesicles (Kim and Kim, 2013; Kim 
et al., 2012b; Tosoni et al., 2005). To examine the cellular localisation of the protein, 
we performed immunofluorescent staining of the endogenous SH3BP4 protein in WT 
HEK293T and colon cancer cells (SW480 and LS174T). Consistent with the previous 
studies, the SH3BP4 protein was indeed localised to the nuclei, plasma membrane 
and vesicles (Figure5.6A-B). The perinuclear staining was not obvious in HEK293T 
cells, but was clear in colon cancer cells such as SW480 and LS174T (Figure 5.6B). 
Our current data show that SH3BP4 inhibits Wnt signalling downstream of b-catenin 
phosphorylation/ubiquitination, and is strongly localised to the perinuclear membrane 
and nucleus. This prompted us to speculate that SH3BP4 might regulate b-
catenin/TCF4 transcription or nuclear shuttling of b-catenin. Since APC has been 
reported to regulate b-catenin nuclear transport (Henderson, 2000), we therefore 
investigated whether SH3BP4 could interact directly with b-catenin, TCF4 and/or 
APC proteins. To avoid non-physiological overexpression of the protein, LS174T 
cells (with higher levels of SH3BP4 protein and wild-type APC) were chosen for the 
subsequent endogenous immunoprecipitation (IP) experiments. In addition, we 
generated the CRISPR-mediated SH3BP4 deletion (DSH3BP4) in LS174T cells 
using the same sgRNA as described in Figure 5.1B to serve as a negative control 
for the interaction experiments. TCF4 did not co-immunoprecipitate with SH3BP4. b-
catenin interaction was inconclusive as the binding was also faintly detected in the 
DSH3BP4 negative control cells, suggesting non-specificity of the SH3BP4 antibody. 
APC protein was difficult to detect and not results were inconsistent between 
experiments (Figure 5.7A). We then performed the reverse co-IP experiments to 
validate the bindings. Interestingly, SH3BP4 was detected in the b-catenin and APC 
co-IP complexes (Figure 5.7B-C). It remains unclear whether the binding of SH3BP4 
with b-catenin and APC is direct or indirect. Further studies will be needed to 
investigate whether SH3BP4 can potentially regulate binding between APC and b-
catenin, mediating b-catenin nuclear shuttling for example.
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Figure 5.6 SH3BP4 is predominantly localised at perinuclear membrane and 
nucleus. 
(A) Immunofluorescent staining of SH3BP4 in HEK293T cells showing high levels of 
nuclear protein (B) Z-stack of co-localisation of SH3BP4 and the nuclear membrane 
marker Lamin in both LS174T (upper panel) and SW480 (lower panel) cells. Scale 
bars, 100µm.
Chapter 5. SH3BP4 inhibits intestinal tumour initiation and growth by negative 






Figure 5.7 SH3BP4 interacts with APC and b-catenin. 
LS174T cells were used to immunoprecipitate SH3BP4 (A) APC (B) and b-catenin 
(C). ∆SH3BP4 LS174T cells were used as negative control. Cell lysates were 
subjected to SDS-PAGE followed by western blot analysis using the indicated 
antibodies.
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5.2.4 Loss of SH3BP4 promotes intestinal stem cell proliferation 
To further understand the biological relevance of SH3BP4 in Wnt/b-catenin 
signalling and intestinal homoeostasis, we obtained the conditional knockout mouse 
model of Sh3bp4 from the International Mouse Strain Resource generated by the 
Wellcome Trust Sanger institute (Sh3bp4tm1a(EUCOMM)Wtsi). Briefly, two loxP sites were 
inserted flanking the critical exon 4 that encodes most of the gene. A lacZ sequence 
followed by neomycin selection cassette under the control of the human b-actin 
promoter and SV40 polyA was flanked by two FRT (flippase recognition target) sites 
and was placed upstream of the first loxP site (Figure 5.8A). The presence of the 
lacZ-neomycin cassette disrupts normal gene transcription and is considered as a 
null allele. We were not able to obtain homozygous Sh3bp4tm1a(EUCOMM)Wtsi pups, 
indicating that Sh3bp4 full knock-out is lethal. The mice were then crossed with 
Tg(CAG-Flpo)1Afst strain to remove the lacZ-neomycin cassette, resulting in the 
conditional Sh3bp4fl/fl mice. Next, Sh3bp4fl/fl mice were crossed with the intestinal 
epithelial-specific VillinCreERT2 mice to obtain the final conditional Sh3bp4fl/flVillinCreERT2 
strain, in which the Cre-mediated Sh3bp4 deletion could be induced upon 
intraperitoneal tamoxifen administration (Figure 5.8B). 
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Figure 5.8 Characterisation of Sh3bp4fl/flVillinCreERT2 mice 25 days after SH3BP4 
loss. 
(A) Schematic diagram showing the mouse conditional knock-out strategy. (B) 
Representative images of Sh3bp4 RNAscope ISH. RNAscope probe was designed 
within the flanked region targeting between nucleotides 754 and 1632. Sh3bp4 
expression is lost 25 days after intraperitoneal tamoxifen injection in 
Sh3bp4fl/flVillinCreERT2 (right), whilst expression remains present in the Sh3bp4fl/fl 
control (left). Scale bar, 50µM (C) Representative image of H&E (upper panels) and 
PAS staining (lower panel) of Sh3bp4fl/fl and Sh3bp4fl/flVillinCreERT2 intestine (n=4). (D) 
Quantification of number of PAS+ cells per villi in Sh3bp4fl/fl and Sh3bp4fl/flVillinCreERT2. 
PAS+ cells were counted in 30 villi per animal. Dots represent the counting for the 
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total 120 villi and means ± SD of the total 4 mice are shown in red. ns - non-significant 
(p>0.05).  
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Initially, Sh3bp4 deletion 5 and 15 days after tamoxifen induction did not result 
in any morphological differences in the intestine (data not shown). We then analysed 
the intestinal tissues 25 days after Sh3bp4 deletion and again no obvious defects 
were detected in tissue morphology or goblet cell differentiation between 
Sh3bp4fl/flVillinCreERT2 and Sh3bp4fl/fl (hereafter named as control) animals (Figure 
5.8C-D). Despite the lack of morphological differences, intestine from 
Sh3bp4fl/flVillinCreER mice (25 days after tamoxifen administration) displayed 
moderately increased expression of the stem cell marker and Wnt target gene Lgr5 
when compared with control mice (Figure 5.9A). The increase in stem cell number 
was confirmed by increased expression of another stem cell-expressing gene, Olfm4 
(Figure 5.9B-C). On average, Sh3bp4fl/flVillinCreERT2   mice contained 8±1 ISCs per 
crypt compared with 6±1 in control mice.  We next asked whether the increase in 
Lgr5-expressing cells was accompanied by an increase in the Paneth cell number. 
Consistently, a moderate increase in Paneth cell number was observed in 
Sh3bp4fl/flVillinCreER animals, as revealed by lysozyme staining (Error! Reference 
ource not found.A). Sh3bp4fl/flVillinCreERT2 mice contained 7±0.2 Paneth cells per 
crypt compared with 5±0.2 in control mice. Finally, increased proliferation was also 
observed in the intestinal crypts upon Sh3bp4 loss (Error! Reference source not 
ound.B). The proliferative region on Sh3bp4fl/flVillinCreERT2 is on average 121±2.5 µm 
compared with 94±2.3µm in control mice. To confirm the increase in proliferation 
observed in Ki67 staining we will administered EdU 25 days after Sh3bp4 loss to 
determine the number of EdU+ cells per crypt.
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Figure 5.9 Loss of Sh3bp4 (25 days) increases expression of ISC markers. 
Representative image of RNAscope ISH of the Wnt target and stem cell marker, 
Lgr5. Middle panels are magnifications of the crypt region from the small intestine 
pictures shown on the left. Scale bar, 100µm. Right panel shows colonic crypts, scale 
bar, 50µm. (B) Representative image of RNAscope ISH of another ISC marker, 
Olfm4. Scale bar, 100µm. Images are representative of 4 animals per condition. (C) 
Number of Olfm4 expressing cells per crypt. Dots represent the number of cells in 
150 crypts from 3 animals/group (50 crypts/animal). Error bars represent ±SD. ***P< 
0.001.
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Figure 5.10 Sh3bp4 deletion (25 days) increases lysozyme expression and crypt 
proliferation. 
(A) Staining for lysozyme to detect Paneth cells. (B) Number of Paneth cells per crypt 
in Sh3bp4fl/fl and Sh3bp4fl/flVillinCreERT2. (C) Ki67+ staining in Sh3bp4fl/fl and 
Sh3bp4fl/flVillinCreERT2 intestines. (D) Length of the proliferative region measured from 
the bases of the crypt up to the last detected Ki67+ cell. Images on the right are 
magnifications of crypt regions from small intestine on the left. Images are 
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representative of 4 animals per condition. Lysozyme positive cells were counted in 
20 villi per animal. Dots represent the counting for the total 120 villi and means ± SD 
of the total 4 mice are shown in red. ***P< 0.001. Scale bar, 100µm. 
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To further analyse if depletion of Sh3bp4 for a longer period would yield a 
stronger phenotype, intestinal tissues were analysed 3 months after tamoxifen 
administration. Interestingly, prolonged Sh3bp4 loss resulted in longer small intestine 
and colon than in control animals (Figure 5.11A-B). Ki67 staining also revealed 
increased proliferation in the Sh3bp4fl/flVillinCreER mice intestines compared with 
controls (Figure 5.11C). To better assess the increase in proliferation we are now 
performing EdU staining in Sh3bp4fl/flVillinCreER and Sh3bp4fl/fl animals to quantity the 
number of EdU+ cells per crypt. Moreover, we are currently analysing changes in the 
expression of stem cell markers, Wnt target genes, differentiation and proliferation. 
Taken together, the results suggest long-term loss of Sh3bp4 promotes ISC 
proliferation.
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Figure 5.11 Characterisation of Sh3bp4fl/flVillinCreERT2 mice 3 months after SH3BP4 
loss. 
Mean lengths of small intestine (A) and colon (B) from 5 animals per group are shown 
± SD. *P<0.05, **P< 0.01 (C) Ki67 staining of Sh3bp4fl/fl and Sh3bp4fl/flVillinCreERT2 
intestine. Middle panel are magnifications of the crypt region from the small intestine 
pictures shown on the left. The right panel shows colonic crypts. Scale bar, 100µm.
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5.2.5 Loss of SH3BP4 exacerbates Apc-mediated intestinal tumour initiation 
and progression 
To study the role of SH3BP4 in intestinal tumorigenesis, Sh3bp4fl/flVillinCreERT2 
mice were crossed with Apcmin mice (a mouse model of colon cancer (Li-KuoSu et 
al., 1992)), to generate Sh3bp4fl/flVillinCreERT2Apcmin mice. Tamoxifen was 
administered to 6-7-week-old mice and intestinal tissues were analysed 2 months 
later. Remarkably, Sh3bp4fl/flVillinCreERT2Apcmin mice exhibited almost a 3-fold 
increase in total adenoma numbers in small intestine compared with control Apcmin 
littermates (Figure 5.12A and C). Moreover, despite no significant changes in the 
mean tumour size, larger tumours were detected in Sh3bp4fl/fl VillinCreERT2 Apcmin than 
in Apcmin animals (Figure 5.12B and C). Tumour development in colon is a rare event 
in Apcmin mouse models. Interestingly, colonic tumours were detected in 2 out of the 
6 Sh3bp4fl/flVillinCreERT2Apcmin animals analysed, whilst no tumours were found in 
control Apcmin mice (Figure 5.12D). In addition, the number of tumours with high 
grade dysplasia (HGD) in Sh3bp4fl/flVillinCreERT2Apcmin mice is significantly higher 
when compared to the number of HGD tumours in control Apcmin animals (Figure 
5.12E-F).  
Next, we examined the apoptosis in the adenomas. No difference in apoptosis 
was detected between Sh3bp4fl/flVillinCreERT2Apcmin and Apcmin mice (Figure 5.13A 
and B). We will assess the proliferation of these tumours in 
Sh3bp4fl/flVillinCreERT2Apcmin adenomas by EdU incorporation. PAS staining revealed 
reduced goblet cell differentiation in the Sh3bp4fl/flVillinCreERT2Apcmin adenomas 
(Figure 5.14A and C). An average of 78±5 PAS+ cells was observed in each Apcmin 
adenoma compared with 46±3 in adenomas from Sh3bp4fl/flVillinCreERT2Apcmin 
animals. On the other hand, an increased number of Paneth cells were observed in 
Sh3bp4fl/flVillinCreERT2Apcmin adenomas when compared with control Apcmin animals 
(Figure 5.14B and D). Sh3bp4fl/flVillinCreERT2Apcmin adenomas have 80±4 lysozyme+ 
cells, whilst Apcmin adenomas show a reduction of 63 ±3 cells. Further analysis of the 
intestinal tissues for stem cell markers and Wnt target genes will help to understand 
if the enhanced tumour phenotype upon SH3BP4 loss is caused by upregulated Wnt 
signalling and expansion of the ISC population.
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Figure 5.12 Loss of SH3BP4 exacerbates the Apcmin phenotype. 
(A) Total number of adenomas detected in small intestine from 6 animals per group, 
2 months after induced-SH3BP4 loss (B) Tumour size distribution observed in 
Sh3bp4fl/fl VillinCreERT2Apcmin and Apcmin mice (C) Representative H&E images of the 
Sh3bp4fl/fl VillinCreERT2Apcmin and Apcmin small intestine. Scale bar, 1mm. (D) H&E 
stained section of colonic adenoma observed in 2 out of 6 Sh3bp4fl/flVillinCreERT2Apcmin 
animals. (E) Representative H&E staining of high grade dysplasia (HGD) adenoma 
detected in Sh3bp4fl/flVillinCreERT2Apcmin mice. Right panel is a magnification of the 
highlighted region in the left image. (F) Number of analysed HGD adenomas per 
animal HGD was defined to be when increased nuclear enlargement and crowding 
was observed together with disrupted cellular architecture. Scale bar, 100µm. Error 
bars represent ±SD. ***P< 0.001. 
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Figure 5.13 Sh3bp4fl/flVillinCreERT2APCmin adenomas display same apoptosis index 
compared to control APCmin adenomas. 
(A) Staining with cleaved caspase-3 antibody. Right panels are magnifications of the 
boxed regions of the left-hand side images. Images are representative of 6 animals 
per condition. Scale bar, 100µm. (B) Number of cleaved Caspase 3 positive cells in 
adenomas sections from Sh3bp4fl/flVillinCreERT2APCmin and APCmin mice. Apoptotic 
index was determined by dividing the number of cleaved caspase 3 positive cells by 
500 cells of the adenoma multiplying by 100. 5 adenomas with sizes between 0.8 to 
1 mm and similar grade of dysplasia were analysed in 6 different animals/group. Dots 
represent the percentage of Caspase 3+ cells counted in each of the 30 adenomas. 
Mean ± SD are shown in red. ns - non-significant (p>0.05). 
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Figure 5.14 Characterisation of goblet cell and Paneth cell differentiation in 
Sh3bp4fl/fl VillinCreERT2APCmin mice. 
(A) PAS (goblet cells) and lysozyme (Paneth cells) (B) staining was performed on 
the adenomas of the indicated strains. Right panels are magnifications of the boxed 
regions of the left-hand side images. Images are representative of 6 animals per 
condition. Scale bar, 100µm. (C) Number of PAS positive cells and Lysosyme 
positive cells (D) in adenomas sections from Sh3bp4fl/flVillinCreERT2APCmin and APCmin 
mice. PAS+ and Lysosyme+ cells were counted in 5 adenomas with sizes between 
0.8 to 1 mm and similar grade of dysplasia, from 6 different animals/group. Dots 
represent the percentage of positive cells counted in each of the 30 adenomas. Mean 
± SD are shown in red. ***P< 0.01, ***P< 0.001. 
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To the best of our knowledge, this is the first study characterising the role of 
SH3BP4 in the context of intestine and Wnt/b-catenin signalling. Our current data 
show that SH3BP4 inhibits Wnt signalling downstream of the b-catenin destruction 
complex and is dependent on the ZU5 domain. Loss of SH3BP4 promotes ISC 
proliferation and tumourigenesis. Taken together the results provide strong evidence 
in support of our initial hypothesis that SH3BP4 is a negative regulator of Wnt/b-
catenin signalling in intestine.  
SH3PB4 functions as a binding protein that is involved in regulation of multiple 
signalling pathways. In particular, SH3BP4 has been reported to be involved in 
receptor trafficking (Francavilla et al., 2013; Tosoni et al., 2005), potentially 
suggesting a regulatory role at the Wnt receptor level. However, the SH3BP4 
deletion construct lacking the putative clathrin-binding LIDL motif (SH3BP4DN) and 
the SH3_1 mutant (SH3BP4W92A) did not affect its ability to suppress Wnt. Moreover, 
SH3BP4 was able to inhibit various Wnt activating models downstream of the Wnt 
receptor level, suggesting that the negative regulatory role of SH3BP4 in Wnt/b-
catenin signalling is unlikely to be via recycling or internalisation of the Wnt receptors. 
In addition, SH3BP4 has also been shown to be a negative regulator of the mTOR 
pathway (Kim et al., 2012b). To test whether Wnt signal activation induced by 
SH3BP4 depletion is caused by activation of mTOR signalling, we treated the 
DSH3BP4 cells with the mTOR inhibitor rapamycin. Inhibition of mTOR signalling did 
not suppress Wnt activation in the DSH3BP4 cells, suggesting that the negative 
regulatory role of SH3BP4 in Wnt/b-catenin signalling is independent of the mTOR 
pathway. Importantly, the SH3_1 domains that mediate the interaction with Rag 
GTPases for mTOR inhibition is not required for Wnt signalling suppression (Kim et 
al., 2012b), whilst ZU5 is the critical domain for Wnt signal inhibition. The data 
support the notion that SH3BP4 negatively regulates both Wnt and mTOR pathways 
independently.  
Our preliminary data suggests that SH3BP4 regulates Wnt/b-catenin 
signalling at the nucleus, possibly via interactions with b-catenin and/or APC proteins. 
Interestingly, APC has been reported to antagonise b-catenin transcriptional activity 
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by promoting its proteosomal degradation (Orford et al., 1997), nuclear 
export(Henderson, 2000) and by interfering with the b-catenin/TCF complex 
formation(Hamada and Bienz, 2004). Since SH3BP4 is predominantly localised at 
the nucleus and perinuclear membrane, we hypothesised that SH3BP4 may function 
to facilitate APC-mediated nuclear export of b-catenin or interfere with b-catenin/TCF 
transcriptional complex formation. Further experiments are required to further 
investigate the Wnt negative regulatory role of SH3BP4 at the nucleus and how 
precisely the ZU5 domain is involved.  
Thus far, our data show that the Wnt negative regulator SH3BP4 is expressed 
at the intestinal crypt bottom and is co-localised with the ISC marker Lgr5. We 
therefore proceeded to characterise its functional implication during normal intestinal 
homeostasis. Despite normal histology, 25 days after SH3BP4 loss, a moderate 
increase in Lgr5- and Olfm4-expressing cells was observed in intestinal tissues, as 
well as enhanced proliferation. In addition, animals analysed 3 months after SH3BP4 
loss had significantly longer small intestines and colons. Taken together, the data 
suggest that Sh3bp4 plays a crucial role in ISC maintenance. We are currently 
analysing the crypt-villus structures of these animals as well as the expression of 
Wnt targets, stem cell and differentiation markers. It will be important to determine 
whether expansion of the pool of ISCs upon Sh3bp4 deletion is caused by 
upregulated Wnt signalling, and if cell differentiation is affected or not. Of note, 
intestinal homeostasis was only affected after prolonged SH3BP4 loss alone, 
suggesting that loss of the Wnt negative regulator SH3BP4 may result in increased 
tumour susceptibility, possibly due to the increase in basal Wnt signalling within the 
crypt compartment. Further investigation of intestinal tissues over longer periods of 
SH3BP4 loss will be important to study its tumorigenic potential. We have already 
induced deletion of Sh3bp4 in a cohort of animals and will collect the intestine for 
analysis after approximately 1 year. 
In addition to the regulatory role in intestinal homeostasis, our data further 
show that loss of SH3BP4 augments the Apcmin intestinal tumour phenotype by 
promoting both tumour initiation and progression. Together, our study uncovers the 
tumour suppressive role of SH3BP4 in the intestine for the first time by modulating 
Wnt signalling/b-catenin.  




Chapter 6. General discussion 
 
Over the past few decades, remarkable insights have been obtained into the 
molecular events underlying the development of CRC. Large scale whole-genome 
sequencing studies have resulted in detailed molecular landscapes of driver events 
and revealed a complex picture of key players in CRC. This large amount of data 
has certainly advanced our collective understanding of CRC and facilitated 
therapeutic development. The Wnt signalling pathway plays a crucial role in both 
intestinal homeostasis and CRC development. In addition to the well characterised 
central players in the Wnt signalling cascade, more recently other novel regulators 
involved in fine-tuning the pathway for ISC maintenance have been identified. Many 
of these have also been reported to be deregulated in CRC, reinforcing the crucial 
link between intestinal homeostasis and tumourigenesis in the context of Wnt 
signalling. The aim of my PhD project was to identify and characterise novel Wnt 
regulators for a better understanding of the mechanisms that regulate ISC 
homeostasis and the corresponding tumour biology. By analysing the publicly 
available genome-wide transcriptomic data from TCGA (TCGA, 2012), we identified 
a “Stem-Cell/Wnt cluster” that is enriched with many stem cell markers, Wnt target 
genes and/or Wnt inhibitors. We hypothesised that some of the genes within this 
cluster are Wnt inhibitors responsible for a negative feedback loop. In particular, we 
have uncovered two novel Wnt negative regulators: ZAK and SH3BP4. Our data 
show that both proteins are responsible for generating a Wnt negative feedback loop 
to refine Wnt/b-catenin signalling levels during tissue homeostasis, regeneration and 
tumourigenesis.  
 
6.1 Wnt/b-catenin negative feedback mechanisms in the ISC 
compartment 
 
Wnt signal activation at the bottom of intestinal crypts is crucial for ISC 
maintenance. Yet, hyperactivation of the pathway can lead to pathological dysplasia 
due to uncontrolled ISC expansion (Figure 6.1). Thus, precise control of the Wnt 




signalling level within the ISC compartment is vital for intestinal homeostasis. To fine-
tune Wnt activity within the intestinal crypts, several negative Wnt regulators are 
transcriptionally regulated by β-catenin/TCF directly to create a negative feedback 
loop to antagonise WNT signalling. These inhibitors act at different subcellular levels 
of the signalling cascade to regulate important intracellular or extracellular 
components. For instance, AXIN2 and RNF43 are both reported to be Wnt targets 
expressed by stem cells that antagonise Wnt signalling at the destruction complex 
and Frizzled receptor levels, respectively. Here we show, for the first time, that both 
ZAK and SH3BP4 are negative Wnt regulators expressed by stem cells. Deletion of 
Zak enhances radiation-induced intestinal regeneration, whilst SH3BP4 loss 
promotes ISC proliferation and augments the Apcmin tumour phenotype (Figure 6.1). 
Our findings highlight the crucial role of the negative feedback mechanisms required 
to regulate key cellular processes during tissue homeostasis, such as stem cell self-
renewal, proliferation and differentiation.  
 
Figure 6.1 Wnt inhibitors and CRC. 
Loss of APC function occurs in 80% of CRC patients and results in activation of Wnt 
signalling and development of early adenomas. Accumulation of mutations in 
components of the Wnt signalling negative feedback mechanism could lead to 
increase in the grade of dysplasia as we have shown to be the case for SH3BP4 in 
the Apc-mutated background. Accumulation of mutations in other proteins like TP53, 
SMAD4, KRAS, and PI3K result in cancer progression to carcinoma.




It has been previously reported that crypt stem cells are the origin of intestinal 
cancer (Barker et al., 2009). Therefore, it is possible that mutations of Wnt inhibitors 
expressed by stem cells could potentiate the transition from stem cell to cancer stem 
cell. In fact, recurrent mutations of AXIN2 and RNF43 have been previously reported 
in CRCs (Giannakis et al., 2014; TCGA, 2012). As mentioned in chapter 3, recent 
sequencing studies with a larger cohort of CRCs showed the presence of mutation 
in SH3BP4 and ZAK in CRCs. The mutations are distributed across the whole gene 
without any hotspot. The majority of the mutations are missense mutations, although 
two truncations are reported in both genes. One might expect a higher frequency of 
mutation in Wnt inhibitors than the one observed for ZAK and SH3BP4. There are 
several possibilities reasons that could explained a low number of mutations in Wnt 
inhibitors in CRC. A potential reason is the principle of random replacement of ISCs, 
known as neutral drift. A ISC in a crypt can be replaced by any other ISC (Lopez-
Garcia et al., 2010; Snippert et al., 2010b), which could result in mutation loss. 
Secondly, despite the fact that mutations in a particular gene could give selective 
advantage to the carrying cell, genes can play a role in multiple cellular pathways 
and be selected accordingly to the overall effect in the different pathways. Finally, it 
is possible that, to find “the just-right” Wnt signalling level, as it has been suggested 
for APC function (Fodde et al., 2001), cancer cells may favour the maintenance of 
some negative feedback responses that confer the “just-right” expression of a subset 
of genes that provide a growth advantage to the cancer cell. 
  
Many studies of transcriptomic or tissue microarray analysis in various CRC 
cohorts have been described, and have revealed differential expression of genes or 
proteins between different samples. Upregulation of certain genes or proteins in a 
subpopulation of CRCs relative to normal tissues are often interpreted as putative 
oncogenes. Contrary to this dogma, our findings suggest that this is not necessarily 
the case. The “Stem-Cell/Wnt cluster” identified from our analysis indeed shows an 
overall upregulated gene expression in MSS-CRCs. However, rather than being 
oncogenes, many of the genes in this cluster are in fact Wnt inhibitors expressed by 
stem cells. The upregulated expression is simply a consequence of being Wnt/b-
catenin transcriptional targets leading to abnormally highly expression in APC-
mutated CRCs. On the contrary, many of the genes are indeed downregulated in 
non-APC mutated CRCs. In fact, many Wnt negative regulators such as AXIN2, 




NOTUM, RNF43 and MULE have all been previous reported to be upregulated in 
intestinal tumours (Dominguez-Brauer et al., 2016; Koo et al., 2012; Lustig et al., 
2002; Robertis et al., 2015), although they are considered tumour suppressors rather 
than oncogenes. Similarly, ZAK has also previously been reported to be upregulated 
in CRCs (Liu et al., 2014b). Here we propose that both ZAK and SH3BP4 are Wnt 
negative regulators expressed by stem cells and function as growth/tumour 
suppressors.  
 
6.2 Mechanistic role of ZAK and SH3BP4 and their therapeutic 
implications 
 
Activation of Wnt signalling in the majority of CRCs is via APC mutations. 
Therefore, therapeutic interventions targeting Wnt components upstream of the b-
catenin destruction complex would not be efficient for this subtype of CRCs. The 
most effective targets would be downstream of the cytoplasmic b-catenin destruction 
complex. However, despite extensive efforts, these targets have proven to be difficult 
to identify (Antas et al., 2015). Here, we identified two novel Wnt negative regulators, 
ZAK and SH3BP4, that function to control Wnt/b-catenin signalling at the “right 
levels”. Interestingly, both genes are able to suppress Wnt signalling in APC-mutated 
cells. Characterising the Wnt inhibitory mechanism of the two genes may shed light 
on approaches to develop therapeutic interventions. 
 
ZAK. Our data show that ZAK inhibits Wnt/b-catenin signalling downstream 
of b-catenin phosphorylation and ubiquitination and is kinase-dependent. 
Cytoplasmic expression of ZAK suggests that its Wnt inhibitory role is unlikely to act 
at the b-catenin/TCF transcriptional level. Previous studies have shown that inhibiting 
tankyrase-dependent degradation of AXIN is able to inhibit Wnt/b-catenin signalling 
in APC-mutated CRC cells and suppress tumour growth (Waaler et al., 2012; Waaler 
et al., 2011). The data suggest that stabilising AXIN can indeed inhibit Wnt signalling 
downstream of the defective b-catenin destruction complex. AXIN is considered to 
be the rate-limiting factor for b-catenin degradation (Salic et al., 2000), whilst 




phosphorylation of AXIN is important for the regulation of the destruction complex 
(MacDonald et al., 2009). Together, we hypothesise that ZAK may function to 
stabilise AXIN, thereby promoting b-catenin degradation (Figure 6.2). On the other 
hand, ZAK may also function to retain b-catenin in the cytoplasm via an unknown 
mechanism, thereby inhibiting b-catenin/TCF complex formation. Further 
investigation will be need to elucidate the inhibitory role of ZAK in Wnt pathway. 
Our in vivo data show that Zak deletion enhances intestinal regeneration, 
whilst its tumourigenic potential has not yet been addressed. Interestingly, ZAK has 
been reported as off-target of several clinically approved kinase inhibitors including 
anticancer drugs (Karaman et al., 2008; Vin et al., 2014a; Vin et al., 2014b; Wong et 
al., 2013). For example, off-target inhibition of ZAK by BRAF inhibitors has been 
associated with secondary cutaneous squamous cell carcinoma (cSSC) in patients 
treated for melanoma (Vin et al., 2014b). In particular, vemurafenib/PLX4720 
supresses apoptosis through off-target inhibition of ZAK. Our data further 
demonstrate that ZAK inhibition could activate Wnt/b-catenin signalling, highlighting 
the risks associated of using these anticancer drugs with off-target activity against 
ZAK.  
As mentioned in chapter 4, Zak-/- animals generated for this project were 
shared with two different laboratories which have reported to us that ZAK seems to 
be important to muscle physiology and to normal function of the endoplasmic 
reticulum (ER). Disturbance in the ER environment causes several stress responses 
such as oxidative stress and DNA damage, long known to be involved in cancer 
biology (Urra et al., 2016). This phenotype is now being explored by our collaborators 
to better understand the physiological significance of ZAK protein in cellular stress 
response.




Figure 6.2 ZAK inhibits Wnt signalling independently of MAPK pathway activation. 
ZAK inhibits Wnt/b-catenin signalling downstream of b-catenin phosphorylation and 
ubiquitination. We hypothesise that ZAK may function to stabilise AXIN, thereby 
promoting b-catenin degradation. On the other hand, ZAK may also function to retain 
b-catenin in the cytoplasm via an unknown mechanism, thereby inhibiting b-
catenin/TCF complex formation. Green arrowa indicate increase in protein levels or 
protein activity. ZAK can activate ERK, p38 and JNK pathways. Our data suggests 
that the Wnt inhibitory role of ZAK is MAPK-independent. Red arrows indicate 




SH3BP4 also inhibits Wnt/b-catenin signalling downstream of b-catenin 
phosphorylation and ubiquitination. Unlike ZAK, SH3BP4 is strongly localised in the 
nucleus and physically interacts with APC and b-catenin. It is plausible that SH3BP4 
plays a role in APC-mediated nuclear shuttling of b-catenin (Figure 6.3). Indeed, a 
study from Henderson has shown that the N-terminal half of APC contains two active 
nuclear export sequences (NES) (Henderson, 2000), which is consistent with the fact 
that SH3BP4 can inhibit Wnt/b-catenin signalling in our HEK293T∆APC cells with 
intact NES. Further studies will help characterise the potential role of SH3BP4 in 
APC-mediated b-catenin nuclear shuttling. Understanding the full mechanism by 




which b-catenin is exported from the nucleus or how the b-catenin/TCF complex 
could be regulated could shed light into new therapeutic strategies against CRC. 
Moreover, we have attempted to identify the specific domain of SH3BP4 that is 
responsible for Wnt signal inhibition. To do so, different SH3BP4 deletion/mutant 
constructs lacking various SH3BP4 domains were generated. The construct lacking 
the ZU5 domain failed to exert full Wnt inhibitory function. This data suggests that 
the inhibitory role of SH3BP4 is dependent on the ZU5 domain, a domain poorly 
characterized. It is plausible that this domain is involved in the interaction of SH3BP4 
with APC or b-catenin (Figure 6.3). Further experiments are required to assess that. 
SH3BP4 has previously been shown to play a regulatory role in clathrin-
mediated internalisation of membrane receptors such as transferrin receptor and 
fibroblast growth factor receptor (Francavilla et al., 2013; Tosoni et al., 2005). Our 
data shows that expression of SH3BP4 is able to inhibit TCF-TopFLASH reporter 
activity induced by the constitutively active form of LRP6 receptor (DN-LRP6), 
suggesting that the inhibitory role of SH3BP4 in Wnt signalling is downstream of Wnt 
ligand receptors. Moreover, the SH3BP4 deletion construct lacking the putative 
clathrin-binding LIDL motif (SH3BP4DN) did not affect its ability to suppress Wnt 
signalling.  
SH3BP4 is also a negative regulator of mTORC1 signalling. SH3BP4 binds 
to inactive GDP-bound Rag GTPase via the SH3 domain and inhibits the formation 
of the active Rag GTPase complex, inactivating mTOR signalling (Kim et al., 2012b). 
On the other hand, previous studies have shown that Apc mutated intestinal tumours 
are dependent on mTORC1 signalling for tumour growth (Faller et al., 2014; Fujishita 
et al., 2008). These facts raise the question whether increase in the number of ISCs 
after Sh3bp4 loss is a consequence of the synergistic effect of both Wnt and mTOR 
signalling activation. Our in vitro data suggest that SH3BP4-mediated Wnt inhibition 
is mTOR-independent. To isolate the contribution of which pathway to the observed 
phenotype, we will be treating Sh3bp4fl/flVillinCreERT2 and Sh3bp4fl/fl animals with the 
mTOR inhibitor rapamycin, and assess changes in proliferation and Wnt target genes 
expression after Sh3bp4 loss.




Figure 6.3 SH3BP4 inhibitory role in Wnt signalling. 
SH3BP4 inhibits Wnt/b-catenin signalling downstream of b-catenin phosphorylation 
and ubiquitination. SH3BP4 is strongly localised in the nucleus and physically 
interacts with APC and b-catenin. We hypothesise that SH3BP4 plays a role in APC-
mediated nuclear shuttling of b-catenin, thereby reducing the levels of nuclear b-
catenin that can bind to theTCF complex and active Wnt transcription program. ZU5 
domain is fundamental for the inhibitory role of SH3BP4 in Wnt signalling. We believe 
that this domain is involved in the interaction of SH3BP4 with APC or b-catenin. 
SH3BP4 also negative regulates mTORC1 signalling. It is plausible that the 
phenotype observed in mice intestine after Sh3bp4 loss is a consequence of the 
synergistic effect of both Wnt and mTOR signalling activation.
 
6.3 Future directions 
In addition to the molecular mechanism, further investigation will be needed 
for functional characterisation in vivo. In fact, organoids are a suitable model for ex 
vivo functional studies of Wnt signalling activation, tumour transformation and 
regeneration. Normal intestinal organoids are well differentiated with budding 
structures recapitulating crypt-villus architecture in vivo, whilst Apc-mutated 
organoids show remain cystic and display a non-budding phenotype as a result of 
Wnt-activated ISC hyperproliferation. It would be interesting to examine whether 
expression of ZAK and SH3BP4 in Apc-mutated organoids would restore the budding 
structure in spheroids as a result of Wnt signalling inhibition.  
As previously mentioned, ZAK has two isoforms distinguished by their unique 
C-terminal protein sequence and these have been shown to be differentially 
expressed in normal and tumour tissues (Liu et al., 2014b). This raises the question 




of whether the two isoforms perform unique or overlapping roles during intestinal 
homeostasis.  
Our preliminary data suggest that the Wnt inhibitory role of ZAK is MAPK-
independent. Although the MAPK inhibitors have been widely used in other studies, 
the efficiency of the inhibitors should be confirmed in our system by examining 
changes in phosphorylation of MAPKs. Moreover, treatments of combined MAPK 
inhibitors should be considered due to the compensatory role of different MAPKs.  
As mentioned in chapter 4, we do not know if deletion of Zak accelerates 
regeneration of the intestinal epithelium or if Zak-null animals are more resistant to 
damage-induced radiation. We will have to analyse the intestine of induced-injury 
mice at earlier time points to answer this question. In addition, we need to further 
investigate the expression of Wnt target genes and stem-cell markers in normal    
Zak-/- mice. In addition, it would be important to further characterise the role of ZAK 
loss in intestinal tumorigenesis in addition to tissue regeneration. We are currently 
breeding the Zak-/-Apcmin mouse strain for further analyses. 
 
SH3BP4 is expressed in the intestinal crypts overlapping with the ISC marker 
Lgr5. To test if stem-cell specific loss of SH3BP4 alters intestinal homeostasis, we 
have generated another mouse strain that allows deletion of Sh3bp4 specifically in 
ISCs (Sh3bp4fl/flLgr5CreERT2). The mice are currently being analysed for markers of 
stem cell, proliferation and differentiation. 
We have not studied the isolated contribution of SH3BP4 deficiency to 
tumorigenesis. To analyse if loss of SH3BP4 alone is sufficient to promote 
tumorigenesis, we will analyse a cohort of animals one year after Sh3bp4 loss.  
In this project, Apcmin mice were used as a model for studying intestinal 
tumourigenesis. However, given the hypothesis that deregulation of ZAK and 
SH3BP4 is an alternative Wnt activating mechanism in CRC, it would be interesting 
to study the tumourigenic roles of ZAK and SH3BP4 using another intestinal tumour 
model. For instance, the inflammation-related cancer model induced by dextran 
sodium sulphate (DSS) and azoxymethane (AOM) will induce colon-specific lesions, 
which may represent a better CRC model for ZAK and SH3BP4.  
The progression of CRC from an early adenoma to carcinoma is accompanied 
by a set of mutations including KRAS, SMAD4, TP53. Identifying genes whose loss 
exerts a selective pressure favouring other mutations rate to facilitate adenoma 




tumorigenesis are of extreme importance. It would be worth investigating whether 
loss of ZAK or SH3BP4 favours CRC-associated mutations. 
 
With the advent of new technologies to examine thousands of genes in 
parallel, the true complexity of CRC has become evident. This big amount of data 
allows us to reassess the nature of CRCs knowledge and it is clear that we still lack 
a deeper understanding of CRC pathology. If cancer is a disease in which genes that 
control cell division are mutated, thus causing cellular overgrowth, why targeted 
inhibitors of cell division fail to cure CRCs? If aberrant Wnt signalling activation is the 
main cause of CRCs initiation, why multiple inhibitors that suppress Wnt fail to cure 
most of CRCs patients? (see our review Antas et al., 2015). In addition, we now know 
that heterogeneity across individual and tumour microenvironment add further 
challenges to the understanding of CRC biology. Every study represents an 
opportunity to refine our knowledge of this disease. Here, we highlight the crucial 
role of the Wnt negative feedback mechanism in intestinal homeostasis. We have 
identified two novel Wnt target genes expressed by stem cells, Sh3bp4 and Zak, 
which act as Wnt inhibitors to fine-tune the levels of Wnt/b-catenin signalling during 
normal tissue maintenance (Figure 6.4). This is the first time that ZAK and SH3BP4 
have been implicated in intestinal homeostasis and cancer via Wnt/b-catenin 
signalling.  
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